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Abstract 
Granulocyte-macrophage colony stimulating factor (GM-CSF) plays multiple 
roles in the development, maintenance and regulation of the immune system.  In 
experimental autoimmune encephalomyelitis (EAE), an animal model of multiple 
sclerosis (MS), the absence of GM-CSF expression by CNS antigen-specific Th1/17 
T cells abolishes their encephalitogenic potential; an effect attributed to the 
inability of GM-CSF-/- T cells to activate myeloid cells within the CNS. To address 
the mechanisms involved, we investigated the effects of GM-CSF in myelinated 
cultures derived from embryonic mouse spinal cord. Our data demonstrate GM-
CSF “activates” microglia inducing marked changes in morphology and enhancing 
their phagocytic potential. However, in isolation, this is unable to damage 
myelin or axons.  
These data suggest GM-CSF synergises with other effector mechanisms to 
mediate tissue damage in EAE. We therefore investigated its ability to 
potentiate the cytopathic effects of IFN-γ and TNF-α, two pro-inflammatory 
cytokines associated with EAE and MS pathogenesis.  
We report a combination of all three cytokines is required to induce rapid and 
extensive cell death. Cell death was associated with induction of iNOS in 
microglia, elevated nitric oxide and was inhibited completely by an iNOS 
inhibitor, AMT hydrochloride. Additionally, cell supernatant analyses revealed 
that the synergy between GM-CSF, IFN-γ and TNF-α is also responsible for 
extensive pro-inflammatory cytokines release, including IL-6 and IL-1β.  
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1 Introduction 
1.1 Multiple sclerosis  
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the 
central nervous system (CNS) and the most common cause of chronic disability 
among young adults in Europe and North America (Lebrun-Frenay, Kobelt, Berg, 
Capsa, & Gannedahl, 2017). Neurological deficits in MS are due to demyelination 
and axonal injury attributed to the detrimental effects of repeated episodes of 
autoimmune T cell mediated inflammation. A concept developed from studies on 
experimental autoimmune encephalomyelitis (EAE), an animal model that 
replicates many of the pathological and clinical features of the human disease. 
This resulted in a number of treatments that reduce disease activity by 
suppressing immune-mediated inflammation in the CNS. However their efficacy 
remains limited by factors including large numbers of non-responders, side 
effects and cost. There is therefore a continuing need to develop more effective 
treatments, and more importantly strategies to stop disease developing in the 
first place. Current preclinical strategies include immune modulation and 
modalities to promote neuroprotection, remyelination and repair (Gholamzad et 
al., 2019).   
1.1.1 Epidemiology and aetiology 
It is estimated that there are 110,000 people living with MS in the UK, the 
highest incidence being in Scotland where it is > 200 per 100,000 (MS Trust, 
2018) and in Orkney results in about 1 in every 170 women having the disease 
(Visser, Wilde, Wilson, Yong, & Counsell, 2012). This reflects the situation 
observed in several other autoimmune diseases in which more women are 
affected than men, the ratio for MS being between 2.3 - 3.5 to 1 (Harbo, Gold, & 
Tintora, 2013). 
The exact cause of MS remains to be elucidated. There are extensive studies on 
environmental, genetic and epigenetic risk factors that individually or combined 
are associated with an increased incidence of multiple sclerosis (Ciccarelli, 
2019). Environmental factors thought to play a role in causing MS are vitamin D 
deficiency, diet, and smoking (Ciccarelli, 2019), as well as certain infections 
such as Epstein-Barr virus (Levin et al., 2005). The dominant genetic risk factors 
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are associated with the MHC class II locus, for example it is three times more 
likely HLA DRB1*15:01 carriers will develop MS (Patsopoulos et al., 2013). 
Additionally, genome wide association studies (GWAS) are continuing to identify 
an increasing number of common non-HLA genetic variants associated with 
increased susceptibility to MS, virtually all of which are associated with immune 
function including IL2RA, IL7RA, CD58, TYK2, STAT3, and TNFRSF1A (Ciccarelli, 
2019; Hafler et al., 2007). 
1.1.2 Pathology and disease course 
The main pathological hallmarks of MS are chronic inflammation, demyelination, 
and axonal loss that result in patients developing persistently demyelinated 
plaques of astrocytic scar tissue traversed by varying numbers of surviving axons 
(Brück, 2005; Lassmann, 2014; Prineas et al., 2001). There are three main 
disease courses in MS: relapsing remitting multiple sclerosis (RRMS), primary 
progressive multiple sclerosis (PPMS) and secondary progressive multiple 
sclerosis (SPMS).  
1.1.2.1 Remitting relapsing multiple sclerosis  
RRMS is the initial presentation in approximately 85 % of MS cases the majority 
of whom are in young adults, although about 5% of cases occur in children 
(Özakbaş, 2015). It is often is preceded by a clinically isolated syndrome (CIS) 
characterised by acute onset of neurological symptoms such as optic neuritis or 
numbness in the extremities which in many cases resolves spontaneously. The 
overall risk of CIS patients going on to develop MS is approximately 20%, but this 
increases to 60 to 80% if white matter (WM) lesions are detected by MRI (Fisniku 
et al., 2008). Typically, patients with RRMS will relapse on average every 1.5 
years, although there is enormous variation in relapse frequency between 
patients.  
These spontaneous and unpredictable episodes of neurological symptoms are 
associated with inflammatory activity in the corresponding regions of brain or 
spinal cord region. Symptoms often resolve completely during remission but over 
time complete recovery becomes less likely as patents accumulate an increasing 
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burden of chronic neurological deficits due to irreversible axonal injury and loss 
(Ciccarelli, 2019).  
Histological evidence demonstrates 90% of immune cells in these inflammatory 
lesions are of myeloid origin (monocytes, monocyte-derived macrophages and 
microglia) and the remaining 5-10 % are compromising various lymphocyte 
subsets inflammation and large numbers of T cells (CD8+ T cells > CD4+ T cells) 
infiltrate the CNS parenchyma (Meinl, Krumbholz, & Hohlfeld, 2006). It is 
generally believed this inflammatory response is initiated in the CNS by 
autoantigen-specific CD4+ T cells. Reactivation of these T cells by professional 
antigen presenting cells within CNS triggers production of cytokines that 
orchestrate recruitment of peripheral immune cells across blood-brain and 
blood-CSF barriers (BBB) (Lucchinetti et al., 2011; Lassmann, 2014; Perriard et 
al., 2015; Setiadi et al., 2019). These inflammatory lesions are associated with 
demyelination characterised by the presence of complement activation 
products, immunoglobulins and phagocytes laden with myelin debris (Breij et 
al., 2008; Geurts and Barkhof, 2008), as well as widespread axonal injury and 
loss (Trapp et al., 1998). This axonal pathology is the underlying cause of clinical 
deficits in MS, but nonetheless MS is still considered a primary demyelinating 
disease. Loss of myelin not only disrupts axonal function per se, but also 
increases axonal susceptibility to inflammatory mediators whilst at the same 
time disrupting metabolic/trophic support normally provided by 
oligodendrocytes via the myelin sheath. A combination of effects believed to 
induce profound energy deficits that compromise the function and survival of 
affected axons (Brück, 2005; Fünfschilling et al., 2012; Lee et al., 2012). 
Multiple effector mechanisms can contribute to demyelination and axonal injury 
in EAE, but their relative importance in driving lesion development in MS remains 
controversial (Constantinescu, Farooqi, O’Brien, & Gran, 2011; Gold, Linington, 
& Lassmann, 2006; Schuh et al., 2014). Nonetheless a consensus exists that 
tissue damage is initially dependent on recruitment and activation of immune 
cells in the CNS. Although it remains to be determined precisely how this 
inflammatory response leads to demyelination and axonal loss (Krementsov, 
Thornton, Teuscher, & Rincon, 2013; Lassmann, 2014). At early stages of lesion 
development axons are relatively preserved but over time sustained or repeated 
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inflammatory activity leads to irreversible axonal damage, the underlying cause 
of chronic disability in MS (Trapp et al., 1998; Brück, 2005). Unravelling the 
mechanistic basis of tissue damage in these lesions is complicated by their 
immunopathological heterogeneity. Four distinct patterns of demyelination were 
defined on the basis of immunopathological criteria and attributed to different 
effect mechanisms (Lucchinetti et al., 2000;   Lassmann, Brück and Lucchinetti, 
2007). Demyelination in Pattern I lesions is attributed to a T cell-mediated 
inflammatory response. Pattern II is similar to pattern I but accompanied by 
immunopathological evidence for antibody-mediated, complement-dependent 
demyelination and is the most prevalent being present in approximately 50% of 
cases (C. Lucchinetti et al., 2000). Pattern III lesions are characterised by 
selective loss of immune reactivity for myelin associated glycoprotein (MAG) and 
oligodendrocyte death at the active edge of lesions, whilst Pattern IV lesions are 
associated with oligodendrocyte death within periplaque white matter. The fine 
details of this classification scheme and its relationship to disease activity and 
lesion repair remain controversial (Chandran et al., 2008; Frischer et al., 2015; 
Lassmann et al., 2007). Although it appears remyelination is more frequent in 
cases associated with Patterns I and II (Chandran et al., 2008), whilst Pattern IV 
is far more frequent in patients diagnosed with PPMS (Popescu, Pirko, & 
Lucchinetti, 2013). 
1.1.2.2 Progressive multiple sclerosis 
A majority of patients with RRMS will progress to develop secondary progressive 
MS (SPMS) within 20 years of disease onset. This is characterised by a continuous 
and often insidious increase in neurological disability in the absence of acute 
inflammatory episodes in the CNS as defined by MRI and neuropathological 
criteria. In view of this lack of evidence for acute inflammatory flares in SPMS it 
is perhaps not surprising the majority of patients do not benefit from current 
immunomodulatory, “anti-inflammatory” DMT’s  (Ciotti & Cross, 2018; Faissner, 
Plemel, Gold, & Yong, 2019). In addition to SPMS, approximately 10% of patients 
present with a progressive disease course from the onset which is classified as 
primary progressive MS (PPMS) (Tutuncu et al., 2013). 
In progressive MS lesions slowly expand leading to an increasing burden of 
neurological deficits due to irreversible axonal injury (Sáenz-Cuesta, Osorio-
21 
 
Querejeta, & Otaegui, 2014). Immunohistological studies demonstrate this is 
associated with low grade inflammation in the absence of pronounced 
perivascular infiltrates of inflammatory cells recruited from the periphery, a 
pathological hallmark of RRMS (Confavreux, Vukusic, Moreau, & Adeleine, 2000; 
Gold et al., 2006). Demyelination and axonal loss in these lesions is associated 
with a pronounced microglial response (Trapp et al., 1998; Confavreux et al., 
2000; Magliozzi et al., 2007) and in white matter, infiltrating B and T 
lymphocytes (Frischer et al., 2009; Kutzelnigg et al., 2005). However, the extent 
of lymphocyte recruitment from the periphery is far lower than in RRMS. 
Phagocytes containing myelin debris are relatively scarce suggesting a slow rate 
of demyelination (Kutzelnigg et al., 2005), but when these studies were 
published there were no markers available to distinguish between resident 
microglia and invading myeloid cells. It therefore remains to be clarified 
whether these cells are microglia or monocyte-derived macrophages recruited 
from the periphery.  
Grey matter lesions in particular cortical demyelination is a common and 
extensive feature of progressive multiple sclerosis (Kutzelnigg et al., 2005). 
These are also characterised by a pronounced microglial response at sites of 
ongoing demyelination and axonal damage that occur in the absence of large 
numbers of infiltrating lymphocytes. The role of microglia and their relationship 
to tissue injury in these lesions remains uncertain. Specifically the question 
remains do microglia actively contribute to tissue damage, or does microgliosis 
reflect their response damage mediated by some other mechanism? Cortical 
demyelination is often extensive in SPMS and in many cases is associated with 
inflammation and B cell follicle-like structures in the adjacent meninges 
suggesting this drive cortical pathology (S. R. Choi et al., 2012; Serafini, 
Rosicarelli, Magliozzi, Stigliano, & Aloisi, 2004). This may well be the case, but 
in view of the pathological heterogeneity of MS this probably represents just one 
facet of the mechanisms contributing to disease pathogenesis. Moreover, PPMS is 
also associated with cortical and other grey matter tracts but in this case B cell 
follicles are rare or possibly absent (Choi et al., 2012). 
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1.1.3 Treatments 
All current treatments for MS are immunomodulatory in nature and act primarily 
by reducing inflammatory activity in the CNS. As a consequence they have little 
or no impact on accumulation of disability in patients with progressive forms of 
the disease (Gholamzad et al., 2019). The only exception is ocrelizumab 
(Ocrevus®) that the US Food and Drug Administration approved as a treatment 
for PPMS and SPMS in 2017 (S. L. Hauser et al., 2017; Montalban et al., 2017). 
Approval was subsequently granted by the European Commission for ocrelizumab 
for treatment of RRMS and early active PPMS a year later. The efficacy of B cell 
depletion in MS was first reported in 2008 (Stephen L. Hauser et al., 2008) and 
provided unexpected new insights into the critical role played by B cells in 
disease pathogenesis (Lehmann-Horn, Kinzel, & Weber, 2017). Unfortunately 
whilst highly effective treatments are now available for RRMS, and to a limited 
extent progressive forms of the disease (Table 1.1), their efficacy is limited by 
factors including cost, adverse effects and large populations of non-responders. 
This identifies a large unmet clinical need that can only be met by increasing our 
understanding of the aetiology and pathogenesis of MS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
Treatment              
Year approved 
Efficacy Mechanism of action 
Ocrelizumab 
(RRMS,PPMS)           
2017 
46% reduction in relapses 
(RRMS), 40% reduction in 
progression of disability (RRMS), 
30-36 % reduction in disability 
over 6 months (PPMS) 
Anti-CD20 mediated B cell depletion  
Daclizumab          
(RRMS) 2016 
DISCONTINUED 
41% reduction in relapses Anti-IL-2rα mediated T cell depletion  
Dimethyl fumarate 
(RRMS) 2013 
50% reduction in relapses, 
reduces progression of disability  
Unclear, immunomodulatory and 
immunoprotective,  
Alemtuzumab   
(RRMS) 2013 
78% reduction in relapses, 71% 
reduction in disability progression 
Anti-CD52 mediated lymphocyte 
depletion  
Teriflunomide 
(RRMS) 2012 
30% reduction in relapses and 
disability progression 
inhibition of T and B cell proliferation 
Fingolimod        
(RRMS) 2010 
50% reduction in relapses, 70% 
reduction in new lesions, brain 
atrophy slowed by 30%  
Sequestration of lymphocytes in 
lymph nodes by sphingosine-1 
phosphate inhibition 
Natalizumab     
(RRMS) 2004 
68% reduction in relapses, 42% 
reduction in disability progression 
Prevents lymphocyte recruitment 
across the BBB by α4β1-integin 
blockade 
Mitoxantrone    
(RRMS, SPMS) 2000 
Reduces probability of relapses, 
new lesion formation, and 
progression of disability 
Reduced immune cell proliferation by 
Inhibits DNA synthesis reduces 
immune cell proliferation 
Glatiramer acetate 
(RRMS) 1997 
Reduces relapses, no effect on 
progression of disability 
MBP mimetic, promotes Treg 
expansion 
β interferons    
(RRMS) 1993 
30% reduction in relapses, 
effective in 70% of patients 
Reduced expression of pro- 
inflammatory cytokines, increases 
expression of anti-inflammatory 
cytokines and nerve growth factor, 
reduces CNS inflammation 
Plasma exchange 
(RRMS) 1980 
Improves recovery from acute 
steroid resistant relapses 
Reduced levels of circulating 
lymphocytes and immunoglobulins 
Corticosteroids 
(RRMS) 1950s 
Shortens relapse duration  
General anti-inflammatory and 
immunosuppressive 
 
Table 1.1. Table showing the current approved therapies in MS. Adapted from MS 
trust and Weiner et al., 1983; Gholamzad et al., 2019. 
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1.2 Experimental autoimmune encephalomyelitis  
Our current understanding of the mechanistic basis of inflammatory 
demyelination in MS derives almost completely from studies on experimental 
autoimmune encephalomyelitis (EAE), an animal model that can reproduce many 
of the clinical and pathological features of MS. In its simplest form EAE is a CD4+ 
T cell mediated autoimmune disease of the CNS in which inflammation is 
accompanied by varying degrees of demyelination and axonal injury (Gold et al., 
2006). However, its pathophysiology and clinical manifestations are critically 
dependent on variables including genetic factors i.e. the species and strain in 
which disease is induced; the nature of the immunogen used to induce disease 
(e.g. whole CNS tissue homogenates versus CNS proteins or peptides and the 
composition of the adjuvant in which these are emulsified, or adoptive transfer 
of activated T cells); and route of immunization (Gold et al., 2006). Faced with 
this variability it is important to employ the EAE model most appropriate to 
investigate a specific question such as the effect of different therapeutic 
strategies on disease onset and severity (Gold et al., 2006). However, this is a 
very simplistic view as there are crucial differences between EAE and MS. The 
most evident one is being EAE is an induced autoimmune disease, whilst MS is 
spontaneous and what triggers disease development in susceptible individuals 
remains unknown. Several spontaneous models of EAE do now exist but these all 
require transgenic manipulations to counteract intrinsic regulatory mechanisms 
that normally suppress autoaggression (Waldner et al., 2000; Zehntner et al., 
2003).  In addition, most protocols used to induce EAE require a strong adjutant, 
an intense “immunological boost” which biases the T cell response to favour an 
encephalitogenic Th1/Th17 phenotype (Gold et al., 2006; Kerschensteiner et al., 
2004). It is rather improbable this occurs under physiological conditions in man, 
even during infections. Finally to improve reproducibility EAE is mainly induced 
in inbred laboratory rodents, although MS patients are genetically heterogeneous 
(Gold et al., 2006). For these reasons one must interpret EAE data cautiously 
when extrapolating them to the situation in MS. Despite these constraints EAE 
has provided many insights into the pathogenesis of T cell mediated 
neuroinflammation and was used widely to develop new therapies.  
Historically the first species reported to develop encephalomyelitis following 
sensitisation with nervous system antigens was the man.  This occurred as a 
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complication of using dried spinal cord tissue from of rabies-infected rabbits to 
generate a rabies vaccine (Mackay & Anderson, 2010; Sabin & Wright, 1934). This 
resulted in some patients developing a demyelinating encephalomyelitis 
triggered by an autoimmune response to spinal cord contaminants in the 
vaccine. To gain a better understanding of the pathogenesis of this form of 
encephalomyelitis Rivers and colleagues injected primates and rabbits 
repeatedly with CNS tissue homogenates (Rivers & Schwentke, 1935). In some 
case this resulted in inflammatory demyelinating lesions similar to those seen in 
patients with MS. However, induction of reproducible models of EAE only 
became available following the introduction of complete Freund’s adjuvant 
(CFA) to generate encephalitogenic emulsions (Mackay & Anderson, 2010).  
Active EAE is induced in susceptible species/strains by immunization with CNS 
tissue homogenates, CNS myelin proteins or peptides (e.g. MBP, PLP, MOG) 
emulsified in complete Freund’s adjuvant (CFA) (Stromnes & Goverman, 2006). 
Disease incidence is generally high and the first clinical signs of disease generally 
develop 9 to 14 days post immunization. The subsequent course of disease, its 
severity and pathology are then determined by the genetic background of the 
animal and the encephalitogen used to induce disease (Gran, O’Brien, 
Fitzgerald, & Rostami, 2008). A classical example is the response of strain 13 
guinea pigs to immunization with MBP or CNS homogenate in CFA; the former 
results in acute monophasic and predominantly inflammatory disease whilst the 
latter initiates a chronic relapsing–remitting variant of EAE associated with 
development of macroscopic plaques of persistently demyelinated scar tissue 
(Alvord, Driscoll, & Kies, 1982). Relapsing-remitting disease can also be induced 
by immunizing SJL/J mice with PLP139-151, a disease course characterised by an 
expanding TCR repertoire to new myelin componenets following relapses , 
phenomenon known as epitope spreading (McRae, Vanderlugt, Dal Canto, & 
Miller, 1995).   
EAE can also be induced by passive or adoptive transfer of encephalitogenic CD4+ 
T cells harvested from actively immunised donors into syngeneic recipients 
(Stromnes & Goverman, 2006). Adoptive-transfer EAE models were of 
tremendous help in dissecting how myelin-reactive encephalitogenic T cells drive 
disease pathogenesis (Pettinelli & McFarlin, 1981). These models have the 
advantage they bypass the induction phase of EAE allowing elucidation of events 
contributing to the effector phase of disease. As previously described for MS, 
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EAE lesion pathology varies based on what animal strain was used (Gran et al., 
2008). Table1.2 describes commonly used EAE models and their applicability to 
MS. 
Spontaneous models of EAE have been developed using transgenic approaches 
that overcome regulatory events that normally subdue tissue-specific 
autoimmunity (Gold et al., 2006). Lafaille et al. generated a spontaneous EAE 
model by backcrossing TCR transgenic mice specific for myelin basic protein with 
Rag-1-/- mice, creating a strain where only T cells and no other lymphocytes 
express the transgenic TCR.  These transgenic animals developed spontaneous 
EAE with varying disease course, but no remission (Lafaille, Nagashima, Katsuki, 
& Tonegawa, 1994). More recently other groups have created models of 
spontaneous EAE by generating transgenic TCRs targeting other CNS antigens 
using similar approaches as Lafaille et al. (Bettelli et al., 2003; Waldner et al., 
2000). 
In addition to EAE, viral models of inflammatory demyelination that mirror MS-
like features are also employed (Lassmann & Bradl, 2017). The most common 
viral chronic encephalomyelitis models are induced by Theiler’s virus (TMEV) or 
mouse hepatitits corona virus (MHV). These models allowed identifying the roles 
of different lymphocyte types in the inflammatory-demyelination process and 
axonal injury (Lassmann & Bradl, 2017).  To study demyelination, remyelination 
and axonal degeneration in the absence of inflammation serveral toxic models 
were developed. The cuprizone, lysolecithin and ethidium bromide models were 
of tremendous use due to their reliable demyelination and remyelination 
timeline and well-defined pathomechanisms of demyelination (Lassmann & 
Bradl, 2017; Praet et al., 2014). 
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Model 
Analogy to human 
disease 
Differences from 
human disease 
Additional comments 
Lewis rat 
Active EAE 
(CNS myelin, 
MBP, MOG, 
PLP          
T cell inflammation and 
weak antibody 
response 
Monophasic, little 
demyelination 
Reliable model, commonly 
used for therapy studies. Whit 
guinea-pig MBP little 
demyelination 
Adoptive 
transfer EAE 
(MBP, S100, 
MOG, GFAP) 
Marked T cell 
inflammation. 
Topography of lesions 
Monophasic, little 
demyelination 
Homogenous course, rapid 
onset. Differential 
recruitment of T cells/ 
macrophages depending on 
autoantigen 
Active EAE or 
Adoptive 
transfer EAE + 
co-transfer of 
anti MOG 
antibodies 
T cell inflammation and 
demyelination 
Only transient 
demyelination 
Basic evidence for role of 
antibodies in demyelination 
Congenic 
Lewis, DA, BN 
strains Active 
EAE 
(recombinant 
MOG aa 1–
125)  
Relapsing–remitting 
disorders, may 
completely mimic 
histopathology of 
multiple sclerosis and 
subtypes  
No spontaneous 
disease 
Chronic disease course, 
affection of the optic nerve, 
also axonal damage similar to 
multiple sclerosis  
Murine EAE 
(SJL, C57BL/6, 
PL/J, Biozzi 
ABH) Active 
EAE (MBP, 
MOG, PLP and 
peptides) 
Relapsing–remitting 
(SJL, Biozzi) and 
chronic-progressive 
(C57BL/6) disease 
courses with 
demyelination and 
axonal damage  
No spontaneous 
disease 
Pertussis (toxin) required for 
many strains, whilst it is often 
not needed for SJL and some 
Biozzi EAE models. Higher 
variability of disease 
incidence and course, often 
cytotoxic demyelination in 
C57BL/6. With rat MBP 
inflammatory vasculitis with 
little demyelination  
Murine EAE in 
transgenic 
mice or 
knockout mice 
(mostly 
C57BL/6 
background)  
Specifically addresses 
role of defined immune 
molecules/neurotrophic 
cytokines/ 
neuroanatomical tracts  
Most results 
obtained with 
artificial permanent 
transgenic or 
knockouts  
Extensive backcrossing (>10 
times) on C57BL/6 
background required.   
 
Table 1.2. Commonly used rodent models of EAE. Adapted from (Gold et al., 2006) 
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1.3 GM-CSF 
GM-CSF is a pleotropic growth factor and immune modulator (Hamilton, 2002). It 
was discovered in conditioned medium from lung tissue isolated from mice 
treated with lipopolysaccharide and shown to stimulate formation of 
granulocytes and macrophages from mouse bone marrow (Burgess, Camakaris, & 
Metcalf, 1977). The GM-CSF gene (CSF2) is located on chromosome 5q22-31 in 
humans in close proximity CSF1, IL-3, IL-4, and CSF1R (Van Leeuwen, Martinson, 
Webb, & Young, 1989).  The human gene has four exons (Wong et al., 1985) and 
its murine homologue (Csf2) is located on chromosome 11 (Gough, Metcalf, 
Gough, Grail, & Dunn, 1985). 
GM-CSF is produced as a small monomeric protein that exists in different 
glycosylation states due to the presence of with six glycosylation sites; O-linked 
at amino acid residues 22, 24, 26, and 27, and N-linked at amino acid residues 44 
and 54 (Forno et al., 2004). The functional significance of glycosylation remains 
unknown, but because of different degrees of glycosylation the molecular mass 
of GM-CSF ranges from 14 to 35 kDa (Burgess et al., 1977). Human and murine 
GM-CSF are derived from a larger pre-protein containing a classical hydrophobic 
signal peptide. The amino acid sequence is species specific, human and murine 
GM-CSF contain 127 and 124 amino acid residues respectively, but exhibit an 
amino acid sequence homology of only with 56%. GM-CSF is present in normal 
human serum both as free cytokine, but also bound to naturally occurring GM-
CSF-specific antibodies (Uchida et al., 2009). It can also complex with heparan 
sulphate proteoglycans in the extracellular matrix or expressed at the cell 
surface (Coombe, 2008).  
GM-CSF is a key regulator of steady state/ systemic myelopoiesis as well as 
acting as a pro-inflammatory cytokine. It is produced by a variety of cell types, 
including macrophages, monocytes, T-cells, mast cells, fibroblasts, natural killer 
(NK) cells, and endothelial cells (Aram et al., 2019). Its expression is modulated 
by other cytokines and pattern/damage associated molecular patterns. The 
major cytokines influencing GM-CSF expression by T cells can be found in table 
1.3. Additionally, depending on the cellular source GM-CSF expression is also 
stimulated by LPS, ionomycin, epidermal growth factor (EGF) and IgE (Griffin et 
al., 1990) and in the case of microglia, IFN-γ (Olson & Miller, 2004). 
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Cytokine 
Effect on GM-CSF 
prodution 
Reference 
IL-2 stimulation  Noster et al. 2014 
IL-12 
stimulation on Th1 
cells        
inhibition on Th17 
cells 
Codarri et al. 2011 
Noster et al. 2014 
Grifka-Walk et al. 
2015  
IL-23 
stimulation on Th17 
cells 
Codarri et al. 2011       
El-Behi et al. 2011 
IL-4 inhibition 
Jansen et al. 1989 
Codarri et al. 2011 
IL-10 inhibition Sagawa et al. 1996 
TGF-β inhibition 
Jacobsen et al. 
1991 
IFN-γ 
no effect on Th1 cells        
inhibition on Th17 
cells 
Codarri et al. 2011 
Noster et al. 2014 
Grifka-Walk et al. 
2015                      
IL-27 
inhibition on Th1 
cells 
Young et al. 2011 
IL-1β stimulation Lukens et al. 2012 
TNF-α stimulation 
reviewed by 
Hamilton, 2008 
IL-7 stimulation Sheng et al. 2014 
 
Table 1.3. GM-CSF production regulation by major cytokines. Adapted from (Aram et 
al., 2019) 
1.3.1  GM-CSF receptor and signal transduction 
Signal transduction by GM-CSF is mediated by high-affinity binding to the GM-CSF 
receptor (GM-CSFR). GM-CSFR is a heterodimer composed of GM-CSF-specific, 
but low affinity α chain (CD116), and a high affinity β chain (CD131) which is 
shared with receptors for IL-3 and Il-5 (Hayashida et al., 1990a) (Figure 1.1). 
Based on structural and functional evidence the current model of GM-CSF 
signalling proposes the GM-CSFRβ induces affinity conversion and is the main 
signal transducer of the receptor complex (Gearing, King, Gough, & Nicola, 
1989).  Initially, GM-CSF binds to its specific α chain with low affinity to 
generate GM-CSF/GM-CSFRα binary complexes that are then transformed to a 
high-affinity state by recruitment of preformed β chain dimers to generate a 
2:2:2 hexameric complex (Hayashida et al., 1990b; Hercus et al., 2009).  GM-
CSFR lacks intrinsic kinase activity and signalling is conveyed by the initiation of 
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the receptor dodecamer complex.  GM-CSFβ transduces the signal by binding to 
JAK2, which autophosphorylates and mediates phosphorylation of specific 
tyrosine and serine residues within the GM-CSFRβ cytoplasmic tail (Figure 1.1). 
The absence of JAK2 or alternatively GM-CSFβ mutations that impede JAK2 
binding, abolish GM-CSF signalling (Quelle et al., 1994). The major pathways 
downstream of GM-CSF receptor activation that are responsible for its biological 
effects are JAK2/STAT5 (Janus Kinase 2/ Signal Transducer and Activator of 
Transcription 5), MAPK (mitogen-activated protein kinase), and PI3K 
(phosphoinositide 3-kinase) pathways (Carr et al., 2001).  
 
Figure 1.1. Signal transduction through the GM-CSF receptor.  To initiate signal 
transduction GM-CSF binds to its high affinity receptor subunit GMRα. The GM-CSF/ 
GMRα complex binds to preformed homodimers of the common β subunit (βc) which 
have consitutively bound Jak2. Jak2 autophosphorylates and mediates signalling via the 
intracytoplasmic βc tail which includes the mutual exclusive phosphorylation of residues 
tyrosine577 (Y) and serine585 (S). Phosphorylation of these two residues are necessary for 
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GM-CSF signal transduction. Low GM-CSF concentrations (0.01-10 pM) induce 
phosphorylation of serine585 which recruits the adapter protein 14-3-3 leading to 
sigalling via PI3K and Akt promoting cell survival. Conversely, high GM-CSF 
concentration (above 10 pM) prompts phosphorylation tyrosine577 which conveys the 
signal through STAT5 and Shc leading to cell survival, differentition and proliferation. 
Adapted from (Hercus et al., 2009; Trapnell et al.,  2009). Diagram created in 
Biorender. 
GM-CSFR is expressed on myeloid cells and some cells of non-haematopoietic 
origin such as endothelial cells, but is absent on lymphocytes (Prevost et al., 
2002). There is a lack of consensus regarding expression of GM-CSFR outside of 
the immune system during steady state. In the healthy human CNS it was 
reported GM-CSFR is present on a small subset of activated microglia and 
astrocytes (Vogel et al., 2015), although others suggest GM-CSFRα is also present 
in astrocytes, ependymal choroid plexus cells and ubiquitously in grey matter 
neurons (Ridwan, Bauer, Frauenknecht, Von Pein, & Sommer, 2012). However, 
Vogel et al. (2015) were unable to identify GM-CSFR in normal grey matter 
(Vogel et al., 2015). A functional GM-CSFR was also reported on cultured rat 
oligodendrocytes (Baldwin, Benveniste, Chung, Gasson, & Golde, 1993), although 
transcriptional studies indicate only microglia can express functional GM-CSFR in 
postnatal murine brain (Y. Zhang et al., 2014).  
1.3.2 GM-CSF expression and function 
GM-CSF is expressed at a low basal level in healthy rodents, but it is rapidly up 
regulated in response to infection, inflammation and autoaggression (Becher, 
Tugues, & Greter, 2016; Yifan Zhan, Lieschke, Grail, Dunn, & Cheers, 1998). The 
main sources of GM-CSF are: macrophages, monocytes, T-cells, mast cells, 
fibroblasts, natural killer (NK) cells, and endothelial cells (Aram et al., 2019). 
These sources were identified primarily in in vitro experiments in which cells 
were stimulated with cytokines or pathogen associated molecular patterns 
(PAMPs).In vitro, GM-CSF promotes survival, differentiation and proliferation of 
monocytes/macrophages and granulocytes (Figure 1.1) (Gasson, 1991) . Because 
of overlapping functions with other cytokines, the homeostatic functions and 
sources of GM-CSF in healthy mammals are still under debate (Becher et al., 
2016), although it is clear that in the lung GM-CSF is produced primarily by 
epithelial cells.  
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The most obvious characteristic of mice in which GM-CSF signalling is disabled 
(GM-CSF or GM-CSFR KO mice) is pulmonary alveolar proteinosis (PAP), no 
haematological and extra-pulmonary immune abnormalities were observed. PAP 
is characterized by accumulation of lipid and protein surfactant within the 
alveolar spaces caused by a lack or dysfunction of alveolar macrophages (Dirksen 
et al., 1998; Robb et al., 1995). Alveolar macrophages originate from foetal 
monocytes in the foetal liver and GM-CSF is crucial for their differentiation and 
maturation (Guilliams et al., 2013). The same study demonstrated alveolar 
macrophages require GM-CSF signalling to catabolise pulmonary surfactant 
(Guilliams et al., 2013).  Additionaly, GM-CSF KO or GM-CSFR KO mice are more 
susceptible to pulmonary infections due to impaired alveolar macrophage 
function. GM-CSF -/- and GM-CSFR -/- alveolar macrophages exhibit decreased 
clearing of bacteria, fungi and viruses. GM-CSF deficient pulmonary macrophages 
showed reduced phagocytosis, cells adhesion, internalization of viruses and 
production of superoxide (LeVine, Reed, Kurak, Cianciolo, & Whitsett, 1999; 
Paine et al., 2000). Altough GM-CSF-/- and GM-CSFR-/- animals presented an 
exgerated inflammatory response in the lung when chanllenged with pathogens, 
GM-CSF-/- and GM-CSFR-/-  alveolar macrophages did not produce TNF-α when 
challenged with LPS. On the same note, GM-CSF-/-/ GM-CSFR-/- alveolar 
macrophages presented decreased expression of pathogen-associated molecular 
patterns such as the Toll-like receptors TLR4 and TLR2, but also the mannose 
receptor (Shibata et al., 2001). The symptoms presented by mice lacking GM-CSF 
signalling are consistent with human pulmonary proteinosis, a primary 
immunodeficiency characterised by the production of GM-CSF autoantibodies or 
disruptions in GM-CSFR signalling (Trapnell et al., 2009). These observations 
highlight the role of GM-CSF in lung homestasis and innate immune defense. 
More recently it has been shown that mice deficient in GM-CSF signalling also 
have reduced numbers of non-lymphoid-tissue cDCs (conventional dendritic cells) 
in the lung, as well as intestine and dermis indicating GM-CSF is also important 
the development and/or survival of these cells (Greter et al., 2012). 
Additionally, it was demonstrated that GM-CSFR signalling was required in lung 
DCs to mount a CD8 + T cell response following immunazation with particulate 
antigens (Greter et al., 2012). Altogether, GM-CSF is generally considered 
inessential for steady-state myelopoiesis (Becher et al., 2016).  
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GM-CSF is also involved in non-haematopoietic functionas such as the 
maintenance and growth of lung epithelial cells. Overexpression of GM-CSF in 
this subset of epithelial cells resulted in increased lung size and weight (Huffman 
Reed et al., 1997). Histological assessment of lung tissue in mice with the same 
genotype as mentioned above showed that GM-CSF overexpression prevented 
hyperoxic lung injury (Paine et al., 2003). Additionally, GM-CSF treatment in 
wild type mice during hyperoxic lung injury reduced apoptosis of pulmonary cells 
(Paine et al., 2003). 
1.3.3 GM-CSF in disease 
As stated above GM-CSF is present at very low levels in systemic circulation 
(Becher et al., 2016; Yifan Zhan et al., 1998). Conversely, GM-CSF is produced 
locally at inflammation sites. The current consensus suggests that GM-CSF is 
involved in emergency haematopoiesis during infection/inflammation by 
stimulating production and survival of monocytes and granulocytes and their 
functional activation and/or priming at the site of insult (Hercus et al., 2009). 
For example, skin biopsies from patients with late-phase cutaneous reactions 
present increased levels of GM-CSF (Kay et al., 1991). Elevated concentrations of 
GM-CSF have also been detected in tissues from patients with autoimmune 
diseases including synovial fluid from rheumatoid arthritis patients and in CSF 
from patients with multiple sclerosis (Carrieri et al., 1998; Williamson, Begley, 
Vadas, & Metcalf, 1988). Experimentally, the level of circulating GM-CSF in mice 
can be raised by injecting endotoxin (Sheridan & Metcalf, 1972). Clinical 
observation and experimental data from animal models emphasize the role of 
GM-CSF in promoting and supporting inflammation  (Becher et al., 2016). The 
experiments performed for thesis aimed to explore the mechanism through 
which GM-CSF mediate tissue damage in the CNS with respect to MS and EAE, so 
from now we will explore the available evidence involving GM-CSF in the 
pathogenesis of MS and EAE.  
1.3.3.1 GM-CSF in MS and EAE 
Preclinical and clinical data support involvement of GM-CSF in the pathogenesis 
of MS and its animal model, EAE. Initial studies identified GM-CSF a non-
redundant cytokine required to induce EAE in mice, but more recent studies 
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indicate its relative importance is strain and/or model dependent. As a 
consequence its role was revised and it is now considered a key communicator 
between pathogenic lymphocytes and inflammatory myeloid cells (Komuczki et 
al., 2019). 
Studies indicating GM-CSF plays a non-redundant role in induction of EAE were 
performed using the MOG peptide induced model in wild type and Csf2-/- 
C57BL/6 mice. During the prodromal stage of disease the number of infiltrating 
immune cells was similar wild type and Csf2-/- mice, but in the absence of GM-
CSF this incipient inflammatory response was unable to support a full blown 
inflammatory response in the CNS and clinical disease activity was minimal. It 
was concluded from these studies that GM-CSF deficient mice are resistant to 
EAE (Codarri et al., 2011; McQualter et al., 2001; Ponomarev et al., 2007). This 
concept was supported by experiments demonstrating GM-CSF neutralizing 
antibodies abrogated disease activity (McQualter et al., 2001) whilst systemic 
administration of GM-CSF accelerated disease onset (Marusic et al., 2002; 
McQualter et al., 2001).  Hesske et al. also found that treating mouse primary 
microglia cultures with GM-CSF induces their differentiation into inflammatory 
dendritic cells suggesting this was how it contributed to disease development 
(Hesske et al., 2010). To emphasize the crucial role of T cell derived GM-CSF in 
EAE, and potentially in MS, Ponomarev et al. (2007) demonstrated that myelin 
basic protein (MBP)-specific T cells from GM-CSF deficient mice were unable to 
adoptively transfer EAE to wild type mice (Ponomarev et al., 2007). Very 
recently a discrete GM-CSF expressing Th cell subset was identified in which GM-
CSF expression is under the control of IL-23 and IL-1β. In agreement with 
previous studies selective ablation of this Th cell subset reduced accumulation of 
phagocytes but not T cells in the CNS of mice with EAE. An observation 
indicating GM-CSF is not just a marker for encephalitogenic T cells, but plays an 
important role in mediating inflammatory demyelination (Komuczki et al., 2019). 
On a similar note, conditional induction of GM-CSF in mature peripheral CD4+ T 
cells triggers a neuroinflammatory response characterised by myeloid cell 
recruitment, production of ROS and spontaneous neurological deficits (Spath et 
al., 2017). 
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In contrast, another study reported adoptive transfer of wild-type MOG–auto-
reactive T cells in to Csf2−/− mice resulted in monophasic disease characterised 
by an attenuated disease course, reduced recruitment of immune cells and less 
tissue damage in the CNS (Duncker, Stoolman, Huber, & Segal, 2018). 
Observations that led the authors to conclude: “GM-CSF drives chronic tissue 
damage and disability in EAE via pleiotropic pathways, but it is dispensable 
during early lesion formation and the onset of neurologic deficits...”. Further 
evidence of GM-CSF redundancy was obtained in an adoptive transfer model of 
EAE in C3HeB/FeJ mice (Pierson & Goverman, 2017). In this case, lack of GM-CSF 
signalling did not prevent EAE due to an IL-17 compensatory mechanism. In this 
model a critical step in disease development is GM-CSF mediated neutrophil 
recruitment into the brain, but disrupting GM-CSF signalling did not prevent EAE 
due to an IL-17 compensatory mechanism. This highlights the heterogeneity of 
EAE and how genetic background influences the relative importance of specific 
effector pathways in disease development inbred strains of mice (Pierson & 
Goverman, 2017). It is important to bear this in mind when attempting to 
extrapolate these observations to MS, for which EAE is at best an incomplete 
model. 
Nonetheless there is an increasing body of evidence implicating T- and B-cell 
derived GM-CSF as a factor contributing to the immunopathogenesis of MS. CD4+ 
Th cells are believed to play a key role in MS pathogenesis and their production 
of GM-CSF is stimulated by interleukin-2 (IL-2) expression of which is elevated in 
MS lesions. Moreover, IL2RA polymorphisms are important risk factors of MS 
(Hafler et al., 2007; Rose et al., 2007). Binding of IL-2 to its receptor stimulates 
STAT5 dependent production of GM-CSF by human Th cells in vitro and 
intriguingly, IL2RA MS-associated polymorphisms enhance the number of GM-CSF 
producing Th cells in healthy individuals (Hartmann et al., 2014). These 
observations led Hartmann and colleagues to speculate this represents a 
mechanistic connection between an immunologically relevant genetic risk factor 
and a pathologically important Th subset in MS (Hartmann et al., 2014).  
The role of STAT5 in determining encephalitogenicity of autoreactive Th cells 
was reinforced by studies in EAE (Sheng et al., 2014). This group reported Il-7-
activated STAT5 promotes GM-CSF secretion by Th cells and this was strikingly 
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diminished in STAT5 deficient CD4+ T cells. Additionally, adoptive transfer of in 
vitro polarised MOG-reactive CD4+ T cells into Rag2_/_ mice identified GM-CSF-
secreting Th cells as the most encephalitogenic when compared to traditional 
Th1 and the Th17 T cell subsets. These GM-CSF-producing cells potentially 
constitute a new Th cell subset with a unique differentiation and cytokine 
profile, defined in part by GM-CSF as a signature cytokine and co-expression of 
interleukin-3 (Sheng et al., 2014). The potential clinical significance of these 
observations is only now becoming apparent following reports that GM-CSF is 
present at considerably high levels in plasma and cerebrospinal fluid of patients 
with relapsing-remitting MS (Carrieri et al., 1998); GM-CSF immune reactive T 
cells are present in MS lesions (Vogel et al., 2015, 2013); the frequency GM-CSF 
producing T cells is increased in MS patients ( Rasouli et al., 2015; Restorick et 
al., 2017; Imitola et al., 2018; Ghezzi et al., 2019) ;and the recent identification 
of a disease associated subset of Th cells co-expressing GM-CSF and CXCR4 (Galli 
et al., 2019). The most obvious target for T cell derived GM-CSF within the CNS 
are microglia and macrophages, a view supported by the observation the 
phenotype of human macrophages exposed to GM-CSF in vitro is comparable in 
their expression of MHC II, CD40 and MR (mannose receptor) to macrophages 
present in MS lesions (Vogel et al., 2015).The same group also found the GM-CSF 
receptor on microglia in astrocytes and neurons in the rim of gray/white matter 
lesions   These in vitro and in vivo data support the conclusion that GM-CSF 
produced by T cells in the periphery has an important role in the hyperactivation 
of the immune system in MS (Carrieri et al., 1998; Rasouli et al., 2015; Vogel et 
al., 2013). 
 
There are also strong links between GM-CSF and B cell biology, a subject of 
increasing interest following the demonstration B cell depletion abrogates 
inflammation and clinical disease activity in MS. Harris et al. found GM-CSF 
promotes the survival of normal and malignant B cells in an autocrine fashion 
(Harris et al., 2000) and also behaves as a differentiation factor for cultured 
murine B cells. When combined with dextran-conjugated anti-IgD antibodies 
(alpha delta-dex), GM-CSF increases the IgM secretion in resting murine B cells, 
compared to alpha delta-dex, IL-1, and IL-2 only stimulation (Snapper et al., 
1995). There is a growing interest in clarifying the role of cytokine-defined B cell 
subsets in the pathogenesis of MS.  It has been shown that abnormal cytokine 
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production by B cells plays an important role in disease pathogenesis  (Bar-Or et 
al., 2010). In MOG-induced EAE, Hesske et al. demonstrated that subcortical 
injection with GM-CSF-producing B16 cells (mouse melanoma cells) promoted the 
accumulation of dendritic cells and exacerbated the disease (Hesske et al., 
2010). Recently, Li et al., identified a subset of pro-inflammatory GM-CSF-
producing B cells in patients with MS and found following B cell depletion pro-
inflammatory myeloid responses also diminished, presumably due to the loss of B 
cell derived GM-CSF  (R. Li et al., 2015).  The same group also found reciprocal 
regulation of GM-CSF and IL-10 production by human B cells via STAT5/6 
signalling. Individual or combined inhibition of STAT5/6 strikingly decreased the 
induction and production of GM-CSF, while simultaneously increasing IL-10 
production. It was also elucidated that GM-CSF is capable of inducing pro-
inflammatory myeloid cell responses (R. Li et al., 2015). Furthermore, these pro-
inflammatory responses decreased after anti-CD20 therapy (a mechanism to 
deplete B cells) in MS patients and remained diminished during B cell 
reconstitution (R. Li et al., 2015).  
1.3.1 GM-CSF as a therapeutic target in MS 
The evidence outlined above provides a logical rationale for pursuing GM-CSF 
signalling as therapeutic target in MS and other T cell mediated autoimmune 
conditions and several biologics targeting GM-CSF signalling have already been 
developed for possible use in rheumatoid arthritis, psoriasis and MS (Shiomi, 
Usui, & Mimori, 2016).  
GlaxoSmithKline (GSK) licensed MOR103 (otilimab), a high affinity recombinant 
human IgG1 antibody against GM-CSF. MOR103 binds to GM-CSF blocking its 
interaction with the receptor therefore abrogating signalling (Behrens et al., 
2015; Steidl, Ratsch, Brocks, Dürr, & Thomassen-Wolf, 2008). MOR103 initially 
entered clinical trials for rheumatoid arthritis (RA), there were no safety or 
tolerability issues and patients showed significant clinical improvement 
compared to placebo (Behrens et al., 2015). Based on the positive tolerability, 
safety, and efficacy data in patients RA, a phase1b trial commenced in patients 
with MS (Constantinescu et al., 2015). The goal of the trial was to determine the 
safety, immunogenicity and pharmacokinetics of MOR103 in MS. Adverse effects 
were mild or moderate, the most frequent was nasopharyngitis and overall the 
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antibody was well tolerated (Constantinescu et al., 2015). These outcomes are 
important since immune therapies can present unexpected or different adverse 
effects depending on the autoimmune condition (Aram et al., 2019). 
Mavrililumab is a human monoclonal IgG1 against GM-CSFRα initially licensed by 
Medimmune. Mavrililumab binds to GM-CSFRα preventing GM-CSF binding and 
abrogating signalling and like otilimab, was developed initially for rheumatoid 
arthritis. Mavrililumab showed a good safety and tolerability profile and 
significant efficacy compared to placebo (Burmester et al., 2013). Although of 
potential as an MS therapy, clinical trials of mavrilimumab are restricted to giant 
cell arteritis, an inflammatory disease affecting the large blood vessels of the 
scalp, neck and arm (Pupim et al., 2019). 
1.4 Microglia 
1.4.1 General introduction  
Microglia are the resident tissue macrophages of the central nervous system and 
represent 5-10% of the total brain cell population (Q. Li & Barres, 2018). The 
current consensus is microglia are derived from erythromyeloid precursors which 
generate yolk sack macrophages. Yolk sack macrophages are the immediate 
migratory precursors that enter the embryonic brain (Ginhoux & Guilliams, 
2016). Mouse studies demonstrate microglial population of the CNS coincides 
with the development of the cardiovascular system and precedes the 
appearance of astrocytes and oligodendrocytes and closure of the BBB (reviewed 
by Lannes et al., 2017; Petrik et al., 2013; Minocha et al., 2017). Under normal 
steady-state conditions microglia are self-renewing in the adult CNS (Ajami, 
Bennett, Krieger, Tetzlaff, & Rossi, 2007; Ginhoux et al., 2010).  Besides 
microglia, other three types of CNS macrophages exist: perivascular, meningeal 
and choroid plexus macrophages. These macrophages are found at the interface 
between the parenchyma and circulation but their function is not very well 
understood (Prinz, Erny, & Hagemeyer, 2017).  
1.4.2 Microglia function 
Microglia support a variety of functions in the developing and adult brain, such 
as support of CNS developments and synaptogenesis, homeostasis and sustaining 
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structure, adult neurogenesis and regeneration, and the most recognized role in 
response against pathogens (Ginhoux & Guilliams, 2016). Microglia are also 
involved in neurodegenerative diseases, stroke and trauma (Ginhoux & Guilliams, 
2016). The involvement of microglia in disease will be discussed in the next 
section entitled “Microglia in disease”. 
“Resting” microglia are dynamic cells, time-lapse imagining studies have shown 
that microglia survey the entire brain parenchyma every few hours 
(Nimmerjahn, Kirchhoff, & Helmchen, 2005; Wake, Moorhouse, Jinno, Kohsaka, 
& Nabekura, 2009). During this process microglia using their processes make 
contact with neurons, including synaptic clefts. Evidence from animal studies 
demonstrate that microglia are active players in synapse remodelling and 
maturation (Hoshiko, Arnoux, Avignone, Yamamoto, & Audinat, 2012; Paolicelli 
et al., 2011; Schafer et al., 2012). The interaction between CX3CL1 (fractalkine) 
expressed on neurons and its receptor CX3CR1 expressed on microglia appears to 
be important synapse architecture. Silencing CX3CR1 in mice was associated 
with increased density of dendritic spines on hippocampal CA1 neurons. This was 
accompanied with a decrease in microglial number and a build-up of immature 
synapses, resulting in loss of functional connectivity across brain regions and 
autism-like behaviour (Paolicelli et al., 2011; Yang Zhan et al., 2014). The 
mechanism through which CX3CR1 mediated microglial control of synapse 
function remains to be elucidated (Q. Li & Barres, 2018). Microglia are also 
involved in complement-mediated synapse pruning (Q. Li & Barres, 2018). Mice 
lacking the complement proteins C1q or C3 show impaired CNS synapse 
elimination in the visual system (Schafer et al., 2012; Stevens et al., 2007). C1q 
and C3 tag synapses for elimination, which are subsequently phagocytised by 
microglia. C1q-tagged synapses have been detected throughout the CNS during 
development, indicating that microglial synaptic pruning extends beyond the 
visual system. This hypothesis is supported by the observation that C1q KO mice 
present with spontaneous seizures and have an abnormal high number of 
excitatory synapses in the neocortex (Chu et al., 2010).  
Microglia are the professional phagocytic cells of the CNS.  Microglial 
phagocytosis contributes to embryonic and adult neurogenesis (Q. Li & Barres, 
2018). For example, it was showed that during cerebellar development, 
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microglia produce ROS which induce Purkinje neurons death. Subsequently, the 
dead neurons are engulfed by microglia (Marín-Teva et al., 2004). Steady-state 
microglia also sculpt the adult brain by phagocytosing apoptotic cells (Sierra et 
al., 2010). 
Microglial function is dependent upon microglial survival. CSF1R signalling is 
necessary for microglial development and maintenance (Chitu, Gokhan, Nandi, 
Mehler, & Stanley, 2016; Chitu & Stanley, 2017). Yolk sack macrophages require 
CSF1R signalling for proliferation, differentiation, and survival (Ginhoux et al., 
2010). The deletion of Csf1r in mice leads to a lack of yolk sack macrophages 
and subsequent absence of tissue resident macrophages, including microglia. 
These mice rarely survive after birth, the few surviving mice exhibit abnormal 
brain development and olfactory deficits (Dror Michaelson et al., 1996; Erblich, 
Zhu, Etgen, Dobrenis, & Pollard, 2011). Tonic CSF1R signalling is also essential 
for maintaining microglia in adult mice (Elmore et al., 2014). Pharmacological 
inhibition for 7 days depleted more than 90% of the microglial population in 
adult mice (Barres, 76). The CSF1R ligands are M-CSF and IL-34. Not much is 
known about the expression patterns of these microglial mitogens, although it is 
thought that neuronal cells and later the astrocytes are the main contributors 
(Lannes et al., 2017).   
The evidence presented above is compelling that a lack of microglia or 
dysregulation in microglial developments and function affect normal neuronal 
function. Moreover, rare point mutations in both copies of the human CSF1R 
cause acute loss of microglia visualised using Iba1 (Oosterhof et al., 2019). Iba1 
is a calcium binding protein expressed on macrophages/microglia involved in 
membrane ruffling and phagocytosis (Kanazawa et al., 2002). Increased Iba1 
expression was also detected on microglia in the facial nucleus after facial nerve 
axotomy (Ito et al., 1998).  Oosterhof et al. found that acute loss of microglia 
caused severe cerebral and cerebellar abnormalities, such as the absence of the 
corpus callosum and failure to develop parts of the cerebellum (Oosterhof et al., 
2019). But more recently, mice without microglia due to a deletion in the Csf1r 
enhancer showed no neurological or developmental abnormalities (Rojo et al., 
2019). The perpetual technological advances will be crucial to elucidate the 
roles of microglia. 
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Microglia are the primary innate immune effector cells in the CNS. Microglia 
initiate innate immune responses and mediate adaptive immune responses by 
engaging various pattern recognition receptors (PRRs) (Lannes et al., 2017). PRRs 
can sense endogenous danger-associated molecular patterns (DAMPs), such as 
heatshock proteins (Holtman et al., 2017). PRR also detect exogenous pathogen-
associated molecular patterns (PAMPs), which include microbial production such 
as proteins, lipids, saccharides and nucleic acids (Saijo, Crotti, & Glass, 2013). 
Signalling through PRRs, such as toll-like receptors (TLRs) activate microglia in 
the case of inflammation resulted from CNS infection or damage. Activated 
microglia exert their functions via phagocytosis of invading pathogens/tissue 
damage products and by secreting soluble factors such as cytokines and ROS/ 
RNS (Jiang, Jiang, & Zhang, 2014; Voet, Prinz, & van Loo, 2019). Activated 
microglia can have deleterious or beneficial effects, an aspect that will be 
focused on later.   
Signals from the surrounding environment drive microglia/macrophage 
heterogeneity. When microglia sense infection or injury, they become activated 
and migrate to the injury site (Voet et al., 2019). Initially, 
microglia/macrophages were categorised in two classes: M1- pro-inflammatory 
and M2- anti-inflammatory. Macrophages/ microglia are polarised towards an M1 
phenotype by TLR stimulation with microbial products such as LPS, alone or 
combined with IFN-γ. M1, or classically activated microglia/ macrophages 
produce pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, IL-12, and IL-
23, as well as chemokines, such as, CXCL2, CXCL4, CXCL9, CXCL10, CCL4, CCL5, 
and CCL8. Additionally, M1 microglia release other reactive nitrogen species, 
such NO, produced by inducible nitric oxide synthase. M1 microglia/ 
macrophages also show enhanced phagocytosis of pathogens and antigen 
presentation (Voet et al., 2019)  
M2 microglia/ macrophages also known as alternatively activated were initially 
observed after stimulation with IL-4 and IL-13 (Ransohoff, 2016; Stein, Keshav, 
Harris, & Gordon, 1992). M2 microglia/ macrophages release anti-inflammatory 
cytokines, such as IL-10, IL-13, and TGF-β. Additionally, M2 also produce 
neurotrophic factors, VEGF (vascular endothelial growth factor), EGF (epidermal 
growth factor) and IL-1RA (IL-1β receptor antagonist. Classic M2 markers include 
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arginase-1 and MR (mannose receptor, CD206). M2 microglia/ macrophages have 
immunoregulatory roles, including inhibition of inflammation, tissue 
remodelling, and promotion of angiogenesis. Nowadays, this simplistic view of 
microglia is challenged (Ransohoff, 2016). Microglia expressing M1 and M2 
markers simultaneously were detected in mice following traumatic brain injury 
and also at MS lesions (Kumar, Alvarez-Croda, Stoica, Faden, & Loane, 2016; 
Vogel et al., 2013). 
 
Until recently, it was very difficult to distinguish between microglia and other 
monocytes using phenotypical markers. Most studies based their discoveries on 
the fact that microglia in steady-state are CD45low or do not express CD44, Ly6c 
or CCR2. However, it should be taken in consideration that the expression or 
these markers changes in pathological conditions, making it impossible to 
discriminate between resident microglia and infiltrating myeloid cells (Korin et 
al., 2017; Masliah et al., 1991; Ponomarev, Shriver, & Dittel, 2006; Puli et al., 
2012). New technologies combining single cell RNAseq and mass cytometry have 
emerged to allow discrimination between microglia and other myeloid cells in 
steady-state and disease (Voet et al., 2019). In addition, a new microglia 
marker, Tmem119, compatible with immunocytochemistry and FACS technique 
was discovered (Bennett et al., 2016). 
1.4.3 Microglia in MS and EAE 
There is still a lot to be uncovered about the role of microglia in disease, but it 
is now recognised that microglia can be both protective and detrimental in 
pathological conditions. Regardless of the vast unknowns, it is well established 
that microglia are the primary responders in the CNS to danger signals generated 
in response to infection, neurodegeneration, ageing and trauma (Jiang et al., 
2014).  
Although MS is pathologically heterogeneous microglial activation is common to 
virtually all active lesions irrespective of their anatomical localisation and 
extends out into normal appearing white matter (Zrzavy et al., 2017a). Clusters 
of activated microglia or microglial nodules can also be found in apparently 
unaffected white matter, where they are associated with degenerating axons 
and oligodendrocytes and complement activation products in the absence of 
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infiltrating leuokocytes. It has been suggested these microglial clusters 
represent “pre-active lesions” that have the potential to develop into “full-
blown” demyelinating lesions (Ramaglia et al., 2012; S. Singh et al., 2013). Using 
Tmem119 as a microglia specific marker revealed large numbers of microglia are 
present at the advancing edge of active lesions. These cells express phagocytic 
markers implying they play an early role in lesion formation and tissue 
destruction (Zrzavy et al., 2017b) and express a pro-inflammatory profile 
characterised by proteins associated with phagocytosis (CD68), oxidative damage 
(p22hox, iNOS), antigen presentation and T cell stimulation (HLA-D, CD86), and 
increased iron loading (ferritin) (Zrzavy et al., 2017a). Chronic and slowly 
expanding lesions also feature a rim of activated microglia displaying a similar 
phenotype (Frischer et al., 2009). Van Loo and colleagues suggested that 
microglia are educated by soluble immune factors in MS to mediate pro-
inflammatory functions, but are not themselves primary inducers of disease 
(Voet et al., 2019).  
1.4.3.1 Mechanistical insights into how microglia contribution to lesion 
development in MS. 
The role of microglia in MS remains unclear, as it is impossible to study directly 
their contribution to disease development in the living patient. We are therefore 
dependent on data obtained using animal models to define how they contribute 
to the pathogenesis of T cell mediated neuroinflammation. Presentation of auto-
antigens to T cells by APC within the CNS is essential to reactivate 
encephalitogenic T cells and trigger an inflammatory response. The current 
dogma is that CNS antigen-reactive T cells are primed in the peripheral lymph 
nodes and then migrate into the CNS to be restimulated by any of a number of 
potential APCs (Dendrou, Fugger, & Friese, 2015). These include microglia which 
can present antigens and reactivate effector memory T cells, and up regulate 
MHC expression in EAE and MS (S. K. Singh et al., 2011; Sosa, Murphey, Ji, 
Cardona, & Forsthuber, 2013; Zrzavy et al., 2017a). Time course studies indicate 
microglia are the cells to engulf myelin debris post disease induction  (Sosa et 
al., 2013) and express co-stimulatory markers such as CD40, CD80, and CD86 
necessary to support efficient T cell stimulation (S. Singh et al., 2013; Wolf et 
al., 2018). However, whilst it would appear logical that microglia might 
therefore play a key role in disease induction recent studies indicate this is not 
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the case, as lack of microglial MHC class II expression is not required to initiate 
EAE (Wolf et al., 2018). This does not disqualify a role for microglia in antigen 
spreading during disease (Voet et al., 2019). On the contrary, using MHC I 
mismatch bone-marrow chimers to distinguish between resident microglia and 
invading monocytes revealed that microglia priming/activation by GM-CSF was 
essential for EAE onset (Ponomarev et al., 2007). Together these observations 
imply initiation of EAE may require an initial T cell reactivation event mediated 
by APC’s at the blood/CSF – brain interface. This provides a local, T cell derived 
source of GM-CSF that can then prime microglia to amplify the local 
inflammatory response and/or tissue damage. In GM-CSF deficient mice this can 
be circumvented by using LPS or CpG (oligodeoxynucleotide) to activate 
microglia to promote induction of clinical disease (Ponomarev et al., 2007) 
Once lesion formation is initiated microglial phagocytosis plays an important role 
in determining whether there is effective remyelination once the inflammatory 
insult resolves, as myelin debris must be cleared from the site of injury to allow 
for effective remyelination (Kotter et al., 2006; Voet, Prinz and van Loo, 2019). 
It was demonstrated that in EAE invading monocytes are damaging and initiate 
demyelination (Yamasaki et al., 2014). Same study also illustrates that microglia 
phagocyte myelin debris and promote remyelination (Yamasaki et al., 2014). 
Blockade of Trem2 in EAE, a receptor involved in phagocytosis and lipid 
metabolism, lead to an aggravated disease course and increased demyelination 
(Piccio et al., 2007). Taken together this data suggest that microglia play 
multiple and contrasting roles in EAE, a concept supported by studies 
investigating the effects of microglial depletion on disease development and 
pathogenesis.   
Using a transgenic mouse model in which microglia depletion is triggered by 
treatment with ganciclovir it was shown that depletion of microglia abolished 
microglial production of TNF-α, NO and CCL4 in organotypic cultures and 
repressed development of EAE (Heppner et al., 2005).  These data are consistent 
with the concept microglial activation in EAE contributes to recruitment of 
inflammatory cells and tissue damage. Similar results were obtained following 
pharmacological depletion of microglia reinforcing that they are necessary to 
drive disease progression (Nissen, Thompson, West, & Tsirka, 2018). However 
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this study should be interpreted with care as pharmacological inhibition of CSF1R 
in vivo not only depletes microglia in the CNS, but also monocyte-derived 
macrophages that would normally infiltrate the inflamed CNS. In contrast to this 
evidence that microglial activation is detrimental in EAE, Wlodarczyk and 
colleagues found intrathecal stimulation of CSF1R signalling with M-CSF and IL-34 
at EAE onset ameliorated neurological deficits and demyelination in the CNS. 
This effect was attributed to microglia identified by FACS on the basis of their 
low level of CD45 expression (Wlodarczyk et al., 2019). However one has to be 
careful when interpreting these data as microglia can up regulate expression of 
CD45 to become CD45high in EAE and other pathological conditions (Masliah et al., 
1991; Ponomarev et al., 2006; Puli et al., 2012). 
The introduction of new transcriptomic and mass cytometry tools is providing 
new insights into the heterogeneity of myeloid cells in the CNS and how they 
respond during ageing and neurological disease models (Mrdjen et al., 2018). 
This strategy revealed microglia were highly reactive in EAE and had a very 
different phenotype to “steady state” microglia in healthy age matched control 
mice. This included down regulation of CX3CR1, MerTK, CD14 and Siglec-H, 
whilst expression of CD44, CD86, PDL1 and CD11c was increased in EAE. This 
disease-associated change in microglial phenotype was global, affecting the 
entire microglial population in mice with EAE. This was in contrast to the 
situation in aged mice and neurodegenerative disease models that were 
characterised small populations of activated microglia that co-exist with cells in 
“steady state“. This is of great interest as it demonstrates that although lesion 
formation is focal it nonetheless impacts on microglial function throughout the 
CNS in animals with EAE. This may reflect a response to leuokocyte-derived 
cytokines and other factors diffusing from developing lesions to activate 
microglia at remote sites throughout the CNS (Becher, Spath, & Goverman, 2017; 
Becher et al., 2016; Mrdjen et al., 2018). Similar effects mediated by diffusion 
of soluble factors may well explain the widespread microgliosis seen in MS and 
augment disease chronicity and neurodegeneration (Mrdjen et al., 2018).  
 
In response to inflammation activated microglia can mediate a range of effector 
functions via activation of NF-κB, Jak/STAT, JNK, ERK1/2, and p38 dependent 
signalling pathways which under steady state conditions are regulated tightly 
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(Kaminska, Mota, & Pizzi, 2016). This results in generation of archetypical pro-
inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12, IL-23), chemokines (CCL2, 
CCL3, CCL4, CCL5, CCL7, CCL12, CCL22), and neurotoxic factors (ROS, RNS, 
glutamate) but the massive pool of invading leuokocytes that also produce these 
factors makes it difficult to assess the contribution to lesion formation made by 
microglia (Jiang et al., 2014; Voet et al., 2019). To add another layer of 
complexity many of these factors are pleiotropic. A classical example is TNF-α 
which can mediate pro-inflammatory or cell survival functions depending on 
receptor usage (Pegoretti, Baron, Laman, & Eisel, 2018; Probert, 2015). In 
globally TNF-α produced by microglia is dispensable for EAE, but ablation of the 
protective TNFR2 in microglia resulted in earlier disease onset associated with 
increased inflammation and demyelination (Gao et al., 2017; Wolf et al., 2017). 
Inhibition of the IL-1β cascade at disease onset also ameliorates EAE, as 
demonstrated by pharmacological inhibition of caspase 1 to block microglial 
NLRP3 inflamasome activation and pyroptosis (Sutterwala et al., 2006; Voet et 
al., 2018). However factors produced by activated microglia also orchestrate the 
behaviour of other cells and vice versa. For example activated microglia can 
induce astrocyte-mediated neuronal and oligodendrocyte cell death (Liddelow et 
al., 2017), whilst IL-23 produced by microglia modulates T cell 
encephalitogenicity during the effector phase of EAE (Becher, Durell, & Noelle, 
2003).  
A major executor of microglial/myeloid mediated tissue damage in these models 
is oxidative injury due to increased production of ROS, RNS and glutamate (Jiang 
et al., 2014). Pharmacological inhibition of NADPH oxidase to suppress 
production of ROS reduced white matter damage and attenuated the clinical 
course EAE (B. Y. Choi et al., 2015). Furthermore, microglial NADPH oxidase is 
responsible for continuing synaptic dysfunction in the hippocampus and cognitive 
impairment during the remission stage in EAE (Di Filippo et al., 2016). However 
once again it should also be appreciated that in addition to causing tissue 
damage and enhancing inflammation, microglia also express anti-inflammatory 
and neuroprotective factors in a context dependent manner. Mice lacking 
expression of the anti-inflammatory protein A20 on microglia exhibit NLRP3 
inflammasome hyperactivation and develop more severe EAE (Voet et al., 2018). 
Microglia also secrete factors that can promote remyelination; microglial IL-4 
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can promote oligodendrogenesis during EAE (Butovsky et al., 2006), whilst 
activin A secreted by M2-like microglia enhances remyelination (Miron et al., 
2013). 
There have been tremendous advances in elucidating microglial ontogeny and 
function but their roles in disease pathogenesis remain elusive and many 
questions remain unanswered (Voet et al., 2019). Addressing this question is 
complicated as many microglial markers are lost when they are cultured in 
isolation and it is difficult to replicate pathological environments in vitro (Jiang 
et al., 2014; Ponomarev et al., 2007; Voet et al., 2019). Moreover, the 
development of complex human microglial co-cultures that replicate the CNS 
environment is in its infancy. Fortunately, human and murine microglia they 
share a considerable number of disease relevant genes, including 76 associated 
with increased susceptibility to MS, meaning it is still relevant to used murine 
models to study microglial responses (Galatro et al., 2017; Gosselin et al., 2017; 
Voet et al., 2019).  
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1.5 Aims 
The goal of this project was to investigate how GM-CSF influences microglia 
phenotype and function. As outlined above, GM-CSF plays a crucial role in the 
development of EAE but the underlying mechanisms remain unknown. I therefore 
set out to address the following questions in myelinated cultures that replicate 
the cellular complexity of the CNS: 
1. Does GM-CSF mediated activation of microglia induce demyelination 
and/or axonal injury? 
2. Does GM-CSF prime microglia to mediate demyelination and/or axonal 
injury? 
3. Define the effector mechanisms by which GM-CSF mediates effects 
identified in points 1 and 2.  
These investigations demonstrated that GM-CSF sensitises for IFN-γ and TNF-
α to induce microglial, iNOS dependent cytotoxicity in the CNS, whilst 
simultaneously enhancing microglial phagocytosis. These effects were long 
lasting and are predicted to exacerbate lesion development and disease 
chronicity in EAE, and by extrapolation in MS. Future studies defining the 
mechanistic basis of these effects may identify new treatment strategies to 
slow if not halt accumulation of disability in MS.  
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Chapter 2 
Materials and methods 
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2 Materials and methods 
2.1 Animals 
Mice C57BL/6 wild type (WT) and Csf2rbtm KO on a C57BL/B6 background were 
obtained from Jackson Laboratories. Sprague Dawley (SD) rats were purchased 
from Harlan Laboratories (Blackthorn, UK). Animals’ age ranged between 8 
weeks and 1 year old. Animals were maintained and culled at the University of 
Glasgow Central Research Facility in accordance with the UK Home Office 
standards.   
2.2 Cell culture 
Cell culture preparation and maintenance was carried out aseptically. 
Instruments and dissection tools were sterilised before use with 70% methylated 
spirit or by autoclave. Tissue harvesting and dissection was performed at the 
bench. Cell harvesting and all in vitro work were carried out using laminar flow 
cabinets to prevent contamination. Cell culture media contained the antibiotics 
penicillin and streptomycin and were sterilized using a 0.22 μm vacuum filter 
(Millipore).  
2.2.1 Mouse myelinating cultures 
Myelinating cultures were prepared as described previously by (C. E. Thomson et 
al., 2008; Christine E. Thomson, Hunter, Griffiths, Edgar, & McCulloch, 2006). 
Mouse embryos (WT or KO) for myelinating cultures were collected on embryonic 
day (E) 13.5 with the day of the plugging considered E 0.5. Pregnant females 
were sacrificed by cervical dislocation and death was ensured by decapitation. 
The abdomen and dissection tools were sterilised with 70% methylated spirit. An 
incision was made in the inguinal area of the animal and the skin and abdominal 
wall were cut in a V close to expose the embryos. The gravid uterus was 
removed and placed in a petri dish on ice. Once the embryos were removed from 
the embryonic sacs, they were place in a 35 mm petri dish containing HBSS with 
     and      (on ice). The embryos were dissected under the microscope using 
forceps and pointed-tweezers. Initially, embryos were decapitated with a cut 
rostral to the cervical flexure to preserve the medulla. The skin covering the 
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spinal cord was gently removed longitudinally and the cord was carefully lifted 
out. Spinal cords were stripped off meninges along with the dorsal root ganglia 
and placed in a bijou with 2 ml HBSS (Hank’s balanced salt solution, Invitrogen) 
without      and      and enzymatically dissociated with 2.5% trypsin (Sigma) 
for 15 min at 37  and 7%    .  The enzymatic reaction was stopped with 2 ml of 
a solution containing 0.52 mg/ml soybean trypsin inhibitor, 3.0 mg/ml bovine 
serum albumin, and 0.04 mg/ml DNase (all from Sigma).  The digested tissue and 
all the media present in the bijou were transferred to a 15 ml tube and 
triturated to obtain a single cell suspension using a sterile glass Pasteur pipette.  
Five ml of plating media (PM) (50% DMEM, 25% horse serum, 25% HBSS with      
and     ) were added to the cell suspension. The cell suspension was 
centrifuged at 141 g for 5 min at room temperature.  After centrifugation the 
supernatant was removed, and the pellet was resuspended in 3 ml of PM.  Viable 
cells were counted using trypan blue viability dye (Sigma) (1: 1 cell suspension 
to dye) on a haemocytometer.  The cell suspension was further diluted to 1.5 
million viable cells/ml.  The cells were plated at a density of 150,000 
cells/coverslip on poly-L- lysine coated coverslips into 35 mm Petri dishes (3 
coverslips/ dish) and left to adhere for 3 hours at 37  and 7%    .  After the 
appropriate time has passed 300 µl PM and 600 µl differentiation media (DM+) 
(DMEM 4500 mg/ml glucose, 10 ng/ml biotin,0.5X N1 supplement, 50 nM 
hydrocortisone, and 0.1 µg/ml insulin (all reagents from Sigma) were mixed and 
gently added to each petri dish. Cultures were fed 2-3 times/week with DM+ for 
the first 12 days and with DM without insulin (DM-) afterwards.  During each feed 
500 µl of old media was withdrawn and replaced with fresh media. Cultures were 
kept in a humidified incubator at 37  and 7%     (C. E. Thomson et al., 2008; 
Christine E. Thomson et al., 2006). 
Glass coverslips were prepared in advance and stored at 4   . Boric acid buffer 
concentration at pH 7.4 was made by dissolving sodium tetraborate and boric 
acid in distilled water. PLL was dissolved in boric acid buffer to give a final 
concentration of 13 mg/ml. Glass coverslips (13 mm diameter; VWR 
International) were coated in the PLL mixture for at least 2 hours at 37 . Next, 
coverslips were rinsed three times with sterile water and plated into 35 mm 
petri dishes. Coverslips were allowed to dry in a sterile environment. Prepared 
plates were sealed and stored at 4  until ready to be used.  
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2.2.2 Rat myelinating cultures 
2.2.2.1 Neurospheres 
Neurospheres were generated using the methods described by Sorensen et al., 
2008 utilising the corpus striatum of post-natal day one (P1) rats (Sorensen et 
al., 2008). P1 rats were culled by intraperitoneal injection of Euthanal and 
decapitated. Brains were excised and transferred to a petri dish containing cold 
Leibovitz’s L-15 media (Invitrogen). With the help of a scalpel, the brain was 
separated in the two cerebral hemispheres. The part of the cortex where the 
striatum is located was isolated by cutting coronal segments through the cortex 
at the corpus callosum and just prior to the olfactory bulb. The striatum was 
then excised out of the cortex and transferred into a bijou containing 1 mL of 
Leibovitz’s L15 media, on ice. One flask of neurospheres requires 5-6 striata. 
The striata were mechanically dissociated into a single cell suspension by 
triturating repeatedly using a glass Pasteur pipette. The cell suspension was 
transferred into a 15 ml centrifuge tube and centrifuged at room temperature 
for 5 min at 136 g. The supernatant was discarded and the pellet was 
resuspended in 2 ml of neurosphere media (NSM). The NSM is composed of 
DMEM/F12 (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12) (1:1, 
DMEM containing 4500 mg/l glucose), supplemented with 7.5% NaHCO3, 2 mM 
glutamine, 5000 U/ml penicillin, 5 µg/ml streptomycin, 5.0 mM HEPES, 0.0001% 
bovine serum albumin (BSA) (all from Invitrogen), 25 g/ml insulin, 100 g/mL 
apotransferrin, 60 M putrescine, 20 nM progesterone, and 30 nM sodium selenite 
(all from Sigma). Next, the cell suspension in NSM was enriched with 4 µL of EGF 
(20 ng/mL mouse submaxillary gland epidermal growth factor from R&D 
Systems). The cell suspension was added into a 75 cm3 uncoated tissue culture 
flask (Greiner), already containing 18 ml of NSM, preheated at 37 . The 
neurosphere cultures were maintained in a humified incubator at 37  and 7% 
    and fed twice a week with 5 ml NSM and 4 µL EGF. By visual inspection, 
after 7- 10 days the neurospheres grew sufficiently large to be plated down and 
grow astrocytes.  
2.2.2.2 Neurosphere-derived astrocyte monolayer  
Astrocytes were differentiated from neurospheres as described by Thomson et 
al., 2008 (C. E. Thomson et al., 2008). Glass coverslips were prepared similarly 
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as described before for mouse myelinating cultures with some exceptions. 
Distilled water instead of boric acid buffer was used to dissolve PLL and the 
coverslips were plated in 24 well plates. When the neurospheres were ready to 
be harvested, the flasks were scraped using a cell scraper (Greiner). One flask of 
neurospheres would typically yield 5- 6 24 well plates of astrocyte monolayers. 
The cell suspension was placed into a 50 ml centrifuge tube and centrifuged at 
136 g for 5 minutes at room temperature. The pellet was dislodged using a glass 
Pasteur pipette resulting in a single cell suspension. The suspension was diluted 
to yield 12 ml per 24 well plate with low-glucose DMEM supplemented containing 
10% foetal bovine serum and 2 mM L-glutamine (DMEM-FBS) (Sigma Aldrich). Each 
well was filled with 0.5 ml of cells suspended in DMEM-FBS followed by 0.5 ml of 
DMEM-FBS. The plates were placed in a humified atmosphere at 37  and 7% 
   . The monolayer was fed twice a week by replacing half of the media with 
fresh DMEM-FBS until it reached confluence. Typically, confluency was reached 
after 7- 10 days. As the astrocyte monolayer did not undergo cell-specific 
selection, other CNS cells can be present in small numbers. According to data 
previously produced in our lab by Daniel McElroy, the major contaminants at 7 
DIV are oligodendrocyte lineage cells.  
2.2.2.3 Seeding of embryonic spinal cord cells on astrocyte monolayer  
Time-mated female SD rats were sacrificed by     asphyxiation at E15.5. 
Embryos were removed and cells were prepared following the same procedure as 
described above for mouse myelinating cell cultures with a difference in the 
enzymatic digestion. Collagenase I (1.33%, 100 µl, Invitrogen) and trypsin were 
necessary for enzymatic digestion.  
Coverslips covered with a neurosphere-derived astrocyte monolayer prepared as 
described in section 2.2.2.2 were removed from the 24 well plates with 
sterilised tweezers and transferred into 35 mm petri dishes (3 per dish). Fifty µl 
(150,000 cells) of the spinal cord suspension was added onto each coverslip. The 
coverslips were incubated for 2 hours at 37  to allow adherence to the 
monolayer. The next steps comprising of the maintenance of the cultures were 
identical to the ones described above for mouse myelinating cultures.   
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2.2.3 Mouse primary microglia cultures  
Primary mouse mixed glial cultures were prepared as described by Nicol et al., 
2018 (Nicol et al., 2018). P2 C57BL/6were culled using an intraperitoneal 
injection of Euthanal and decapitated. Brains were extracted with caution to 
avoid damaging the cortices and placed a petri dish and were transferred to a 
laminar flow cabinet. Five-six brains were sufficient to yield a flask of mixed 
glial cultures. Brains were rolled on sterile filter paper to remove the meninges 
and vasculature, before placing into a 50 ml centrifuge tube already containing 
warm DMEM containing 10% FBS and 1% penicillin/ streptomycin (total volume 
brains and media 20 ml). To mechanically dissociate, brain tissue was triturated 
vigorously using a 10 ml pipette for 2 mins and subsequently passed through a 40 
µm cell strainer (aiming for a single cell suspension). The single cell suspension 
was centrifuged at 300 g for ~7 min, and cells were re-suspended in a total 
volume of 40 ml per 175 cm2 flask (Corning). Cells were left for 1 week for the 
astrocyte layer to become confluent with microglia sitting mainly on the top. To 
increase the number of microglia in the mixed glial prep, 7 days later the media 
of each 175 cm2 flask was refreshed by adding 5 ng/ml of murine GM-CSF 
(Immunotools). The cells were left in the GM-CSF-enriched media for one more 
week, to increase the yield by 5-6-fold. Microglia were removed by “shaking” 
overnight in an orbital shaker incubator (37 , 100 rev per min, but no CO2). To 
compensate for the difference in CO2 HEPES was added to the media (50 mM 
final) just prior to shaking the cells overnight. Following overnight shaking, the 
supernatant was collected from the flasks (containing the dissociated microglia). 
Microglia were centrifuged and cells were re-suspended in media (10% FBS) 
without GM-CSF and counted using the haemocytometer and Trypan blue stain. 
Cells in media containing FBS were plated in 96 well plates (Greiner, for 
microscopy) at a density of 50,000 cells per well and left to adhere for 2 hours. 
After the cells adhered, media containing FBS was washed off and replaced with 
100 µl of DMEM containing only 1% penicillin/ streptomycin. Cells were 
maintained at 37  and 7%    . As verified by Nicol et al., 2018 using flow 
cytometry, microglia cultures consistently exceeded a purity of at least 95%.  
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2.3 Cell culture treatments  
2.3.1 Mouse myelinating cultures 
2.3.1.1 Developmental setting treatments 
Mouse myelinating cultures (one petri dish per experimental condition) were 
treated with mouse recombinant GM-CSF (Immunotools) at a final concentration 
of 100 ng/ml. Treatment started at DIV 6 when myelination had not begun, and 
axonal density was not maximal until 24 DIV. 
2.3.1.2 Mature setting treatments 
Mouse myelinating cultures (one petri dish per experiment condition) were 
treated with 100 ng/ml GM-CSF (Immunotools) at 24 DIV when myelination was 
established, and axonal density reached its peak. The duration of the treatment 
varied depending on the experimental design. Detailed descriptions of each 
experiment can be found in the results section. Briefly, the cells were either 
treated with GM-CSF alone or in the case of the GM-CSF priming experiments in 
combination with mouse recombinant interferon-γ (IFN-γ, R&D Systems) 100 
ng/ml, mouse recombinant tumour necrosis factor α (TNF-α, R&D Systems) 25 
ng/ml, 1 µg/ml LPS (lipopolysaccharide, Sigma), or 10 µg/ml poly I:C 
(polyinosinic:polycytidylic acid, Sigma).  
2.3.2 Rat myelinating cultures 
Rat myelinating cultures (one petri dish per experiment condition) were 
primed/unprimed with rat recombinant 100 ng/ml GM-CSF (Immunotools) from 
24 DIV until 30 DIV. At 30 DIV the cultures were treated with various 
combinations of rat recombinant interferon-γ (IFN-γ, R&D Systems) 100 ng/ml 
and rat recombinant tumour necrosis factor α (TNF-α, R&D Systems) 25 ng/ml 
for 72h. 
2.3.3 Mouse primary microglia 
Mouse primary microglia (one well per experimental condition) were 
primed/unprimed with mouse recombinant 100 ng/ml GM-CSF (Immunotools) 
from 0 DIV (plating) until 3 DIV. At the end of the priming period the cells were 
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treated with various combinations of with mouse recombinant interferon-γ (IFN-
γ, R&D Systems) 100 ng/ml and mouse recombinant tumour necrosis factor α 
(TNF-α, R&D Systems) 25 ng/ml for 72h. 
2.4 Cell culture assays  
2.4.1 Phagocytosis assay 
Mouse myelinating cultures (one petri dish per experiment condition) were 
primed with 100 ng/ml GM-CSF from DIV 24 until DIV 30. At 30 DIV various 
phagocytic material were added for 2 hours as described below. At the end of 
the assay coverslips were fixed with 4% paraformaldehyde (PFA) and processed 
for immunocytochemistry. Coverslips were imaged as described in the section 
2.5.1.2 and manually quantified. All reagents used for immunocytochemistry 
were maintained at 7.4 pH to avoid pHRodo activation and subsequent 
fluorescence when outside the cell.  
2.4.1.1 Fluorescently-labelled latex beads  
Latex beads (Polysciences) with a diameter of 1 μm were added to GM-CSF 
primed and unprimed cultures (3 x     beads per petri dish). The stock beads 
solution was dissolved directly in media before use. 
2.4.1.2 pHRodo labelled E. coli particles 
pHrodo labelled E. coli particles (Thermofisher) were reconstituted in PBS (pH 
7.4) and used at a final concentration of 0.1 mg/ml. The tubes containing the E. 
coli particles were vigorously vortexed to disintegrate the large aggregates 
which could interfere with phagocytic process. 
2.4.1.3 pHRodo labelled myelin particles 
Rat myelin extracted and labelled with pHRodo as detailed in section 2.6.1 was 
added to GM-CSF primed and unprimed cultures at a final concentration of 0.1 
mg/ml. As described above, the tubes containing labelled myelin were 
vigorously vortexed before use, to disintegrate large aggregates.  
 
57 
 
2.4.2 Lactate dehydrogenase (LDH) cytotoxicity assay 
Cell viability was assessed using a lactate dehydrogenase (LDH, Promega) kit 
following the manufacturer’s instructions. Briefly, 25 µl of cell supernatants 
(three technical repeats) were pipetted in a flat bottom 96 well plate (Corning).  
Next, 25 µl of CytoTox 96® Reagent were added to each sample well. The plate 
was covered and incubated for 30 mins in the dark at room temperature. At the 
end of the incubation period, the reaction was stopped with 25 µl of Stop 
Solution. Any large bubbles were pierced using a syringe needle. The absorbance 
was recorded at 492 nm using a Tecan Sunrise microplate reader. Additionally, 
cells lysed with 10X lysing buffer 1 hour prior to the start of the assay served as 
the maximum LDH release control. Media was used as a negative control. To 
evaluate the results the percentage cytotoxicity was calculated. Initially, the 
average value of the culture media background was subtracted from all 
experimental values. To compute percentage cytotoxicity the following formula 
was used: Percentage cytotoxicity=  
                        
                   
 x 100.  
2.4.3 Griess assay  
The levels of nitric oxide (NO) in culture supernatant were detected using nitrite 
(NO2
–) as a surrogate readout. NO2
– was measured using the Griess Reagent 
System (Promega) according to the manufacturer’s protocol. Prior to the start of 
the assay NO2
– standards were made by dissolving the nitrite standard stock. 
Twenty-five µl of fresh cell supernatants (three technical repeats) and standards 
were pipetted in a flat bottom 96 well plate (Corning). Next, 25 µl of 
sulphanilamide solution were added to each sample well. The plate was covered 
and incubated for 5-10 min in the dark at room temperature. At the end of the 
incubation period, 25 µl of NED solution were dispensed to each well. The 
absorbance was measured at 570 nm using a Tecan Sunrise microplate reader. A 
standard curve was generated to calculate the amount of NO in each sample. 
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2.5 Immunocytochemistry and Microscopy  
2.5.1.1 Staining  
At the end of the treatment, coverslips were fixed and stained with antibodies 
to perform immunofluorescence microscopy. All staining procedures were 
performed at the bench. Media was removed from culture dishes and depending 
on the antibody’s specifications (Table 2.1), the cells were fixed for 10 min with 
4% PFA at room temperature or acetone at -20 . When PFA was used, the 
fixation step was followed by 3 washes with PBS and permeabilization with 
Triton X-100 0.5% (Sigma Aldrich) for 10 mins. Coverslips were then washed 
again (x3) with PBS and blocked for 1 hour in blocking buffer containing (1% BSA 
(bovine serum albumin), 10% horse serum, in PBS. If acetone was used as a 
fixation method, the permeabilization step was not required. Acetone was 
washed off with PBS and the coverslips were transferred into blocking buffer. 
Next, the coverslips were incubated overnight 4  at in 50 µl primary antibody 
(Table 2.1) dissolved in blocking buffer. The following day, coverslips were 
washed three times in PBS and incubated with fluorescently-tagged secondary 
antibodies (Table 2.2), diluted in blocking buffer, for 30 mins in the dark at 
room temperature. Secondary antibodies were washed off 3X with PBS and a 
final wash in distilled water and mounted on glass slides (Thermofisher) using 
Mowiol 4-88 + DAPI (4',6- Diamidino-2-Phenylindole, Dihydrochloride) (Sigma). 
When cells were grown in a 96 well plate the staining procedure was identical, 
except for the mounting step. Instead of using Mowiol + DAPI, the nuclei were 
identified with Hoechst stain (1: 10,000 in PBS, Thermofisher) for 10 min in the 
dark. the Hoechst solution was washed off and replaced with PBS.  
2.5.1.2 Imagining and quantitative analysis 
Olympus BX51 fluorescent microscope and Ocular software were used to image 
and capture all cells grown on glass coverslips. Quantitative analysis of each 
experiment was performed by taking 10-5 random images of each coverslip 
(depending on the number of experimental conditions) at x20 magnification. 
Therefore, the number of images between experiments varied between 15 to 30 
(3 coverslips per condition).  
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Pipelines developed for CellProfiler software (http://www.cellprofiler.org/) 
were used to measure fluorescence intensity of each antibody staining. The 
pipelines quantified pixel intensity from individual colour channels; pipelines can 
be downloaded from https://github.com/muecs/cp. The percentages of 
myelination and axonal density were quantified using myelin.cp pipeline. The 
total cell number was determined using dapi.cp which counts DAPI positive 
nuclei. The number of cell positive for a marker of interest was determined by 
manual counting.   
Antigen Host Isotype Dilution Fixation Source 
Catalog 
number 
CD45 Rat IgG2b 1 in 300 Acetone Biorad MCA1388 
Dectin2 Rat IgG2a 1 in 100 PFA Miltenyi 130-094-481 
Iba1 Rabbit IgG 1 in 800 PFA Wako Chem 019-19741 
iNOS Rabbit IgG 1 in 100 Acetone Abcam ab15323 
MOG Mouse IgG2a 1 in 500 PFA Hybridoma Z2 clone 
NF-H Mouse IgG1 1 in 1000 PFA Biolegend SMI 31P 
 
Table 2.1. Primary antibody list  
Antibody 
AlexaFluor 
488 
AlexaFluor 
568 
Goat-anti-mouse IgG1    +   
Goat-anti-mouse IgG2a  +     
Goat-anti-rabbit IgG  +     
Goat-anti-rat IgG    +   
 
Table 2.2. Secondary antibody list. All secondary antibodies were purchased from 
Thermofisher and used at a dilution of 1:600. 
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2.6 Biochemical methods 
2.6.1 Myelin fraction extraction and labelling 
2.6.1.1 Myelin fraction extraction 
Spinal cords were removed from SD female rats (after embryo collection), 
placed in an autoclaved tube and immediately frozen at -80 . The spinal cord 
removal was performed on the bench with care to avoid any hair contamination. 
Utensils and animals were cleaned thoroughly with 70% methylated spirit. When 
sufficient cords were collected (5 spinal cords, aprox. 3g of tissue) they were 
thawed on ice. The tissue was weighted and place in 25 ml of pre-cooled 0.32 M 
sucrose solution containing 10 mM HEPES. The tissue was homogenised on ice 
using a polytron homogenizer at high speed. Prior to use, the homogeniser was 
soaked in Distel overnight, rinsed well, sprayed with ethanol and UVed. The 
tissue homogenate was divided in two equal parts and place in autoclaved 
centrifuge tubes. The tubes were spun in a fix angle centrifuge using a pre-
cooled J25.5 rotor at 20,000 rpm (48831g) for 30 min at 4 . The heavier/denser 
myelin fraction pelleted through the less dense 0.32 M sucrose solution. The 
supernatant was discarded and tubes containing the pellet were placed on ice. 
Each pellet was resuspended in 7 ml of 0.32 M sucrose. Gradient centrifuge 
tubes (compatible with Beckam SW41 rotor) were filled with 6 ml of 0.85 M 
sucrose 10 mM HEPES solution. The 0.32 M sucrose myelin homogenate was laid 
gently on top of the 0.85 M sucrose with a gun pipette set on gravity mode. The 
weight of the tubes was checked and in case of discrepancy more 0.32 M solution 
was added to balance the weights. The tubes were centrifuged in a swinging 
bucket rotor centrifuge (Beckam SW41 Ti) at 49,392 g for 45 min at 4 . The less 
dense myelin/fat fraction floated on top of the denser 0.85M sucrose while the 
rest of the unwanted material (nuclei, mitochondria etc.) sank to the bottom of 
the tube. After centrifugation, the interphase was carefully removed with a 
glass Pasteur pipette from each tube without disturbing the upper or the lower 
phase. The interphase was transferred into centrifuge tubes (compatible with 
J25.5 fixed angle rotor) and resuspended in 20 ml of sterile PBS. The tubes were 
centrifuged rotor at 48,831 g for 30 min at 4 . The supernatant was discarded 
after centrifugation and the pellet was resuspended in PBS as described above 
and centrifuged again. This process was repeated once more. The pellet was 
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resuspended in 10 ml of PBS, retaining a small aliquot to test the protein 
concentration. The protein concentration was evaluated using the BCA assay 
(described below). The entire myelin fraction obtained was diluted to 1 mg/ml 
in sterile PBS under a laminar flow hood. Finally, the myelin fraction sample was 
sterilised using an ARAD 225 X-ray generator and given a dose of 50,000 cGy. The 
myelin fraction was stored at -80 .   
2.6.1.2 pHrodo labelling 
The myelin fraction was conjugated with an amine-reactive pH-sensitive 
pHrodo® Green STP ester dye (Thermofisher). The STP ester reacts with primary 
amines on proteins, labelling them. The dye only fluoresces in acidic pH, an 
increase in fluorescence correlates with the acidification of the environment. 
The labelling reaction was performed according to the manufacturer’s protocol 
in a laminar flow hood to avoid contamination. Before performing the labelling 
reaction, the myelin fraction was centrifuged and resuspend in sterile 0.1 M 
sodium bicarbonate buffer pH 8.3 at 1 mg/ml. Five hundred μg of amine-reactive 
pHrodo™ Green STP ester was reconstituted in 75 μL of DMSO to yield 
approximately 8.9 mM. The dye solution was added to the myelin fraction, 
mixed by pipetting up and down and left to incubate for 45 min at room 
temperature protected from light. To remove the unconjugated dye the myelin 
fraction was centrifuged for 5 min at 94 g. The supernatant was discarded, and 
the pellet was resuspended in PBS pH 7.4. This process was repeated three 
times. At the end myelin was diluted in PBS pH 7.4 at 1 mg/ml, aliquoted in 
autoclaved Eppendorf tubes and frozen immediately at -80 . 
2.6.2 BCA assay 
The protein concentration in samples was determined using the Thermo 
Scientific™ Pierce™ BCA Protein Assay following the manufacturer’s protocol with 
some alterations. For protein quantification in the myelin fraction, due to its 
high lipid content 0.1% SDS final concentration (same as RIPA lysing buffer) was 
added to the samples (including the blank). As lipids interfere with protein 
reading, breaking down by detergent was necessary to impede light scattering 
artefacts.  
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Briefly, the first step was making bovine serum albumin (BSA) standards as 
detailed in the manufacturer’s instructions. The sample of interest was diluted 1 
in 2 and 1 in 10 to take into account if the protein concentration of the original 
sample exceeds the working range of the assay. Next, 12.5 µl of standards and 
un/diluted samples were added to a flat bottom 96 well plate (Corning). One 
hundred µl of WR (working reagent) were dispensed onto the plate. The plate 
was covered and incubated at 37  for 30 min. At the end of the incubation time 
the plate was cooled at room temperature and the absorbance was measured at 
570 nm using a Tecan Sunrise microplate reader. A standard curve was 
generated to calculate the protein concentration in each sample, accounting for 
the dilution factor.  
2.6.3 Western blotting  
2.6.3.1 Cell lysis 
Cells were lysed using RIPA buffer (Sigma). To ensure that sufficient amount of 
protein will be obtained, three cell culture dishes were used for each condition. 
Before lysis, culture dished were placed on ice, the supernatant was removed, 
and the coverslips were washed with ice-cold PBS. PBS was removed and 20 µl of 
RIPA buffer was added to each coverslip. Cells were scraped off with the pipette 
tip, triturated and transferred to Eppendorf tubes to be further triturated. A 
BCA assay was performed to measure the protein concentration and the samples 
were frozen immediately.  
2.6.3.2 Gel electrophoresis and protein detection 
Twenty-six µl of sample were mixed with 10 µl 4X Laemmli sample buffer and 4 
µl NUPAGE reducing agent (all from Thermofisher) and heated at 65  for 10 
mins. Chameleon duo pre-stained protein ladder (Li-cor) and equal amounts of 
protein were loaded onto a NUPAGE NOVEX Tris-acetate gel and the gel was run 
(4–12%; Invitrogen) at 200 volts for 45 mins. The gel was then transferred using 
the iBlot Western Detection system (Thermofisher) to a PVDF membrane. Next, 
the membrane was incubated in Odyssey blocking buffer (Li-cor) for 1 hour at 
room temperature. At the end of the blocking step, the membrane was 
incubated in primary antibody (Table 2.3) diluted in Odyssey blocking buffer (Li-
cor) overnight at 4ºC on a shaker. The membrane was quickly washed in PBS 
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followed by 5 washes (5 min) with PBST (0.5% Tween in PBS) on a shaker. 
Following the washes, the membrane was incubated in the appropriate NIR-
tagged secondary antibodies (Li-cor, Table 2.4) diluted in Odyssey blocking 
buffer for 1 hour at room temperature on a shaker. The membrane was washed 
as described above and incubated in PBS. The membrane was imaged using 
the Odyssey CLx Near-Infrared Fluorescence Imaging System. The fluorescence 
intensity of the protein bands was evaluated using densitometer Gels tool on 
Image J software. 
Antigen Host Isotype Dilution Source 
Catalog 
number 
b-actin Mouse IgG1 1 in 100 Abcam ab8226 
iNOS Rabbit IgG 1 in 100 Abcam ab15323 
 
Table 2.3 Primary antibody list for western blotting 
 
Antigen Host IRDye Tag Source 
Catalog 
number 
Mouse  Donkey 680RD (red) Li-Cor 926-68072 
Rabbit IgG Donkey 800CW (green) Li-Cor 926-32213 
 
Table 2.4 Secondary antibody list. All secondary antibodies were purchased from Li-
cor and used at a dilution of 1:10,000. 
2.7 Meso Scale Discovery assay 
To study the production of proinflammatory cytokines culture supernatant was 
screened using the MSD (Meso Scale Discovery) U-PLEX® platform according to 
the manufacturer’s instructions. Briefly, U-plex plates were coated with a 
cocktail of individual U-PLEX-coupled antibody solutions and incubated at 4ºC 
overnight. The plate was washed 3 times with PBST (PBS plus 0.05% Tween-20). 
Next, the plate was incubated with samples and standards for 1 hour on an 
orbital shaker at room temperature. Plate was washed as previously described 
and incubated with the detection antibody cocktail at room temperature while 
shaking for 1 hour. The detection antibody solution was washed with PBST 
followed by the addition of 1X MSD Wash Buffer. The plate was read and 
analysed on an MSD instrument.  
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2.8 Molecular biology 
2.8.1 Total RNA extraction 
RNA from myelinating cultures was extracted following the PureLink RNA Mini Kit 
(Ambion Life Technologies) protocol. Briefly, three petri dishes were used for 
RNA extraction for each experimental condition. Culture supernatant was 
removed and store for screening if necessary. Cells were lysed with 1 ml of 
TRIzol® Reagent Solution (Ambion™) for 10 min at room temperature. After 
complete lysis, 200 µl of chloroform were added for 5 min at room temperature 
to allow phase separation. The tubes were vigorously shacked for 15 seconds and 
centrifuged at 12,000 g and 4ºC for 15 min. Five hundred µl of the clear aqueous 
phase were transferred to a new RNAse-free Eppendorf tube containing an equal 
volume of 70% ethanol and vortexed. The content of the tube was pipetted into 
a spin cartridge containing RNA binding silica-based membrane and centrifuged 
at 12,000 g for 15 seconds at room temperature. The flow-through was discarded 
and the membrane was subjected to DNAse treatment for 20 min. Next, 700 µl 
of Wash Buffer I was added onto the column and centrifuged at 12,000 g for 30 
seconds. The column was inserted into a new tube and 500 µl of Wash Buffer II 
was added followed by centrifugation at 12,000 g for 30 seconds. The flow-
through was discarded and the wash step was performed one more time. The lids 
were removed, and tubes were centrifuged at 12,000 g for 2 mins to dry the 
membranes. The columns were inserted into collection tubes and 30 µl of RNAse-
free water was added onto the membranes and incubated for 3 mins at room 
temperature. The purified RNA was eluted by centrifugation at maximum speed 
or 2 mins. The RNA was quantified using NanoDrop 1000 Spectrophotometer, 
diluted according to downstream requirements and stored at -80°C.  
2.8.2 Gene expression by RNAseq 
2.8.2.1 RNAseq 
RNA from myelinating cultures treated with 100 ng/ml GM-CSF at 24 DIV for 24 
hours was extracted as described above. RNA quality and integrity were 
evaluated using Agilent Bioanalyser 6000 Nano LabChip platform system by 
Edinburgh Genomics at The University of Edinburgh. The sequencing was 
performed on Illumina HiSeq 4000 sequencing platform. Reads were adapter 
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trimmed using cutadapt version 1.3 with the parameters -q 30 -m 50 -a 
AGATCGGAAGAGC. Trimmed reads were aligned to the Mus musculus genome 
(Ensembl version 84) with star (version 2.5) using default parameters. Read 
counts were produced using htseq-count version 0.6.0, with parameters “ -m 
union -s reverse -i gene_id -t exon -r pos “ using the Ensembl gene annotation 
corresponding to Ensembl version 84 of the Mus musculus genome. 
2.8.2.2 RNAseq analysis 
Differential expression analysis was generated by Edinburgh Genomics using 
Bioconductor package EdgeR (version 3.10.5) with R version 3.2.1. The “glmFit” 
function was used to compare the treated to the control samples, and the cell 
culture ID of was taken into account. Genes with less than 20 reads mapping to 
them across all samples were excluded from the analysis. False discovery rate 
(FDR) was set at FDR < 0.05.  
The gene list produced by Edinburgh Genomics was used to perform pathway 
analysis using DAVID (The Database for Annotation, Visualization and Integrated 
Discovery; https://david.ncifcrf.gov/). Maintaining default settings, DAVID 
interpreted the differentially expressed gene list into biological pathways by 
utilising the KEGG Mus musculus database.  
2.8.3 qRT-PCR validation 
2.8.3.1 cDNA synthesis 
The Qiagen QuantiTect Reverse Transcription Kit and instructions were used to 
synthesise cDNA from 500 ng of purified RNA diluted in 12 µl with RNase free 
water. Two µL of genomic DNA wipe-out buffer were added to the sample and 
incubated 42°C for 2 minutes using a thermocycler. Samples were immediately 
cooled on ice. Next, 4 µl reaction buffer, 1 µl reverse transcriptase and 1 µl 
random primer mix were added to the reaction and incubated 42°C for 20 mins, 
then 3 mins for 95°C. cDNA was diluted 1 : 5 with RNAse-free water and stored 
at -20°C. 
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2.8.3.2 Primer design 
Mouse specific primers were designed using Primer3: WWW primer tool 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi) from FASTA 
sequences in the NCBI nucleotide database. The primer specifications can be 
found in table 2.5. BLAST tool was used to test primer specificity (BLAST; 
ttp://blast.ncbi.nlm.nih.gov/Blast.cgi). Primers were purchased from Integrated 
DNA Technologies. Prior to use, primers were dissolved in RNAse-free water at 
100µM concentration and made into a master mix containing f 1:1 forward and 
reverse primers. Primers were stored at -20°C. Primer sequences can be found 
in table 2.6.  
Primer size 18 to 23 base pairs (bp) (20 bp optimal) 
Melting temperature (Tm) 59.0°C to 61.0°C (60.0°C optimal) 
GC content 40 % to 65 % (50 % optimal) 
Max self-complementarity 2. 00 
Max 3’ complementarity 1. 00 
 
Table 2.5. Primer design parameters. 
Target 
Inner Primer (5' - 3') Outer Primer (5' - 3') 
Forward Reverse Forward Reverse 
18 S 
GACTCAACACGGGA
AACCTC 
TAACCAGACAAATCG
CTCCAC 
CGTAGTTCCGACCA
TAAACGA 
ACATCTAAGGGCATC
ACAGACC 
Tbt 
GACTCAACACGGGA
AACCTC 
TAACCAGACAAATCG
CTCCAC 
CGTAGTTCCGACCA
TAAACGA 
ACATCTAAGGGCATC
ACAGACC 
Mgl2 
TTGGAGCGGGAAG
AGAAAA 
AGGGAGAACAGGAG
GAGGTG 
TCGCCTCTGGTCATT
GCT 
TCACCTTCTGGCTCA
AGTCTC 
Ccr2 
GTGGGACAGAGGA
AGTGGTG 
TGAGGAGGCAGAAA
ATAGCAG 
CTTCATCAGGCACA
GAGAGC 
CCACAGACCACAAAC
CACAA 
Clec4n 
CAGAAGAGCGGTG
TGTTTCA 
ACATCATTCCAGCCC
CATT 
GGATGCTGCCCAAA
TCAC 
CAAGAAAATGCCCCC
AGAC 
Tnfsf8 
CTGGTGGGGTTCCT
GTTATG 
TGGATAGGGATTGG
TGTTCC 
ACAATGACCAGAAG
GCAAGG 
AATGGCAGGGGTAC
ACAAAG 
Csf2rb 
GAGCAAGTGGAGC
GAAGAGT 
GGAGCAAGGTGAGG
ATGAGA 
GAGCCAGACACCTC
ATACTGC 
GGTCCCTCTACTTGA
ACATTGG 
 
 Table 2.6. Primer sequences. 
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2.8.3.3 Primer testing by end-point PCR 
Primer specificity was tested using end-point PCR using cDNA containing the 
gene of interest. Specificity was considered accurate if only one amplicon was 
produced of the correct size. The PCR reaction was performed using REDTaq® 
ReadyMix™ PCR Reaction Mix (Sigma) following the manufacturer’s protocol. 
Briefly, 2 µl cDNA, 2 µl primer mix, 5 µl master mix and 1 µl nuclease-free water 
were mixed and placed in thermocycler. Cycling parameters were as follows: 5 
min at 50°C, 10 min at 95°C, followed by 15 seconds at 95°C, 1 min 60°C, 30 sec 
95°C, 15 seconds at 60°C repeated 40 times. The PCR products were run on an 
1.5% agarose gel using ethidium bromide labelling.  
2.8.3.4 qRT-PCR 
A panel of genes (table 2.6) differentially modulated in the RNAseq study were 
selected to be validated by qRT-PCR. Quantitative PCR was performed on an 
Applied Biosystems Fast Real-Time PCR System (ABI 7500) following the same 
cycling setting described in section 2.8.3.3. The reaction mix consisted of 7.5 µl 
1X SYBR Green master mix (Applied Biosystems), 10 ng cDNA template (2 µl), 50 
pmol/µL (0.3 µl) primer mix and 5.2 µl RNase-free water per sample. The 
difference in gene expression was assessed using quantitative analysis based on 
standard copy number method where the gene of interest was normalized to the 
housekeeping gene (18S or Tbt).  
2.9 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.0 software. 
Depending on the experimental set up, statistical significance was calculated 
using Paired Student’s T test, or one-way ANOVA followed by a Tukey post-hoc 
test. Significance was set at p < 0.05*. Data were expressed as means ± standard 
deviation (SD) except for MSD proinflammatory cytokine profiles. MSD data were 
represented as means ± standard error of the mean (SEM). 
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3 GM-CSF alone is incapable of inducing 
pathology in an in vitro model of the CNS, but it 
exerts a pronounced effect on microglia 
3.3 Introduction 
Recent studies identified GM-CSF as a key T cell-derived effector cytokine 
required to initiate tissue damage and neurological deficits in EAE (Ponomarev 
et al., 2007), but precisely how it contributes to disease development remains 
unclear. This influential publication emphasised effects of GM-CSF in the 
periphery where it was described as “licensing” myeloid cells to mediate tissue 
damage in the CNS (Ponomarev et al., 2007). In view of this report we addressed 
the question whether GM-CSF itself can mediate demyelination and/or axonal 
injury in the CNS. Microglia are the only cells in the CNS that express both GM-
CSF receptor subunits (Y. Zhang et al., 2014) leading us to predict microglia will 
be the only cells that respond directly to GM-CSF in myelinating cultures derived 
from embryonic mouse spinal cord (C. E. Thomson et al., 2008). We therefore 
used this culture system to determine if GM-CSF mediated activation of 
microglia had any impact on myelination and/or neuronal function/survival. 
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3.4 Results 
3.4.1 GM-CSF alone is insufficient to induce axonal or myelin loss 
To study the effects of GM-CSF on neurite outgrowth and myelination mouse 
myelinating cultures were treated with GM-CSF. In this in vitro model, neurite 
outgrowth is essentially complete by day in vitro (DIV) 15-17 and 
oligodendrocytes start myelinating axons from 15 DIV onwards (C. E. Thomson et 
al., 2008). Therefore, cultures were treated with 100 ng/ml GM-CSF from (i) 6 to 
24 DIV to determine if it affects neurite outgrowth or myelin formation in a 
developmental setting and (ii) DIV 24 until DIV 30 to determine if it affects 
established myelinated axons. Following treatment cultures were fixed and 
stained with antibodies specific to MOG (clone Z2) and phosphorylated heavy and 
medium chain neurofilament (clone SMI31) and axonal density and myelination 
were quantified from fluorescence micrographs as described in the materials and 
methods section 2.5. Cultures with axonal density below 50% and percentage 
myelination less than 1% were discarded.  
3.4.1.1 GM-CSF has no effect on myelin formation or axonal growth in vitro 
GM-CSF was found to have no effect on neurite outgrowth and myelination. 
There was no visible difference in staining for neurofilaments (SMI31) or myelin 
(MOG) between untreated control or GM-CSF treated cultures in a developmental 
setting (6 to 24 DIV) (Figure 3.1 a, b). This was confirmed when random fields of 
view were quantified for neurite density (untreated = 62.14 ± 4.590 %; GM-CSF = 
55.77 ± 9.345 %; p = 0.182) and myelination (untreated = 3.926 ± 2.170 %; GM-
CSF = 4.427 ± 2.202 %; p = 0.755) (Figure 3.1 c, d). 
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Figure 3.1. GM-CSF has no effect on myelin formation and axonal growth in vitro. (a, 
b) Representative images of myelinating cultures grown in the presence or absence 
of 100 ng/ml GM-CSF from 6 to 24 DIV. Images were aquired at 24 DIV. Myelin and axons 
were visualized with anti-MOG (clone Z2, green) and anti-neurofilament (SMI31, red) 
antibodies, respectively. GM-CSF had no effect on either (c) neurite out growth (p = 
0.182) or (d) myelination (p= 0.755). Data presented as mean ± SD from four 
independent experiments, p values were calculated using a paired Student's t test.  
 
3.4.1.2 GM-CSF does not induce demyelination or axonal loss in vitro 
Adding GM-CSF to myelinating cultures in which myelin was already established 
had no effect on myelination or neurite density. There was no reduction in 
either SMI31 or MOG staining in response to GM-CSF, demonstrating that GM-CSF 
did not mediate demyelination and/or axonal damage in the CNS (Figure 3.2 a, 
b). This was reflected by lack of change in neurite density (SMI31 staining; 
untreated = 69.28 ± 2.720 %; GM-CSF = 75.09 ± 3.789 %; p= 0.131) or myelination 
(MOG staining; untreated = 3.954 ± 2.418 %; GM-CSF = 5.426 ± 1.706 %; p= 0.096) 
(Figure 3.3 c, d).  
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Figure 3.2. GM-CSF does not induce demyelination or axonal loss in vitro. (a, b) 
Representative images of myelinating cultures grown in the presence or absence 
of 100 ng/ml GM-CSF from 24 to 30 DIV. Images were aquired at 30 DIV. GM-CSF had 
no effect on either (c) neurite density (p= 0.131) or (d) myelination (p= 0.096). Data 
presented as mean ± SD from three independent experiments, p values were 
calculated using a paired Student's t test.  
 
3.4.2 GM-CSF increases microglia number and induces 
morphological changes in these cells  
To investigate the effect of GM-CSF on microglia, microglia were visualised using 
antibodies specific for Iba1 and/or CD45.  
3.4.2.1 Extended exposure to GM-CSF augments microglial numbers and 
modifies their morphology  
Long term treatment with GM-CSF (6 to 24 DIV) was associated with a massive 
increase in microglial numbers (Figure 3.3). The number of CD45+ cells per area 
of interest increased >20-fold from 14.25 ± 7.386 in untreated cultures to 312.4 
± 30.61 in cultures treated with GM-CSF (Figure 3.3 a - c), an increase that 
resulted in a doubling of total (DAPI +ve) cell number per field of view (Figure 
3.3e). However only a relatively small percentage these CD45+ cells expressed 
detectable levels of Iba1, a classical microglial marker; the percentage of CD45+ 
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cells co-expressing Iba1 increased from 2.237 ± 0.905 % in untreated cultures to 
30.22 ± 0.567 % in the presence of GM-CSF (Figure 3.3 a - d). This increase in 
CD45+ microglia was associated with a pronounced change in morphology (Figure 
3.4). This change in microglia morphology was assessed on the basis of dividing 
them into three categories: amoeboid, ramified and rounded (Thored et al., 
2009). The majority of microglia in untreated cultures were ramified (85.59 ± 
5.253%), whilst in GM-CSF treated cultures most adopted a rounded morphology 
(95.87± 2.891%) (Figures 3.4 a – c). This was associated with a phenotypic change 
with respect to Iba1 expression. Virtually all Iba1+ microglia in untreated 
controls were also CD45+ (96.77± 2.636 %), but in GM-CSF treated cultures this 
was reduced to 25.78 ± 2.058 % (Figure 3.4 d). GM-CSF therefore induces the 
appearance/expansion of a population of CD45+, Iba1- cells. 
 
Figure 3.3. Extended GM-CSF treatment in a developmental setting increases the 
density of microglia in vitro. (a, b) Representative images of myelinating cultures 
grown in the presence or absence of 100 ng/ml GM-CSF from 6 to 24 DIV. Images were 
aquired at 24 DIV. Microglia were visualized with anti-Iba1 (red) and anti-CD45 (green), 
respectively. All nuclei were stained with DAPI (blue). GM-CSF treatment increased the 
(c) absolute density of microglia (p< 0.01), (d) the percentage of microglia as a 
proportion of all cells (p< 0.001) and (e) total cell density (p< 0.001). Data presented as 
mean ± SD from three independent experiments, p values were calculated using a 
paired Student's t test. AOI= area of interest. 
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Figure 3.4. GM-CSF induces a change in microglial morphology. (a, b) Representative 
images of myelinating cultures grown in the presence or absence of 100 ng/ml GM-CSF 
from 6 to 24 DIV.  Images were aquired at 24 DIV. Microglia were visualized with Iba1 
(red) and -CD45 (green) specific antibodies. Nuclei were stained with DAPI (blue). 
(c) Microglial morphology was quantified using criteria adapted from (Thored et al., 
2009). GM-CSF induces preferential expansion of microglia with a rounded morphology. 
(d) GM-CSF induces the expansion of Iba1- cells. Data presented as mean ± SD from 
three independent experiments. p values calculated using a (c) one-way ANOVA 
followed by a Tukey post-hoc test and (d) a paired Student's t test. AOI= area of 
interest. 
 
3.4.2.2 GM-CSF treatment in a mature context increases the number of 
microglia which are all Iba1 and CD45 positive 
To determine if GM-CSF has a similar effect on microglia in cultures that were 
already myelinated, cultures were treated with 100 ng/ml GM-CSF from 24 to 30 
DIV. In this treatment paradigm GM-CSF induced a smaller but still significant 
increase in CD45+ cell numbers (Figure 3.5 a – d). However, unlike the 
“developmental” setting, these CD45+ cells also expressed the classical 
microglial marker Iba1 (Figure 3.5 a, b). Higher expression of CD45, reflected in 
increased intensity of staining and increased numbers of CD45+ cells, in the 
developmental setting could be connected to the role of CD45 expression in 
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early myeloid progenitor cell differentiation (Broxmeyer, 1991; Shivtiel et al., 
2008). As all following experiments were performed using cultures at or beyond 
24 DIV these two markers will be used interchangeably to identify microglia in 
order to accommodate co-staining for other targets using antibodies with 
different isotypes and/or from other species. 
 
Figure 3.5. GM-CSF treatment in a mature context increases the number of microglia 
which are both Iba1 and CD45 positive. (a, b) Representative images of myelinating 
cultures grown in the presence or absence of 100 ng/ml GM-CSF from 24 to 30 DIV. 
Images were aquired at 30 DIV. Microglia were visualized with anti-Iba1 (red) and anti-
CD45 (green) antibodies, respectively. All nuclei were stained with DAPI (blue). As 
evident from the photomicrographs all microglia were Iba1 and CD45 double positive in 
both conditions. (c, d) GM-CSF increased the absolute number of microglia and 
percentage of microglia as a proportion of all cells (p< 0.01), (e) but had no effect on 
the total number of cells (p> 0.05). Data presented as mean ± SD from three 
independent experiments, p values were calculated using a paired Student's t test. AOI= 
area of interest.   
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3.4.3 Lack of GM-CSF signalling has no effect on microglia 
number and morphology 
To confirm the effects described above were dependent on signal transduction 
by GM-CSFR we used myelinating cultures derived from Csf2rb KO mouse 
embryos. These cultures lack a functional GM-CSF receptor and are hence 
incapable of responding to GM-CSF stimulation. Microglia in Csf2rb KO-derived 
cultures appear morphologically normal when stained with Iba1 and as 
anticipated, treatment with GM-CSF no longer induced changes in microglial 
numbers or morphology. The dominant microglial morphology remained ramified 
and Iba1+ microglial numbers remained unchanged; 16.61 ± 2.216 per area of 
interest in untreated cultures and 14.69 ± 3.994 in GM-CSF treated cultures 
(Figure 3.6). 
 
 
 
 
 
 
 
 
Figure 3.6. Abolition of GM-CSF signalling eliminates the impact of GM-CSF on 
microglial numbers and morphology (a, b) Representative images of Csf2rb KO 
myelinating cultures grown in the presence or absence of 100 ng/ml GM-CSF 
from 6 to 24 DIV. Images were aquired at 30 DIV. Microglia were visualized with 
anti-Iba1 and the nuclei with DAPI (blue). (c) Microglia density is unaltered by GM-
CSF in Csf2rb KO cultures (p> 0.05). (d) GM-CSF had no effect on microglial 
morphology in Csf2rb KO cultures (p> 0.05). Data presented as mean ± SD from 
three independent experiments. p values were calculated using (c) paired 
Student's t test and (d) a one-way ANOVA followed by a Tukey post-hoc test. AOI= 
area of interest.  
100 μm  Iba1/ DAPI Iba1/ DAPI  
Untreated GM-CSF a) b) 
c) d) 
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3.5 Discussion 
To study the effects of GM-CSF in the CNS in the absence of a peripheral immune 
compartment we used myelinating cultures generated from embryonic mouse 
spinal cord and investigated its effects in two treatment paradigms; a 
developmental setting (DIV 6 to 24) and an ‘adult’ setting (DIV 24 -30). In 
summary GM-CSF had no detrimental effects on quantities of anti-MOG positive 
myelin or phosphorylated neurofilament positive neurites (largely axons), and no 
obvious effect on the morphology of either, under either treatment paradigms. 
However, in both treatment paradigms, GM-CSF increased microglia numbers and 
induced a marked change in microglial morphology.  
These microglial responses are in agreement with published studies documenting 
GM-CSF as a microglial mitogen (Esen & Kielian, 2007) and the distribution of 
mRNA transcripts for GM-CSF receptor subunits which predicts only microglia 
express a functional, high affinity receptor (Zhang et al  2014). Attempts to 
validate microglial expression of GM-CSF receptor by immunofluorescence were 
unsuccessful as available antibodies were found to lack specificity. This may also 
explain why there is no immunohistological consensus as to expression of GM-CSF 
receptor in human brain. On one hand expression was reported to be restricted 
to a small subset of activated microglia and astrocytes in white matter, and 
undetectable in grey matter (Vogel et al., 2015), whilst according to Ridwan et 
al. GM-CSFRα is not only present in astrocytes, ependymal, choroid plexus cells 
but also uniformly in grey matter neurons (Ridwan et al., 2012). The presence of 
a functional GM-CSFR was also reported on cultured rat oligodendrocytes 
(Baldwin et al., 1993), but again this observation may be attributed to lack of 
reagent specificity and/or contamination by microglia.  
GM-CSF treatment also induced a profound change in microglial morphology from 
a ramified to round phenotype indicative of a change in their activation status 
(Davis, Foster and Thomas, 1994; Kettenmann et al., 2011). Rounded 
“activated” microglia are associated with lesion formation in MS as well as other 
neurodegenerative disorders. In the context of MS, Tmem119+, rounded/oval 
microglia containing myelin debris were identified in early active lesions, an 
observation suggesting a significant number of phagocytes at this point in lesion 
development are derived from resident microglia (Zrzavy et al., 2017a). 
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Rounded CD45+ microglia with negligent Iba1 expression were also reported to be 
increased in the brain parenchyma of APP/PS1dE9 mice, a transgenic mouse 
model of Alzheimer’s disease (Puli et al., 2012).  A corresponding increase in 
CD45 immune reactivity is also observed in AD brain (Masliah et al., 1991) ,whilst 
rounded Iba1+ CD68+ cells have been observed in the corticospinal tract of 
amyotrophic lateral sclerosis patients (Brettschneider et al., 2012). However not 
only does the functional relevance of these morphological changes in microglia 
remains controversial, but it is difficult to assess whether these 
     /     cells are indeed microglia or invading peripheral phagocytes. My 
study demonstrates there are not invading peripheral cells. In the wider context, 
treatment of microglia with other pro-inflammatory stimuli also results in a 
transition toward a rounded “activated” morphology, as demonstrated following 
treatment of primary rat microglia with LPS or mixed neuronal-glial cultures 
infected with Borna disease virus, where a transition towards a round 
morphology of microglia was observed (Ovanesov et al., 2006). 
 In this experimental setting lack of GM-CSF signalling had no effect on 
microglial development, no differences in microglial morphology or numbers 
were observed in Csf2rb KO myelinating cultures. Lack of GM-CSF signalling did 
not result in major difference in haematopoietic compartment, but induced lung 
pathology (Stanley et al., 2006). Microglia survival in the CNS is dependent on 
tonic signalling via the Csf1r receptor by M-CSF or IL-34 (Erblich et al., 2011;  
Elmore et al., 2014). 
However, although GM-CSF changes the morphology of microglia in myelinated 
cultures, it is clear that whatever pathways this response is associated with, in 
isolation this is unable to mediate tissue damage in this culture system, at least 
under the conditions investigated. This observation led us to explore in more 
detail how GM-CSF might contribute to the immunopathogenesis of 
demyelination and axonal injury in EAE.
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4 GM-CSF induces an immune signature and 
increases the phagocytic capacity of microglia  
4.1 Introduction 
The previous chapter demonstrated GM-CSF had no detrimental effect on 
neurites or myelin in vitro but increased microglial numbers and affected their 
morphology. The observation that GM-CSF targets microglia selectively is in 
accordance with data demonstrating microglia are the only CNS cell type 
expressing its high affinity receptor (Zhang et al 2014). However, in the absence 
of any obvious impact of GM-CSF signalling on cell survival, neurite outgrowth or 
myelin, it was important to determine the functional significance of this 
microglia response. Previous studies using isolated neonatal microglia led us to 
anticipate GM-CSF would up-regulate expression of genes encoding products 
associated with immune cell activation, migration, antigen presentation and 
phagocytosis. However, it was unknown if selective activation of quiescent 
microglia by GM-CSF in the CNS would trigger off-target transcriptional effects in 
other cell types. To investigate this and define the CNS transcriptome induced 
by GM-CSF, myelinated cultures (24 DIV) were treated with GM-CSF for 24h and 
then processed for RNAseq analysis.  
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4.2 Results 
4.2.1 RNAseq based analysis of the effects of GM-CSF in 
myelinated cultures 
To define the transcriptional response induced by GM-CSF an RNAseq study was 
performed on mouse myelinating cultures treated with100 ng/ml GM-CSF for 24 
hours (DIV 24 to 25) (Figure 4.1). Fluorescence microscopy using Iba1 as a 
microglial marker revealed short-term treatment with GM-CSF had no effect on 
either microglial morphology or density in these cultures (Untreated = 45.91 ± 
12.98 Iba1+ cells/AOI; GM-CSF = 54.34 ± 9.003 Iba1+ cells/AOI; p= 0.0839). The 
quality of the cell cultures was verified by quantifying neurite density, defined 
as neurofilament positive staining as a percentage of the total area of the AOI 
(Untreated = 75.61 ± 2.243 %; GM-CSF = 71.55 ± 4.758 %) and myelination, 
defined as MOG positive staining as a percentage of neurofilament positive 
staining (Untreated = 8.062 ± 1.780 %; GM-CSF = 7.495 ± 0.494 %) (Appendix 7.1). 
 
Figure 4.1. 24h GM-CSF treatment does not affect microglial number. (a, b) 
Representative images of mouse myelinating cultures grown in the presence or absence 
of 100 ng/ml GM-CSF for 24h from 24 DIV. Images were aquired at 24 DIV. Microglia 
were visualized with anti-Iba1 and the nuclei with DAPI (blue). (c) There was no 
difference in microglia number when GM-CSF was added for 24h compared to control 
82 
 
(p> 0.0839). Data presented as mean ± SD from three independent experiments, p 
values were calculated using a paired Student's t test. AOI= area of interest. 
200μm  
 
Input messenger RNA (mRNA) was quality controlled by Edinburgh Genomics who 
provided multi-dimensional scale (MDS) and volcano plots shown in Figures 4.2 
and 4.3, respectively. The MDS plot demonstrates GM-CSF treatment induced a 
consistent change in the transcriptional profile of myelinating cultures with 
untreated control samples clustering at the bottom of the plot, whilst GM-CSF 
treated were located towards the top.  This plot also indicates there was intra 
group variance. There was no correlation between the number of microglia in 
each biological replicate and the MDS plot distribution.  
After eliminating genes with less than 20 reads across all samples, 137 
differentially regulated genes were identified (108 up-, 29 down-regulated; ± >2 
fold change, FDR < 0.05) (Figure 4.3). A complete gene list can be found in 
Figure 4.4 but it was apparent from visual inspection this was enriched in 
immune related genes. These could be divided into three main categories: 
surface receptors, chemokines/cytokines and chemokine/cytokine receptors 
(Figure 4.5). The latter included Csf2rb (log2FC= 1.992) that encodes the 
common beta chain of the high affinity receptor for IL-3, IL-5 and GM-CSF 
(Figure 4.5). We also compared our transcript list with the Zhang et al. CNS 
RNAseq data base. This comparison revealed that 74.4 % of the genes are 
differentially most expressed by microglia. There was also a much weaker 
endothelial cell signature (18.9 % of the GM-CSF differentially modulated genes 
most expressed in endothelial cells). Only 7.7 % of all differentially expressed 
genes are expressed by neurons, astrocytes, oligodendrocyte progenitor cells 
and/or myelinating oligodendrocytes.  
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Figure 4.2. Multi-dimensional scale plot (MDS) showing the similarities in gene 
expression between untreated and GM-CSF treated samples used for RNAseq. 
Myelinating cultures (n = 3; numbered 1, 2 and 3) were untreated (blue) or treated with 
100 ng/ml GM-CSF (red) at 24 DIV for 24h. RNA was extracted at 24 DIV. Closer grouping 
indicates closer similarity of the transcriptional profiles.  Plot produced in edgeR by 
Edinburgh Genomics.  
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Figure 4.3. Volcano plot showing the distribution of differentially expressed genes in 
untreated and GM-CSF treated myelinating cultures. There were 137 differentially 
modulated genes (FDR< 0.05) in the RNAseq study; 29 genes down regulated (blue) and 
108 upregulated genes (red). The points in grey represent genes with a fold change less 
than 2 (log2 FC= 1). Plot produced in edgeR by Edinburgh Genomics.  
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Gene symbol logFC PValue FDR Zhang et al 
Mgl2 6.545283 4.51E-48 2.98E-44 microglia > 2 FPKM 
Ccr2 4.80661 1.53E-19 2.76E-16 microglia < 2 FPKM 
Ccr1 4.488449 2.03E-49 2.01E-45 microglia > 2 FPKM 
Mmp8 4.48116 2.42E-17 3.43E-14 microglia < 2 FPKM 
Gm16194 4.365004 1.05E-11 7.98E-09 not found 
Spint1 3.981624 1.11E-77 2.19E-73 same level 
Bcl2a1a 3.941623 5.54E-17 7.32E-14 microglia > 2 FPKM 
Trem1 3.747021 4.07E-30 1.61E-26 microglia < 2 FPKM 
Cd300lf 3.583926 1.85E-35 9.18E-32 microglia > 2 FPKM 
Gm1966 3.504852 3.55E-21 7.03E-18 not found 
Clec4n 3.448354 4.52E-28 1.49E-24 microglia > 2 FPKM 
Ccl12 3.40799 4.69E-16 5.81E-13 microglia > 2 FPKM 
Ccl6 3.406591 6.37E-18 1.05E-14 microglia > 2 FPKM 
Rab44 3.323056 2.37E-22 5.87E-19 same level 
Tnfsf8 3.222937 0.000151 0.026008 same level 
Tfec 3.199487 2.05E-17 3.13E-14 microglia > 2 FPKM 
4921529L05Rik 3.179897 0.000215 0.033788 microglia > 2 FPKM 
Cdh1 3.088047 3.18E-21 7.02E-18 same level 
Pilrb2 3.050372 5.94E-05 0.012135 microglia < 2 FPKM 
Serpina3f 3.028043 7.87E-05 0.015613 endothelial cells 
Scimp 2.973231 2.24E-11 1.58E-08 not found 
Clec10a 2.923192 4.70E-07 0.000161 microglia > 2 FPKM 
Cd74 2.852683 7.97E-28 2.26E-24 microglia > 2 FPKM 
Mmp13 2.470581 6.67E-14 7.34E-11 same level 
Amica1 2.444389 1.77E-08 8.35E-06 microglia < 2 FPKM 
H2-DMb2 2.412916 1.61E-15 1.88E-12 microglia > 2 FPKM 
Kynu 2.352608 1.39E-10 8.58E-08 same level 
Siglecf 2.333867 1.65E-08 8.13E-06 microglia > 2 FPKM 
Itgax 2.294974 3.40E-06 0.000964 microglia > 2 FPKM 
Adora3 2.24725 1.95E-08 9.00E-06 microglia > 2 FPKM 
Bcl2a1d 2.223198 3.31E-11 2.26E-08 microglia > 2 FPKM 
Fam167b 2.199645 1.68E-08 8.13E-06 microglia > 2 FPKM 
Gbp4 2.162368 4.49E-07 0.000156 endothelial cells > 2 FPKM 
Trim30c 2.090533 0.000127 0.023067 not found 
 
Figure 4.4a. Complete list of GM-SF differentially expressed genes. Transcripts are 
arranged in descending order based on their Log2FC. List is showing p-value and FDR 
(false discovery rate) for each gene. The last column represents the cellular expression 
of each gene in the resting CNS based on the Zhang et al. CNS transcriptomics data base 
(Y. Zhang et al., 2014). A transcript was considered most enriched in a particular cell 
type if its FPKM (Fragments per Kilobase of transcript per Million mapped reads) was 
higher than 2 and at least twice bigger than the second highest FPKM value. Out of 137 
genes, 121 were found in the Zhang et al. data base, 31 (34.4 %) had the same 
expression level in all cell types, 67 (74.4 %) were most enriched in microglia, 17 (18.9 
%) in endothelial cells, 3 (3.3 %) in oligodendrocyte progenitor cells (OPC), 2 (2.2 %) in 
neurons, 1 (1.1 %) in astrocytes, 1 (1.1 %) in MOC (myelinating oligodendrocytes). 
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Transcripts most enriched in microglia are highlighted in grey. The list continues on 
next 3 pages. 
Gene symbol logFC PValue FDR Zhang et al 
Ccl7 2.051569 1.69E-05 0.004041 microglia > 2 FPKM 
Csf2rb 1.992225 1.21E-13 1.26E-10 microglia > 2 FPKM 
F13a1 1.961582 6.54E-11 4.32E-08 microglia > 2 FPKM 
Tifab 1.957255 1.95E-13 1.94E-10 microglia > 2 FPKM 
Slfn3 1.919753 0.000178 0.029974 same level 
Ccl2 1.869522 7.51E-09 4.02E-06 microglia > 2 FPKM 
Il1rl2 1.831374 3.63E-07 0.000128 microglia > 2 FPKM 
Rasgrp4 1.828526 3.03E-07 0.000109 microglia/ endothelial cells > 2 FPKM 
Pilra 1.806432 0.000212 0.033659 microglia > 2 FPKM 
Gapt 1.79363 0.000183 0.03046 microglia < 2 FPKM 
Mrc1 1.778686 8.00E-09 4.18E-06 microglia > 2 FPKM 
Batf 1.775251 5.39E-07 0.000178 microglia > 2 FPKM 
Sla 1.749324 7.11E-12 5.88E-09 microglia > 2 FPKM 
Il18rap 1.734669 1.94E-12 1.75E-09 same level 
Ccl9 1.696582 7.97E-08 3.16E-05 microglia > 2 FPKM 
Mmp12 1.664113 6.36E-06 0.001704 microglia < 2 FPKM 
Scel 1.655481 1.90E-11 1.39E-08 same level 
I830077J02Rik 1.654689 2.15E-09 1.29E-06 not found 
Ccr5 1.653725 5.42E-08 2.29E-05 microglia > 2 FPKM 
Wfdc17 1.577435 5.05E-07 0.00017 not found 
Gm14005 1.548786 0.000202 0.032857 endothelial cells > 2 FPKM 
Prr15 1.458989 2.53E-05 0.005776 same level 
Cd274 1.45667 6.64E-08 2.69E-05 neurons > 2 FPKM 
P2ry14 1.451709 4.45E-05 0.009591 same level 
Msr1 1.41989 6.11E-08 2.52E-05 microglia > 2 FPKM 
Egr2 1.380003 4.47E-09 2.46E-06 microglia > 2 FPKM 
Ccl8 1.378187 8.32E-05 0.016167 microglia > 2 FPKM 
Rhoh 1.373598 3.53E-06 0.000986 microglia > 2 FPKM 
Fcgr2b 1.341499 4.59E-06 0.001263 microglia > 2 FPKM 
Clec7a 1.329271 1.60E-05 0.003864 microglia < 2 FPKM 
Pik3r6 1.328437 0.000263 0.040791 endothelial cells > 2 FPKM 
Cd33 1.3143 2.81E-07 0.000103 microglia > 2 FPKM 
Clec5a 1.306924 1.39E-07 5.40E-05 microglia > 2 FPKM 
Pstpip2 1.284738 1.18E-05 0.00296 OPC  > 2 FPKM 
 
Figure 4.4b. Complete list of GM-SF differentially expressed genes. (Continues on the 
next page) 
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Gene symbol logFC PValue FDR Zhang et al 
Ms4a4a 1.278668 0.000111 0.020393 microglia > 2 FPKM 
Pyhin1 1.265976 9.41E-05 0.01761 same level 
Ptgs1 1.220168 7.10E-12 5.88E-09 microglia > 2 FPKM 
Slfn2 1.21445 1.41E-05 0.003491 microglia > 2 FPKM 
Il4ra 1.204609 7.26E-07 0.000229 microglia > 2 FPKM 
Gm8995 1.193093 1.86E-06 0.000559 same level 
Runx1 1.141074 5.57E-06 0.001513 microglia > 2 FPKM 
Ch25h 1.087988 3.62E-05 0.008161 microglia > 2 FPKM 
Plaur 1.087022 0.000301 0.044866 microglia > 2 FPKM 
H2-DMa 1.083368 8.20E-11 5.25E-08 microglia > 2 FPKM 
Lsr 1.079997 1.77E-05 0.004166 endothelial cells 
Ctsc 1.068894 8.43E-07 0.000261 microglia > 2 FPKM 
Gbp9 1.06642 1.04E-05 0.002633 endothelial cells 
Cysltr1 1.054882 4.74E-05 0.010098 microglia > 2 FPKM 
Gbp7 1.049414 4.37E-09 2.46E-06 endothelial cells 
Gpr160 1.040466 0.000288 0.043576 endothelial cells 
P2ry13 1.02401 6.14E-07 0.000199 microglia > 2 FPKM 
St14 1.011414 0.000146 0.025567 microglia > 2 FPKM 
Fcgr3 1.007673 2.18E-05 0.005086 microglia > 2 FPKM 
Itgal 0.974566 5.73E-05 0.011961 microglia < 2 FPKM 
B3gnt7 0.914678 8.14E-05 0.01597 same level 
Slco4a1 0.900685 0.000212 0.033659 same level 
Cish 0.887356 4.13E-05 0.009001 endothelial cells > 2 FPKM 
Pnp 0.867774 2.79E-06 0.000803 microglia > 2 FPKM 
Slc1a5 0.863831 5.92E-05 0.012135 microglia / endothelial cells > 2 FPKM 
Emilin2 0.854265 0.000139 0.024538 microglia / MOC > 2 FPKM 
Nabp1 0.844596 1.09E-06 0.000333 not found 
Ier3 0.828143 0.000132 0.023736 not found 
Cebpb 0.825605 0.000323 0.046732 microglia > 2 FPKM 
Coro2a 0.821955 2.74E-07 0.000102 microglia > 2 FPKM 
Rgs14 0.819442 0.000316 0.046408 microglia > 2 FPKM 
Pim1 0.780399 0.000294 0.044221 microglia > 2 FPKM 
Gbp3 0.762526 0.000272 0.041645 endothelial cells > 2 FPKM 
Egr1 0.753026 1.91E-12 1.75E-09 same level 
 
Figure 4.4c. Complete list of GM-SF differentially expressed genes. (Continues on the 
next page) 
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Gene symbol logFC PValue FDR Zhang et al 
Dna2 0.727032 2.39E-05 0.005517726 same level 
Fos 0.557385 3.91E-05 0.008607457 neurons > 2 FPKM 
Coro1a 0.493128 0.000227 0.035427644 microglia > 2 FPKM 
1600014C10Rik 0.425288 0.000137 0.024429769 not found 
Arc 0.423204 0.000314 0.046408271 neurons > 2 FPKM 
Snx2 0.390796 0.000148 0.025727715 endothelial cells > 2 FPKM 
Bcl6 -0.444 7.40E-05 0.014824312 OPC > 2 FPKM 
Kcnj2 -0.61031 0.0001 0.018621618 endothelial cells > 2 FPKM 
Mpeg1 -0.80078 0.000321 0.046732346 microglia > 2 FPKM 
Cd36 -0.8646 0.000192 0.031719307 microglia < 2 FPKM 
Adap2 -0.92037 0.000159 0.027243092 microglia > 2 FPKM 
Pik3ap1 -0.92564 1.01E-05 0.002592218 microglia > 2 FPKM 
Ighm -0.94904 7.09E-06 0.001874517 not found 
Gpr34 -1.01872 2.30E-06 0.000681333 microglia > 2 FPKM 
Fyb -1.06447 8.41E-05 0.016179923 microglia > 2 FPKM 
Ms4a7 -1.07221 0.000273 0.0416452 microglia > 2 FPKM 
Slc16a10 -1.08009 1.43E-05 0.003492744 microglia > 2 FPKM 
Slamf9 -1.10723 7.62E-06 0.001986836 microglia > 2 FPKM 
Pkd2l1 -1.1122 6.32E-05 0.012788404 same level 
Fcgr4 -1.12435 0.000177 0.02991399 microglia > 2 FPKM 
Cd72 -1.17024 2.39E-07 9.11E-05 microglia > 2 FPKM 
Cd180 -1.2116 1.35E-08 6.87E-06 microglia > 2 FPKM 
Cd5l -1.24509 2.25E-08 1.01E-05 microglia < 2 FPKM 
Gm26714 -1.2697 0.00021 0.033658595 not found 
Serpinb6b -1.34647 3.68E-08 1.58E-05 endothelial cells 
G530011O06Rik -1.35035 2.55E-08 1.12E-05 not found 
Hmga2 -1.426 6.41E-07 0.000205044 
astrocytes/ endothelial cells > 2 
FPKM 
Ctla2b -1.52402 3.19E-09 1.86E-06 endothelial cells 
Gm6377 -1.94698 9.39E-05 0.017609898 microglia < 2 FPKM 
Cxcr3 -1.96462 9.14E-05 0.017423451 microglia > 2 FPKM 
Fcrl1 -2.01817 8.04E-12 6.38E-09 microglia > 2 FPKM 
Gm29291 -2.02608 0.000195 0.031891264 not found 
Cmah -2.23445 2.46E-06 0.00071756 same level 
Plxna4os1 -2.35042 3.79E-05 0.008434008 not found 
Rmrp -3.99982 5.66E-05 0.011936182 astrocytes/ OPC > 2 FPKM 
 
Figure 4.4d. Complete list of GM-SF differentially expressed genes. 
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Figure 4.5. List showing the three main categories of immune related genes: surface 
receptors from the lectin family, cytokines and cytokine receptors modulated by 
GM-CSF in myelinating cultures. The three main categories of immune associated 
transcripts were manually selected from the gene list and arranged in descending order 
of log2 FC.  
 
4.2.1.1 Pathway analysis 
Pathway analysis was performed using the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) which allows unbiased biological interpretation 
of the differentially expressed genes and groups them into influential pathways 
utilising the KEGG database (Huang, Sherman, & Lempicki, 2009). This revealed 
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the GM-CSF associated transcriptome was enriched in multiple immune related 
pathways shown in descending order based on the p-value in Figure 4.6, 
alongside the contributing genes differentially regulated by GM-CSF. With the 
exception of “Transcriptional misregulation in cancer pathway” all these 
pathways are related to immune function in health and disease.  
 
 
 
Figure 4.6. Table showing the enriched pathways significantly modulated by GM-CSF 
in myelinating cultures. Pathway analysis of genes with FDR> 0.05 using DAVID (default 
settings) by utilizing the KEGG data base. Table also shows the percentage and identity 
of genes involved in each pathway.  
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4.2.1.2 qRT-PCR validation 
Five genes were selected to validate RNAseq data by qRT-PCR (Mgl2, Clec4n, 
Tnfsf8, Ccr2, Csf2rb) using wild type and Csf2rb-/- myelinated cultures, 
untreated or treated with GM-CSF (Figure 4.5). Significance was calculated using 
log10 relative copy numbers of gene of interest per     copies of 18S ribosomal 
RNA or Tbt housekeeping genes, depending which of them was stable with 
treatment.  
To facilitate direct comparison between RNAseq and qRT-PCR data the copy 
number for each gene after GM-CSF treatment was normalised to the untreated 
control and presented as log2 fold change. Log2 fold change and p-value for 
each gene tested by qRT-PCR and its corresponding RNAseq values can be found 
in Figure 4.5. GM-CSF increased expression of all five target genes in this 
validation study and in all cases this effect was abolished in Csf2rb-/- cultures 
confirming its dependence on GM-CSF signalling. The fold change induced by GM-
CSF as assessed by qRT-PCR was similar to that in the RNAseq study for Mgl2, 
Ccr2 and Clec4, but was less pronounced for Tnfsf8 and higher for Csf2rb, but 
was significant in all cases (p < 0.05 paired Student's t test) (Figure 4.7).  
 
 
 
 
 
 
 
 
92 
 
 
Figure 4.7. Validation of the RNAseq study using qRT-PCR of selected genes 
belonging to the three main immune associated categories presented in fig4.3. qRT-
PCR was performed using cDNA synthesised from wt and Csf2rb KO cultures treated with 
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GM-CSF for 24h at 24 DIV (n=5). RNA was extracted at 25 DIV. 18S was used as a house 
keeping gene for the Mgl2. The rest of the experiments were performed using Tbp 
(TATA box binding protein) as a house keeping gene. Data presented as mean ± SD from 
four independent experiments, p values were calculated using a paired Student's t test. 
The p-value for each qRT-PCR and the corresponding log2 FC for each gene can be found 
in the table above 
 
 
4.2.2 The effect of GM-CSF priming is retained after GM-CSF 
withdrawal    
The data presented so far demonstrate priming with GM-CSF preferentially up 
regulates expression of genes associated with immune function, in particular 
immunity to infectious agents. This led to a number of inter-related questions, 
in particular (1) was this effect focused on microglia as indicated by the cellular 
distribution of GM-CSF receptor, and (2) did the effect persist after withdrawal 
of GM-CSF?  
To address these questions, Dectin2 (encoded by Clec4n) was chosen to validate 
the effects of GM-CSF at the protein level in wild type and Csf2rb-/- myelinated 
cultures. This choice was determined by availability of antibodies specific for 
gene products upregulated by GM-CSF. This provided a limited list of candidates 
of which Dectin2 was a leading contender because Clec4n expression was 
increased 3 to 4 fold within 24 hours of GM-CSF exposure and encodes a cell 
surface pattern recognition receptor (PRR) that binds high mannose-containing 
glycans (Feinberg et al., 2017). Functionally this stimulates phagocytosis and 
leads to activation of the NLRP3 inflammasome in myeloid cells during fungal 
infections (Chiffoleau, 2018), but whether or not it mediates other responses in 
the CNS is unknown. 
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4.2.2.1 GM-CSF induces microglial expression of Dectin2 (Clec4n)  
Mouse wild type cultures were treated with 100 ng/ml GM-CSF from 24 to 30 DIV 
and stained for Iba1 and Dectin2. In untreated cultures Dectin2 
immunoreactivity was restricted to a small population of Iba1+ microglia (5.671 ± 
2.039 % of Iba1+ cells) (Figure 4.8 a-c). GM-CSF treatment resulted in a marked 
increase in Dectin2 immunoreactivity which again was restricted to Iba1+ 
microglia (93.63 ± 3.428 % of Iba1+ cells; Figure 4.7 a, b, d). Consistent with 
previous experiments, 6 days of treatment with GM-CSF induced a significant 
increase in Iba1+ microglia (Figure 4.7 d) almost all which were now Dectin2 
positive. This was not observed in Csf2rb-/- cultures confirming induction of 
Dectin2 is dependent on GM-CSF signalling (Figure 4.9).  
 
Figure 4.8. GM-CSF up-regulates Dectin2 expression exclusively on microglia. (a, b) 
Representative images of myelinating cultures grown in the presence or absence of 100 
ng/ml GM-CSF from 24 to 30 DIV. Images were aquired  at 30 DIV. Microglia were 
visualized with anti-Iba1 (green) and Dectin2 (red). All nuclei were labelled with DAPI 
(blue).  (c) GM-CSF increased numbers of Dectin2 positive microglia (p= 0.0005). (d) GM-
CSF increased the number of Iba1+ microglia (p= 0.03). Data presented are mean ± SD 
from three independent experiments, p values were calculated using a paired Student's 
t test. AOI= area of interest.  
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Figure 4.9. Microglia from Csf2rb KO cultures do not express Dectin2. (a, b) 
Representative images of Csf2rb-/- myelinating cultures grown in the presence or 
absence of 100 ng/ml GM-CSF from 24 to 30 DIV. Images were aquired at 30 DIV. Iba1+ 
microglia (green), Dectin2 (red). Nuclei were labelled with DAPI (blue).  No Dectin2 
immunoreactivity was detected. The experiment was performed twice. 
 
 
 
4.2.2.2 Dectin2 expression by microglia is maintained after GM-CSF 
withdrawal 
To address whether Dectin2 was down regulated after withdrawal of GM-CSF, 
this was investigated in myelinating cultures grown in the presence or absence 
of 100 ng/ml GM-CSF from 24 to 30 DIV after which GM-CSF withdrawn. Dectin2 
and Iba1 immunoreactivity was then investigated six days later (36 DIV). Cultures 
grown in the presence or absence of 100 ng/ml GM-CSF from 24 to 36 DIV (12 
days) were used as controls.  
A majority of Iba1+ microglia (70.91 ± 5.59 %) still co-expressed Dectin2 six days 
after withdrawal of GM-CSF. However, this was significantly lower than in 
cultures treated continuously for twelve days (DIV 24 to 36; 90.23 ± 11.72%; p < 
0.05), and was associated with a marked decrease in intensity of Dectin2 
staining (Figure 4.10). Withdrawal of GM-CSF was also associated with a 
reduction in Iba1+ microglia which decreased to levels similar to that in 
untreated cultures (Figure 4.9 e; Untreated: 59.67 ± 9.391 Iba1+ cells/AOI; GM-
CSF for 12 days: 154.5 ± 41.22 Iba1+ cells/AOI; After GM-CSF withdrawal: 89.65 ± 
9.232 Iba1+ cells/AOI). Further, there was a partial reversal of the GM-CSF 
induced change in microglial morphology from a ramified to rounded phenotype 
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(Percent microglia with a “rounded” phenotype (DIV 36): continuous GM-CSF, 
64.84 ± 10.13%; withdrawal of GM-CSF, 41.9 ± 11.54 %). The dominant microglial 
morphologies in each experimental condition were as follows: untreated- 
ramified (75.38 ± 20.62 %); continuous GM-CSF treatment - rounded (64.84 ± 
10.13 %); after withdrawal - ramified (54.89 ± 14.47 %). Six days after 
withdrawal of GM-CSF, there is a decrease in Iba1+ microglial, and a partial 
reversal of its effects on Dectin2 expression and cell morphology. 
 
Figure 4.10. Dectin2 expression is retained after GM-CSF withdrawal. Representative 
images of myelinating cultures grown in the presence or absence of 100 ng/ml GM-CSF 
from 24 to 36 DIV and (c) and treated with GM-CSF from 24-30 DIV followed by GM-CSF 
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removal from 30 DIV until 36 DIV. Images were acquired at 36 DIV.  Microglia were 
visualized with anti-Iba1 (green) and Dectin2 (red). Nuclei were labelled with DAPI 
(blue).  (d) Removing GM-CSF for 6 days post GM-CSF treatment decreased the 
percentage of microglia expressing Dectin2 (p< 0.05), but the remaining Dectin2 level 
was still significantly different from control? (p< 0.001). (e) GM-CSF treatment increased 
the number of microglia and withdrawing GM-CSF had no statistically significant effect 
compared to untreated control or GM-CSF treatment (p> 0.05). (f) GM-CSF withdrawal 
had no significant effect on microglial morphology compared to continuous GM-CSF 
treatment. Data presented are mean ± SD from three independent experiments, p 
values were calculated using a one-way ANOVA followed by a Tukey post-hoc test. wd: 
withdrawal. AOI= area of interest. 
4.2.3 GM-CSF increases the phagocytic capacity of microglia 
Dectin2 is only one of several cell surface receptors upregulated by GM-CSF that 
are involved in pathogen recognition and phagocytosis; the “phagosome” being 
one of the pathways significantly enriched after GM-CSF treatment. This 
suggests GM-CSF may enhance the phagocytic potential of microglia. To test this 
hypothesis, myelinating cultures were primed with 100ng/ml GM-CSF for 6 days 
(24 to 30 DIV) and the percentage of microglia with phagocytic activity assessed 
using three targets: (1) latex beads; (2) pHRodo labelled E. coli particles; and (3) 
pHRodo labelled myelin (subsequently referred to as myelin debris) for 2 hours. 
pHRodo is a pH sensitive dye that only fluoresces once internalized within the 
lysosome at pH < 4 (Thermofisher.com) to ensure only internalised material was 
detected. Incubations were carried out for 2 hours after which microglia were 
detected by immunofluorescence microscopy using a CD45-specific antibody. 
Priming with GM-CSF increased significantly the proportion of CD45+ microglia 
phagocytosing all 3 targets (Figure 4.11, 4.12, 4.13). Basal phagocytosis in 
untreated cultures was similar for latex beads (51.55 ± 7.89 % of CD45+ 
microglia) and E. coli (41.68 ± 9.92 of CD45+ microglia), but markedly lower for 
myelin debris (14.62 ± 3.1 % of CD45+ microglia). After GM-CSF priming these 
values increased by 1.45-fold for latex beads (74.68 ± 5.009 % of CD45+ 
microglia), 1.80 fold for E. coli (74.68 ± 6.339 of CD45+ microglia) and 2.64 fold 
for myelin debris (37.53 % of CD45+ microglia). GM-CSF therefore enhances 
phagocytosis by microglia in these cultures, an effect predicted to enhance 
remyelination in vivo by accelerating phagocytosis of myelin debris in a 
demyelinating environment (Voß et al., 2012). 
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Figure 4.11. GM-CSF enhances phagocytosis of latex beads by microglia. (a, b) 
Representative images of myelinating cultures grown in the presence or absence of 100 
ng/ml GM-CSF from 24 to 30 DIV and incubated with 3 x     latex beads /ml for 2h. 
Images were acquired at 30 DIV. Microglia were visualized with anti-CD45 (green) and 
the rhodamine-labelled  latex beads are shown in red. GM-CSF treatment increased the 
percentage of microglia phagocyting latex beads (p< 0.05). Data presented are mean ± 
SD from three independent experiments, p values were calculated using a paired 
Student's t test. AOI= area of interest. 
 
 
Figure 4.12. GM-CSF enhances phagocytosis of E. coli by microglia. (a, b) 
Representative images of myelinating cultures grown in the presence or absence of 100 
ng/ml GM-CSF from 24 to 30 DIV and incubated with 0.1 mg/ml E. coli particles for 2h. 
Images were acquired at 30 DIV.  Microglia were visualized with anti-CD45 (green) and 
the E. coli particles are shown in red. GM-CSF treatment increased the percentage of 
microglia phagocyting E. coli particles (p< 0.01). Data presented as mean ± SD from 
three independent experiments, p values were calculated using a paired Student's t 
test. AOI= area of interest.  
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Figure 4.13. GM-CSF enhances phagocytosis of myelin fragments by microglia. (a, b) 
Representative images of myelinating cultures grown in the presence or absence of 100 
ng/ml GM-CSF from 24 to 30 DIV and incubated with 0.1 mg/ml myelin particles for 2h. 
Images were acquired at 30 DIV. Microglia were visualized with anti-CD45 (green) and 
the labelled-myelin fragments are shown in red. GM-CSF treatment increased the 
percentage of microglia phagocyting myelin fragments (p< 0.001). Data presented are 
mean ± SD from three independent experiments, p values were calculated using a 
paired Student's t test. AOI=area of interest.  
 
4.3 Discussion 
To determine if GM-CSF induced functional responses in myelinated cultures, the 
transcriptional response to GM-CSF after 24 hours was investigated by RNAseq. 
GM-CSF differentially regulated expression (> 2-fold) of a small set of 137 
transcripts, which, in agreement with the cellular distribution of the high 
affinity GM-CSF receptor, was enriched in microglial associated genes. Seventy 
four percent of these transcripts encoded gene enriched at least 2-fold in 
microglia compared to astrocytes, neurons, oligodendrocytes or endothelial cells 
in young postnatal mice in vivo (Zhang et al., 2014). Furthermore, > 80% were 
expressed by microglia isolated from mice with EAE (Appendix  Figure 7.2) 
(Lewis, Hill, Juchem, Stefanopoulos, & Modis, 2014). There was little or no 
evidence this microglial response triggered off-target responses in other cell 
types in vitro as GM-CSF had no effect on expression of any 
myelin/oligodendroglial-, astrocyte- or neuron-specific genes. The only 
exception was Cd274, which encodes programmed death-ligand 1 (PD-L1).  
Cd274 is expressed preferentially by neurons in naïve mice in which it is also 
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expressed at lowers level by microglia (Zhang et al., 2014), but is up regulated 
significantly in dorsal root ganglion (DRG) neurons by GM-CSF (Bali et al., 2013). 
This is of interest as PD-L1 is best known as an immunoregulatory molecule that 
down regulates effector T cell function through its interaction with the 
inhibitory checkpoint molecule PD-1 (Hui et al., 2017). However, in the CNS it 
can also inhibit pain by suppressing nociceptive neuronal activity (Chen et al., 
2017).  This suggests GM-CSF may not only act to suppress T cell dependent 
effector functions in the CNS, but also ameliorate pathophysiological sequela 
associated with tissue damage (Bryant-Hudson & Carr, 2012; Kiyota et al., 2018; 
Kosloski, Kosmacek, Olson, Mosley, & Gendelman, 2013). This concept is 
supported further by the observation GM-CSF up-regulated expression of Lsr, an 
endothelial-enriched gene that encodes lipolysis-stimulated lipoprotein 
receptor, a protein required to maintain blood brain-barrier function (Sohet et 
al., 2015). This raises the interesting possibility that activation of GM-CSF 
signalling in microglia is potentially beneficial rather than detrimental in the 
CNS. Certainly our data demonstrate GM-CSF in our experimental setting does 
not up-regulate expression of key genes associated with inflammatory damage in 
the CNS such as Il1, Tnf-α and Nos2 (Conti et al., 2007), or mediate tissue CNS 
damage in vitro by some other pathway. Nonetheless the balance of data from 
EAE models demonstrates GM-CSF is an essential effector cytokine that primes 
myeloid cells to target myelin and exacerbate tissue damage in the inflamed CNS 
(Codarri et al., 2011; Ousman & David, 2001; Ponomarev et al., 2007). The 
transcriptional data generated in this study helps to explain this apparent 
dichotomy as they suggest GM-CSF, whilst not cytopathic in its own right, primes 
microglia to respond to infection and/or interact with infiltrating T cells.  
 
This was first suggested by pathway enrichment analysis that demonstrated the 
GM-CSF associated transcriptome was enriched in pathways related to immune 
function in health and disease (Figure 4.6). Visual inspection of genes 
differentially modulated by GM-CSF associated this “immune genotype” with 
three functional clusters (Figure 4.5). The most obvious were increased 
expression of genes encoding (1) cell surface receptor associated with innate 
immunity; (2) chemokines associated with immune cell migration and (3) 
chemokine/cytokine receptors, all of which are expressed by microglia in EAE 
(Lewis et al., 2014). 
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Cell surface receptors differentially upregulated by GM-CSF included C-type 
lectins (CLR) [Mgl2 and Clec10a which encode CD301b and CD301a, respectively; 
Clec7a encoding Dectin1; Clec4n encoding Dectin2; and Mrc1 encoding Mannose 
Receptor C type 1 (MRC1)], Siglecf which encodes CD170, a sialic acid–binding Ig-
like lectin and two IgG receptors (Fcgr2b and Fcgr3). CLRs are expressed by a 
variety of cells including many innate immune cells such as monocytes, 
macrophages, dendritic cells and microglia (Brown, Willment, & Whitehead, 
2018; Gensel et al., 2015). CLRs  bind a variety of glycans present on pathogens, 
facilitating phagocytic uptake and modulation of inflammation as well direct 
killing of invading microorganisms (Brown et al., 2018). For example Dectin2 
binds to α-mannans and is implicated in innate anti-fungal immunity 
(Drummond, Saijo, Iwakura, & Brown, 2011); Dectin1 recognises fungal β-glucans 
(Brown et al., 2003; Steele et al., 2003); CD301a (Clec10a) and CD301b (Mgl2) 
(homologues of CLEC10A in humans) recognise terminal N-acetylgalactosamine 
residues and are implicated in antigen presentation and antitumor immunity 
(Denda-Nagai et al., 2010; S. K. Singh et al., 2011). These proteins together with 
Siglecf, Fcgr2b and Fcgr3 play multiple roles in orchestrating recognition of 
pathogens and immune complexes to trigger innate and adaptive immune 
responses. Phagocytosis plays a central role in this complex response leading us 
to speculate GM-CSF would enhance phagocytosis by microglia in myelinated 
cultures. This concept is supported by enrichment of the phagosome (Figure 4.4) 
and studies demonstrating GM-CSF enhances phagocytosis of microspheres by 
enriched neonatal mouse microglia (H. Li et al., 2011), sheep erythrocytes by 
peritoneal mouse macrophages (Coleman, Chodakewitz, Bartiss, & Mellors, 1988) 
and Staphylococcus aureus by human neutrophils (Fleischmann, Golde, Weisbart, 
& Gasson, 1986).  
 
It was found that treating myelinating cultures for six days with GM-CSF had only 
a modest effect on enhancing phagocytosis by microglia. GM-CSF increased the 
number of microglia phagocytosing latex beads, pHrodo labelled E. coli 
particles, and pHrodo labelled myelin debris by no more than a factor of two. 
There was no obvious specificity for any particular ligand, although the absolute 
number of phagocytic microglia was consistently lowest in cultures challenged 
with pHrodo labelled myelin debris. However, this may simply reflect 
differences in particle size and/or number as we were unable to accurately 
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assess either the number of myelin particles added, or restrict their size 
distribution to approximate to that of E. coli or latex beads. The functional 
significance of increasing phagocytosis of myelin by microglia is unclear. 
Historically, this was thought to promote disease progression and loss of 
neuronal function by destroying the myelin sheath in MS and EAE but new 
evidence indicates clearance of myelin debris by microglia enhances lesion 
repair (Bijland et al., 2019; Grajchen, Hendriks, & Bogie, 2018; Kotter et al., 
2006; Lampron et al., 2015; Miron et al., 2013). This is yet another mechanism in 
addition to those mentioned earlier by which GM-CSF may mediate a potentially 
beneficial response in the CNS.  
 
However, it must be noted phagocytoses of myelin debris in the context of a 
neuroinflammatory disease such as MS or EAE has the potential to enhance 
presentation of myelin-derived epitopes to infiltrating autoreactive T cells. This 
is supported in particular, by our observation that GM-CSF upregulated 
expression of H2-dma (histocompatibility 2, class II, locus DMa), H2-DMb2 
(histocompatibility 2, class II, locus Mb2) and Cd74, which are involved in 
antigen processing and presentation (Ong, Goldenberg, Hansen, & Mattes, 1999; 
Russell, York, Rock, & Monaco, 1999). This is in line with previous reports that 
GM-CSF primes neonatal microglia for antigen presentation and increases their 
expression of MHC class II proteins and the invariant chain (H. Li et al., 2011; Re 
et al., 2002). The in vivo significance of antigen presentation by microglia is as 
yet unknown, although most studies concur that although this is unlikely to 
prime naïve T cells it may contribute to reactivation of antigen-experienced 
effector and regulatory cells invading the CNS parenchyma (Waisman & Johann, 
2018). 
 
Two other important gene clusters differentially modulated by GM-CSF in our 
sequencing study were cytokines and their cognate receptors involved in 
chemotaxis and cell mobility. Their presence was also reflected in the enriched 
pathway list: cytokine-cytokine receptor interaction and chemokine signalling 
pathways. Chemokines prompt movement of inflammatory cells to the site of 
inflammation/injury by inducing a chemotactic gradient (Adams & Lloyd, 1997).  
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In terms of functional significance, chemokines play a major role in 
orchestrating recruitment of immune cells across the blood brain-barrier into the 
CNS parenchyma (Gyoneva & Ransohoff, 2015). This is facilitated by matrix 
metalloproteinases such as Mmp8, Mmp12 and Mmp13 which up are also 
regulated by GM-CSF and which mediate tissue breakdown to facilitate cell 
migration to sites of inflammation MMPs (Lo, Wang, & Louise Cuzner, 2002). 
MMPs also regulate inflammatory mediators, such as cytokines, which can result 
in loss or gain of function (Chopra, Overall, & Dufour, 2019; Manicone & 
McGuire, 2008). However, in addition to their roles in neuroinflammation these 
molecules all contribute to CNS homeostasis and repair (Trettel, Di Castro, & 
Limatola, 2019; Trivedi et al., 2019). It is therefore difficult to define any single 
function to GM-CSF mediated expression of chemokines and MMP’s in the CNS. 
However, they would certainly promote a dynamic environment in which 
microglia and immune cells recruited from the periphery are attracted via 
chemokine gradients to where GM-CSF is being expressed in the CNS. Intriguingly 
GM-CSF also up-regulated the expression of its common β-subunit (Csf2rβ) 
suggesting it could induce a positive feedback loop as well as enhancing signal 
transduction by IL-3 and IL-5 whose receptors share this signal transducing 
subunit.   
 
Induction of two CLR’s, Mgl2 and Clec4n by GM-CSF was validated by qRT-PCR. 
Expression of both was increased in WT cultures but remained unchanged in GM-
CSF signalling deficient mice (Figure 4.5). It was also possible to validate 
induction of Dectin2 at protein level by immunofluorescence microscopy. In 
unstimulated wild type cultures immune reactivity for Dectin2 was weak and 
restricted to a small population (5.671 ± 2.039 %) of Iba1+ microglia. In contrast 
GM-CSF induced Dectin2 expression on Iba1+ cells. Again, GM-CSF failed to 
induce this response in cultures established from Csf2rb-/- donors. Monitoring 
Dectin2 immunoreactivity provided a simple tool to monitor the longevity of the 
response induced by GM-CSF after its withdrawal. This revealed there was no 
rapid reversion to the Dectin2 negative phenotype. However, there was a trend 
for microglia to adopt the ramified morphology characteristic of microglia 
before they were exposed to GM-CSF. Unexpectedly, the absolute number of 
microglia declined after withdrawing GM-CSF. Why this was the case is unknown, 
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but suggests that in addition to promoting proliferation, GM-CSF also induces 
factors required to supports microglia survival.  
 
Taken as a whole these data demonstrate that whilst GM-CSF does not induce 
microglial expression of cytopathic/demyelinating effector mechanisms in 
myelinating cell cultures it does prime microglia to up-regulate pathways that 
would enable them to respond more rapidly to infectious or autoimmune insults 
to the CNS. Functionally this was demonstrated with respect to phagocytosis, 
but the question remains what are the additional triggers required to push these 
cells into cytopathic effectors able to mediate tissue damage in the CNS.   
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Chapter 5 
GM-CSF sensitises for IFN-γ and TNF-α to 
induce tissue damage 
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5 GM-CSF sensitises for IFN-γ and TNF-α to 
induce tissue damage 
5.1 Introduction 
The previous chapters demonstrated GM-CSF does not induce axonal and myelin 
pathology in myelinated cultures, but nonetheless up regulates expression of 
genes encoding cell surface receptors associated with phagocytosis and innate 
immunity. Bioinformatics and validation studies using Clec4n confirmed 
microglia are the primary target of GM-CSF, but provided no further insight as to 
how GM-CSF might ‘license’ these cells to mediate tissue damage in the CNS. We 
reasoned this may be dependent on synergy with other cytokines and considered 
IFN-γ and TNF-α as potential candidates. These pro-inflammatory cytokines are 
themselves cytotoxic under certain conditions, are involved in the pathogenesis 
of EAE and have been implicated as key factors contributing to lesion 
development in MS (Beck et al., 1988; Montgomery & Bowers, 2012; Patel & 
Balabanov, 2012). IFN-γ in MS lesions may derive in part from infiltrating 
encephalitogenic Th1 cells (Merrill et al., 1992; Nylander & Hafler, 2012). In 
contrast, although TNF-α is produced predominantly by myeloid cells, it is also 
expressed by T cell subsets infiltrating the CNS in MS. Its ability to kill human 
oligodendrocytes in vitro leads to speculation this mechanism contributes to 
lesion development in patients (Jurewicz, Matysiak, Tybor, & Selmaj, 2003; 
Renno, Krakowski, Piccirillo, Lin, & Owens, 1995). We therefore investigated 
whether GM-CSF can enhance the cytolytic activity of IFN-γ and TNF-α in 
myelinated cultures.  
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5.2 Results 
5.2.1 GM-CSF synergizes with IFN-γ and TNF-α to induce axonal 
loss and myelin damage 
Myelinating cultures were primed by treating them with GM-CSF for six days (100 
ng/ml; 24 to 30 DIV) then treated with IFN-γ (25 ng/ml) and TNF-α (100 ng/ml), 
individually or in combination for 72 hours, after which cell death was assessed 
using a commercial LDH release assay. Under these conditions, release of LDH 
was only observed in GM-CSF primed cultures treated with both IFN-γ and TNF-α 
(74.49 ± 15.92 % max LDH release, p < 0.001 relative to untreated control 
cultures). No significant release of LDH was observed with any other treatment 
combination (Figure 5.1a). The high level of LDH release caused by IFN-γ and 
TNF-α was associated with extensive and often complete destruction of GM-CSF 
primed cultures. Immunofluorescence microscopy revealed the dense network of 
neurofilament+ neurites and associated myelin sheaths was often disrupted 
completely; only occasionally did residual neurites and MOG+ myelin debris and 
oligodendrocytes remain. (Figure 5.1 c, d). The number of DAPI labelled nuclei 
remaining after 72 hours was less than 50 % of controls (Untreated, 792.2 +/- 
216.8; GM-CSF primed and 72 hours IFN-γ and TNF-α, 387.9 +/- 143.9I) (Figure 
5.1 b, e, f). These results not only demonstrate priming with GM-CSF massively 
enhances IFN-γTNF-α mediated cytotoxicity in this culture system, but this 
effect requires all three cytokines.   
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Figure 5.1. GM-CSF synergises with IFN-γ and TNF-α to induce tissue damage. Mouse 
myelinating cultures were primed or unprimed with 100 ng/ml GM-CSF from 24 to 30 
DIV, followed by 100 ng/ml IFN-γ and 25 ng/ml TNF-α for 72h. GM-CSF priming followed 
by IFN-γ and TNF-α treatment induced extensive cytotoxicity shown as (a) LDH release 
(n= 6, p< 0.001) and (b) decreased total cell numbers (             (n=4, p= 0.032 < 
0.05). Representative images of (c, e) untreated myelinating cultures and (d, f) cultures 
primed with 100 ng/ml GM-CSF from 24 to 30 DIV, followed by 100 ng/ml IFN-γ and 25 
ng/ml TNF-α for 72h. Images were acquired at 33 DIV. Myelin and axons were 
visualized with anti-MOG (clone Z2, green) and anti-neurofilament (SMI31, red) 
antibodies, respectively and nuclei were stained with DAPI. (d, f) GM-CSF priming 
followed by IFN-γ and TNF-α induced extensive loss of MOG and SMI31 immunoreactivity 
and DAPI positive nuclei. Data presented as mean ± SD, p values were calculated using a 
one-way ANOVA followed by a Tukey post-hoc test or using a paired Student's t test. 
AOI= area of interest. 
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5.2.2 GM-CSF induced tissue damage is mediated by iNOS 
induction, selectively in microglia, and nitric oxide 
production 
Previous studies suggest tissue damage caused by IFN-γ and TNF-α is at least in 
part dependent on induction of iNOS (Gibbons & Dragunow, 2006; Mir, Tolosa, 
Asensio, Lladó, & Olmos, 2008). We therefore investigated if GM-CSF priming 
sensitised for IFN-γ and TNF-α to induce microglia to express iNOS and generate 
nitric oxide. In view of the almost complete destruction observed at 72 hours 
these experiments were performed on cultures treated with IFN-γ and/or TNF-α 
for 24 hours. 
5.2.2.1 GM-CSF priming synergises with IFN-γ and TNF-α to induce rapid 
expression of iNOS in microglia and nitric oxide synthesis  
Myelinating cultures were primed with GM-CSF for six days before being treated 
with 100 ng/ml IFN-γ and/or 25 ng/ml TNF-α for 24 hours. Cultures were then 
fixed and stained for microglia (CD45) and inducible nitric oxide synthase (iNOS). 
Induction of iNOS was observed only under three conditions (Figure 5.2). iNOS 
immunoreactivity was most prominent in GM-CSF primed cultures treated with 
the combination of IFN- and TNF-α which induced expression of iNOS in 78.05 ± 
4.93 % of microglia (Figures 5.2 h and 5.3 a). Far fainter iNOS immunoreactivity 
was also detected in a small number of microglia in cultures primed with GM-CSF 
and treated with IFN-γ only (Figures 5.2 f; Figure 5.3 a: 9.27 ± 10.29 % of 
microglia) and in unprimed cultures treated with IFN- plus TNF-α (Figures 5.2 e; 
Figure 5.3 a: 9.27 ± 5.88 % of microglia). No iNOS immunoreactivity was 
detected in untreated cultures, or in response to any other experimental 
condition investigated in these experiments.  
This pattern of iNOS induction by GM-CSF, IFN- and TNF-α was confirmed by 
western blotting of protein lysates from treated and untreated myelinating 
cultures (Figure 5.3b). A band corresponding to iNOS was only observed under 
the three conditions described above. Semi-quantitative analysis confirmed 
expression was highest in GM-CSF primed cultures treated with IFN-γ and TNF-α 
(0.689 ± 0.321 arbitrary units), an order of magnitude lower in GM-CSF primed 
treated with IFN-γ alone (0.059 ± 0.056 arbitrary units) and lower again in 
unprimed cultures treated IFN-γ and TNF-α (0.040 ± 0.038 arbitrary units)(Figure 
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5.3 b). Once again iNOS was not detected under any other experimental 
condition. 
To determine if induction of iNOS in microglia was associated with a significant 
increase in nitric oxide synthesis, culture supernatants were harvested and 
analysed using a modified Griess assay. Relative to nitrite concentrations in 
supernatants from untreated cultures, a significant increase in nitrite 
concentrations was only observed following GM-CSF priming and treatment with 
IFN-γ and TNF-α (5.787 ± 1.572 μM, p < .001; Figure 5.3 c). The low levels of 
iNOS detected by immunofluorescence microscopy and western blotting in (i) 
unprimed cultures treated with IFN-γ and TNF-α, and (ii) primed cultures 
treated with IFN-γ did not support a statistically significant increase in nitric 
oxide synthesis (in both cases p > 0.05).  
As anticipated from data presented in Chapter 3, priming with GM-CSF for six 
days increased microglial numbers significantly, but this was not influenced 
further by treatment with INF- and/or TNF-(GM-CSF = 163.7 ± 20.22; GM-CSF 
+ IFN-γ = 137 ± 7.172; GM-CSF + TNF-α =176.9 ± 23.42; GM-CSF + IFN-γ + TNF-α = 
144.1 ± 11.32) (Figure 5.3 d).  
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Figure 5.2. GM-CSF priming synergises with IFN-γ and TNF-α to induce rapid 
expression of iNOS in microglia. Representative images of mouse myelinating cultures 
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(a) untreated 31 DIV; (b) primed with 100 ng/ml GM-CSF from 24 to 31 DIV; (c) 100 
ng/ml IFN-γ for 24 hours, DIV 30 – 31; (d) 25 ng/ml TNF-α for 24 hours DIV 30 – 31; (e) 
100 ng/ml IFN-γ and 25 ng/ml TNF-α for 24 hours, DIV 30 – 31; (f) GM-CSF primed plus 
100 ng/ml IFN-γ for 24 hours, DIV 30 – 31; (g) GM-CSF primed plus 25 ng/ml TNF-α for 24 
hours, DIV 30 – 31; (h) GM-CSF primed plus 100 ng/ml IFN-γ and 25 ng/ml TNF-α for 24 
hours. Images were acquired at 31 DIV.  iNOS immunoreactivity (red) is shown in the 
first column. Microglia were visualized using an anti-CD45 antibody (green), second 
column and nuclei visualised with DAPI (blue) in the third column.  The composite of the 
three channels is shown in the last column. Note intense iNOS immune reactivity was 
only observed if cultures were first primed with GM-CSF and the treated with IFN-γ and 
TNF-α. iNOS expression was restricted to CD45+ microglia.   
 
Figure 5.3. iNOS expression in microglia translates into nitric oxide production. 
Mouse myelinating cultures were primed or unprimed with 100 ng/ml GM-CSF from 24 
to 30 DIV, followed by treatment with 100 ng/ml IFN-γ and 25 ng/ml TNF-α for 24h. 
Images were acquired and supernatants were assessed at 31 DIV. (a) GM-CSF priming 
followed by IFN-γ and TNF-α increased the percentage of microglia expressing iNOS (p< 
0.001, n=3), also confirmed by (b) western blotting (p< 0.001, n=4). (c) The iNOS 
expression in GM-CSF primed cultures treated with IFN-γ and TNF-α  translated into (c) 
nitric oxide production (p< 0.001, n=3). (d) GM-CSF priming increased the number of 
microglia in every treatment (p< 0.05- 0.001, n=3). Raw western blot data can be found 
in the appendix (Figure 7.3). Data is presented as mean ± SD, p values were calculated 
using a one-way ANOVA followed by a Tukey post-hoc test. AOI= area of interest.  
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5.2.2.2 GM-CSF priming synergises with IFN-γ and TNF-α to induce iNOS 
expression and NO production in mouse primary microglia 
To determine if these effects of GM-CSF, IFN-γ and TNF-α on iNOS expression 
and nitic oxide synthesis were influenced by other cell types in myelinated 
cultures we used primary mouse microglia isolated from mixed glial cultures 
using the “shake off” method and primed with GM-CSF. Following priming with 
100 ng/ml GM-CSF in serum-free media for 3 days, they were treated with IFN-γ 
and/or TNF-α as described previously. After 72 hours expression of CD45 and 
iNOS was determined by immunofluorescence microscopy. 
Cytokine mediated induction of iNOS in primary microglia mirrored what was 
seen in myelinated cultures (Figure 5.4). In GM-CSF primed cultures treated with 
IFN-γ and TNF-α, the majority of microglial were iNOS+, as were some microglia 
primed with GM-CSF and treated with IFN-γ alone,  ortreated only with IFN-γ 
and TNF-α (Figure 5.4 e and f).  
Induction of iNOS also stimulated nitric oxide production (Figure 5.5). Nitrite 
levels were highest in supernatants from primed microglia treated with IFN-γ 
and TNF-α (89.33 ± 1.443 μM), but nitrite was also present in supernatants from 
GM-CSF primed cells treated with IFN-γ (23.85 ± 8.05 μM) and unprimed cells 
treated with IFN-γ and TNF-α (18.73 ± 1.148 μM) (Figure 5.5).  
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Figure 5.4. GM-CSF priming synergises with IFN-γ and TNF-α to induce rapid 
expression of iNOS in mouse primary microglia. Representative images of mouse 
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primary microglia cultures after different cytokine treatments. (a) untreated 6 DIV; (b) 
primed with 100 ng/ml GM-CSF from 0 to 3 DIV, continued GM-CSF until DIV 6; (c) 100 
ng/ml IFN-γ for 72h hours, DIV 3 – 6; (d) 25 ng/ml TNF-α for 72 hours DIV 3 – 6; (e) 100 
ng/ml IFN-γ and 25 ng/ml TNF-α for 72 hours, DIV 3 – 6; (f) GM-CSF primed plus 100 
ng/ml IFN-γ for 72h hours, DIV 3 – 6; (g) GM-CSF primed plus 25 ng/ml TNF-α for 72 
hours, DIV 3 – 6; (h) GM-CSF primed plus 100 ng/ml IFN-γ and 25 ng/ml TNF-α for 72 
hours. Images were acquired at 6 DIV. iNOS immunoreactivity (red) is shown in the first 
column. Microglia were visualized using an anti-CD45 (green), second column and nuclei 
visualised with DAPI (blue) in the third column.  The composite of the three channels is 
shown in the last column. iNOS immunoreactivity was observed with IFN-γ and TNF-α, 
GM-CSF priming and IFN-γ, and more intense staining if cultures were first primed with 
GM-CSF and the treated with IFN-γ and TNF-α. 
                             
   
Figure 5.5. GM-CSF priming synergises with IFN-γ and TNF-α to induce NO 
production in mouse primary microglia. Mouse primary microglia cultures were primed 
or unprimed with 100 ng/ml GM-CSF from 0 to 3 DIV, followed by treatment with 100 
ng/ml IFN-γ and 25 ng/ml TNF-α for 72h. Supernatants were assessed at 6 DIV. GM-CSF 
priming followed by IFN-γ and TNF-α induced a greater NO production than the 
combinations of IFN-γ with TNF-α and GM-CSF with IFN-γ (p < 0.001). Data is presented 
as mean from three independent wells from cells collected and pooled from two litters 
± SD, p values were calculated using a one-way ANOVA followed by a Tukey post-hoc 
test.  
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5.2.2.3 Inhibition of iNOS abrogates cytokine-induced NO production and 
cytotoxicity 
The contribution of iNOS-dependent mechanisms to cytokine-induced 
cytotoxicity was investigated in myelinating rat rather than mouse cultures as 
they exhibit less variability in myelination. Comparison of myelination across 4 
independent cultures from each species at 33 DIV demonstrated an average 
percentage of 4.279 ± 3.917 % or 17.26 ± 2.482 % for mouse and rat respectively. 
Cultures were primed with GM-CSF and treated with IFN-γ and TNF-α as 
described above, in the presence or absence of 100 μM AMT hydrochloride (2-
Amino-5,6-dihydro-6-methyl-4H-1,3-thiazine HCL), a relatively selective, 
reversible inhibitor of iNOS which only inhibits other NOS isoforms at far higher 
concentrations: iNOS, IC50 = 3.6 nM; nNOS, IC50 = 34 nM; eNOS, IC50 = 150 nM 
(Nakane et al., 1995). 
The response of myelinated rat cultures to these cytokine treatments was 
essentially identical to described for mouse cultures. Specifically, nitric oxide 
production and LDH release were only increased significantly in culture primed 
with GM-CSF and then treated with IFN-γ and TNF-α (Figure 5.6 a, b). 
Immunofluorescence microscopy revealed this was also associated with extensive 
loss of neurites and myelin (Figure 5.6 d). Neurite density and myelination were 
reduced by at least 20 and 65 %, respectively, suggesting myelinating 
oligodendrocytes were more susceptible than axons (Figure 5.6 e, f).  
Inhibition of iNOS abrogated these cytokine-dependent effects completely 
demonstrating they are NOS-dependent (Figure 5.7). AMT reduced NO synthesis 
(Figure 5.7 a) and LDH release (Figure 5.7 b) to levels indistinguishable from 
those in untreated control cultures.  Perhaps not surprisingly this was associated 
with complete preservation of neurites and myelin (Figure 5.7 c, d). 
Quantitative analysis of neurite density and myelination revealed no significant 
differences between cultures treated with AMT alone (Neurite density, 68.51 ± 
5.767 %; myelination, 9.007 ± 3.176 %) or AMT plus GM-CSF  and IFN-γ and TNF-α 
(Neurite density, 68.2 ± 2.084 %; myelination, 9.133 ± 4.64 %) (Figure 5.7 e, f).  
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To confirm this was not a species-specific effect this experiment was repeated in 
mouse cultures in which AMT also completely abolished cytokine-mediated NO 
production and its associated cytotoxicity (Figure 5.8).  
 
Figure 5.6. GM-CSF synergises with IFN-γ and TNF-α to induce tissue damage in rat 
myelinating cultures. Rat myelinating cultures were primed or unprimed with 100 
ng/ml GM-CSF from 24 to 30 DIV, followed by treatment with 100 ng/ml IFN-γ and 25 
ng/ml TNF-α for 72h. Images were acquired and supernatants were assessed at 33 DIV. 
(a) GM-CSF priming followed by IFN-γ and TNF-α treatment induced NO production (p< 
0.001), which translates in (b) significantly elevated LDH level (p< 0.01). Representative 
images of (c) untreated rat myelinating cultures and (d) cultures primed with 100 ng/ml 
GM-CSF from 24 to 30 DIV, followed by 100 ng/ml IFN-γ and 25 ng/ml TNF-α for 72h. 
Myelin and axons were visualized with anti-MOG (clone Z2, green) and anti-
neurofilament (SMI31, red) antibodies, respectively. GM-CSF priming followed by IFN-γ 
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and TNF-α induced extensive loss of MOG and SMI31 immunoreactivity. (e and f) graphs 
of percentage neurites and myelination (p< 0.05, 0.001). Data is presented as mean 
from three different experiments ± SD, p values were calculated using a one-way ANOVA 
followed by a Tukey post-hoc test.  
 
Figure 5.7. Inhibiting iNOS stops NO production and prevents cytotoxicity. Rat 
myelinating cultures were primed or unprimed with 100 ng/ml GM-CSF from 24 to 30 
DIV, followed by treatment with 100 ng/ml IFN-γ and 25 ng/ml TNF-α for 72h in the 
presence of presence 100 μM AMT hydrochloride (iNOS inhibitor). Images were acquired 
and supernatants were assessed at 33 DIV. (a) Priming rat myelinating cultures with GM-
CSF followed by IFN-γ and TNF-α treatment in the presence 100 μM AMT hydrochloride 
(iNOS inhibitor) (a) blocked production of NO and (p > 0.05) (b) reduced LDH back to 
background level (p > 0.05). Representative images of (c) untreated rat myelinating 
cultures and (d) cultures primed with 100 ng/ml GM-CSF from 24 to 30 DIV, followed by 
100 ng/ml IFN-γ and 25 ng/ml TNF-α in the presence of AMT hydrochloride for 72h. AMT 
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rescued neurite and myelin integrity, also observed in the graphs the percentage of 
neurites and myelination (p > 0.05 for both) (e, f). Myelin and axons were 
visualized with anti-MOG (clone Z2, green) and anti-neurofilament (SMI31, red) 
antibodies, respectively. Data is presented as mean from three different experiments ± 
SD, p values were calculated using a one-way ANOVA followed by a Tukey post-hoc test. 
Control cultures without AMT inhibitor are presented in Figure 5.6.  
 
 
Figure 5.8. Inhibiting iNOS ablates cytotoxicity in mouse cultures. Mouse myelinating 
cultures were primed or unprimed with 100 ng/ml GM-CSF from 24 to 30 DIV, followed 
by treatment with 100 ng/ml IFN-γ and 25 ng/ml TNF-α in the presence of 100 μM AMT 
hydrochloride (iNOS inhibitor) for 72h. Supernatants were assessed at 33 DIV. (a) GM-
CSF priming followed by IFN-γ and TNF-α treatment induced NO production (p< 0.001), 
which translated in (b) significantly elevated LDH level.  AMT hydrochloride (c) inhibited 
NO production (p> 0.05) which (d) reduced the LDH back to the untreated level (p> 
0.05). Data is presented as mean ± SD, p values were calculated using a one-way ANOVA 
followed by a Tukey post-hoc test.  
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5.2.2.4 Superoxide-dependent pathways do not contribute to cytokine-
mediated cytotoxicity  
Previous studies suggest peroxynitrite (ONOO−) rather than nitric oxide is the 
major executor of tissue damage mediated by microglia (B. Y. Choi et al., 2015; 
J. Li, Baud, Vartanian, Volpe, & Rosenberg, 2005). As peroxynitrite formation is 
dependent on the reaction of nitric oxide with superoxide radicals (Ríos, Prolo, 
Álvarez, Piacenza, & Radi, 2017), its role in this model of cytokine-mediated 
cytotoxicity was investigated using Tiron (disodium-1,2-dihydroxybenzene-3,5-
disulfonate), a cell permeable superoxide scavenger. We found Tiron had no 
effect on cytokine-induced cytotoxicity (Percent maximal LDH release: GM-CSF + 
IFN-γ + TNF-α = 61.73 ± 15.89 %; GM-CSF + IFN-γ + TNF-α + Tiron = 72.27 ± 13.78 
%) (Figure 5.9). INOS dependent cytotoxicity is therefore independent of 
superoxide dependent effects that might generate peroxynitrite or hydroxyl 
radicals. 
                                         
Figure 5.9. Tiron, a superoxide scavenger, has no effect on cytokine-mediated 
tissue cytotoxicity. Myelinating cultures were primed or unprimed with 100 ng/ml GM-
CSF from 24 to 30 DIV, followed by 100 ng/ml IFN-γ and 25 ng/ml TNF-α in the presence 
or absence of 1 mM Tiron (superoxide scavenger) for 72h. Supernatants were assessed at 
33 DIV. The addition of Tiron did not halt GM-CSF induced cell death (p< 0.001). Data 
presented as mean ± SD from six independent experiments, p values were calculated 
using a one-way ANOVA followed by a Tukey post-hoc test.  
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5.2.3 Microglia retain the ability to mediate tissue damage after 
long term GM-CSF withdrawal 
In Chapter 4 it was shown microglia expression of Dectin2 is retained for at least 
six days following GM-CSF withdrawal suggesting the effect of GM-CSF priming on 
cytokine-mediated cytotoxicity may also be retained for an extended period. To 
test this hypothesis, mouse myelinating cultures were primed with GM-CSF for 
six days (24 to 30 DIV). GM-CSF was then withdrawn and cultures maintained for 
a further 12 days until DIV 42 when they were challenged with IFN-γ and TNF as 
described previously. 
Although GM-CSF was withdrawn twelve days earlier (referred to as ‘previously 
primed’) there was still a demonstrable priming effect on microglia as 
demonstrated by (i) induction of iNOS in CD45+ microglia; (ii) nitric oxide 
production and (iii) LDH release (Figure 5.10).  The percentage of 
      microglia in cultures previously primed with GM-CSF and treated with IFN-
γ and TNF (88.32 ± 5.564%) was significantly higher than in unprimed cultures 
treated with these cytokines (51.24 ± 11.54 %) (Figure 5.10 e). Similarly, 
previously primed cultures produced more nitric oxide (Primed: IFN-γ + TNF-α, 
60.14 ± 6.087 μM; Unprimed: IFN-γ + TNF-α = 12.21 ± 4.03 μM) (Figure 5.10 f) 
and retained their cytotoxic potential compared to unprimed cultures (Primed:  
IFN-γ + TNF-α = 39.53 ± 9.058%; Unprimed: IFN-γ + TNF-α = 10.80 ± 2.65 %; 
Untreated = 7.627 ± 2.944 % maximal LDH release) (Figure 5.10 g).  
The number of microglia after GM-CSF withdrawal was higher than in the 
untreated control (untreated = 85.71 ± 5.545; GM-CSF wd = 130.8 ± 7.616; CD45+ 
cells/field of view), but decreased after 72 hours with IFN-γ and TNF (96.42 ± 
26.91 CD45+ cells/field of view) (Figure 5.10 h). An observation that may reflect 
autocrine killing of microglia by nitric oxide. 
 
 
 
 
122 
 
 
Figure 5.10. Microglia retain the ability to mediate tissue damage after long term 
GM-CSF withdrawal. (a-d) Representative images of myelinating cultures grown (a) in 
the absence of GM-CSF, (b) treated with 100 ng/ml GM-CSF from 24 to 30 DIV followed 
by 12 days GM-CSF withdrawal (wd), (c) treated with 100 ng/ml IFN-γ and 25 ng/ml 
TNF-α for 72h at 42h, and (d) treated with GM-CSF from 24-30 DIV followed by 12 days 
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GM-CSF withdrawal and treated with 100 ng/ml IFN-γ and 25 ng/ml TNF-α. Images were 
acquired and supernatants were assessed at 45 DIV. iNOS immune reactivity (red) is 
shown in the first column. Microglia were visualized using an anti-CD45 antibody 
(green), second column and nuclei visualised with DAPI (blue) in the third column.  The 
composite of the three channels is shown in the last column. (e, f) There were 
significantly more microglia expressing iNOS and NO produced in cultures which were 
previously primed with GM-CSF and treated with IFN-γ and TNF-α than IFN-γ and TNF-α 
alone (p< 0.01, 0.05). (g) Previous GM-CSF priming also caused significantly more LDH 
release when challenged with IFN-γ and TNF-α (p< 0.001). (h) The number of microglia 
after 12 days GM-CSF withdrawal remained significantly higher than in the untreated 
control (p< 0.05). Data presented as mean ± SD from three independent experiments, p 
values were calculated using a one-way ANOVA followed by a Tukey post-hoc test. AOI= 
area of interest. 
5.2.4 GM-CSF priming modulates IFN-γ and TNF-α mediated 
induction of pro-inflammatory cytokines 
As demonstrated, GM-CSF priming has a dramatic effect on cytokine-mediated 
induction of iNOS dependent cytotoxicity. However, as it would be naïve to 
consider this was the only microglial response to GM-CSF priming the study was 
extended invest if this also modulated synthesis of pro-inflammatory cytokines. 
Supernatants were collected from cytokine treated myelinated cultures and 
screened using the MSD platform for the presence of a panel of                     
pro-inflammatory cytokines (IL-1β, IL-6, IL-15, IP-10, KC/GRO, MCP-1, MIP-2α, 
MIP-3α).  
There was significant variation between individual cultures but focusing on the 
effects of GM-CSF priming on the response to IFN-γ and TNF-α some interesting 
trends emerged from these experiments. First, with the exception of IL-15 which 
was slightly elevated, simply priming cultures with GM-CSF had no effect on the 
concentrations of the cytokines studied. However, priming plus combined 
treatment with IFN-γ and TNF-α was associated with increased a significant 
increase in the concentrations of IL-6 and a tendency towards increase in IL-1b. 
Unexpectedly, examining the individual effects IFN-γ or TNF-α on IL-1 and IL-6 
in primed cultures suggest this involves different mechanisms.  TNF alone was 
sufficient to account for the increase in IL-1, whereas the increase in IL-6 could 
not be attributed to either cytokine alone. With respect to the other cytokines 
examined, there was a general trend for priming to increase their 
concentrations, but variation between experiments prevented a clear conclusion 
being drawn. Why this was the case was unclear, but it could reflect differences 
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in microglial density between cultures, effects due to iNOS dependent injury 
and/or cytokine production by astrocytes or other cells present in these cultures 
(Rothhammer & Quintana, 2015) (Figure 5.11, 5.12).  
To address this variability, the study was repeated using supernatants harvested 
from cultures of primary mouse microglia which had been untreated or primed 
with GM-CSF for 3 days and then treated with IFN-γ and TNF-α singly or in 
combination for 72h (Figure 5.13).  This provided data sets with far less 
variability and confirmed the treatment enhanced secretion of IL-, IL-6, IL-15, 
CXCL1, CXCL2 and CCL2 compared to untreated controls. However, it is apparent 
from the data presented in Figure 5.12 the response is complex. This is 
illustrated by the differential effects on CXCL10, CXCL1 and CXCL2, and CCL2. 
First, priming did not significantly alter CXCL10 production in response to IFN-γ 
and TNF-α, but completely abolished the ability of TNF- to enhance CXCL10 
production i.e. GM-CSF appears to antagonize or inhibits the effect of TNF- on 
CXCL10 production. Secondly, priming with GM-CSF enhanced production of 
CXCL1 and CXCL2 in response to TNF-, but this effect was markedly decreased 
by IFN-. Thirdly, priming with GM-CSF also enhanced production of CCL2 in 
response to IFN-, but in this case, TNF- appeared to act as an antagonist.   
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Figure 5.11. GM-CSF synergised with IFN-γ and TNF-α to increase the production of 
some pro-inflammatory cytokines. Mouse myelinating cultures were primed or 
unprimed with 100 ng/ml GM-CSF from 24 to 30 DIV, followed by treatment with 100 
ng/ml IFN-γ and 25 ng/ml TNF-α, singly or in combination, for 24h. Supernatants were 
assessed at 31 DIV. (a-h) Cell supernatants were screened for pro-inflammatory 
cytokines, Il-1β, IL-6, IL-15, IP-10, KC/GRO, MCP-1, MIP-2α, MIP-3α, using the MSD 
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platform. Data are presented as mean from five independent experiments ± SEM, p 
values were calculated using a one-way ANOVA followed by a Tukey post-hoc test. 
 
Figure 5.12. GM-CSF synergised with IFN-γ and TNF-α to increase the production of 
some pro-inflammatory cytokines. Mouse myelinating cultures were primed or 
unprimed with 100 ng/ml GM-CSF from 24 to 30 DIV, followed by treatment with 100 
ng/ml IFN-γ and 25 ng/ml TNF-α, singly or in combination, for 72h. Supernatants were 
assessed at 33 DIV. (a-h) Cell supernatants were screened for pro-inflammatory 
cytokines, Il-1β, IL-6, IL-15, IP-10, KC/GRO, MCP-1, MIP-2α, MIP-3α, using the MSD 
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platform. Data are presented as mean from five independent experiments ± SEM, p 
values were calculated using a one-way ANOVA followed by a Tukey post-hoc test. 
 
 
Figure 5.13. GM-CSF synergised with IFN-γ and TNF-α to increase the production of 
some pro-inflammatory cytokines in primary microglia. Mouse primary microglia 
cultures were primed or unprimed with 100 ng/ml GM-CSF from 0 to 3 DIV, followed by 
treatment with 100 ng/ml IFN-γ and 25 ng/ml TNF-α, singly or in combination, for 72h. 
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Supernatants were assessed at 6 DIV. (a-h) Cell supernatants were screened for pro-
inflammatory cytokines, Il-1β, IL-6, IL-15, IP-10, KC/GRO, MCP-1, MIP-2α, MIP-3α, using 
the MSD platform. Data are presented as mean from five independent experiments ± 
SEM, p values were calculated using a one-way ANOVA followed by a Tukey post-hoc 
test. 
 
5.3 Discussion               
GM-CSF synthesis by encephalitogenic CD4+ Th cells (Th-GM cells) plays an 
important role in development of EAE due to effects that include microglial 
activation, activation and recruitment of monocyte-derived macrophages, and 
enhanced antigen presentation (Codarri et al., 2011; Komuczki et al., 2019; 
Ponomarev et al., 2007; Sheng et al., 2014). However, the pathophysiological 
consequences and underlying mechanisms by which GM-CSF mediates its effects 
on microglia to contribute to disease development remain obscure.  
As GM-CSF had no direct effects on the physical integrity of myelin and axons in 
tissue culture (Chapters 2 and 3) we reasoned any contribution to lesion 
development involved synergy with other cytokines secreted by encephalitogenic 
Th-GM, Th1 and/or Th17 T cells (Ponomarev et al., 2007). Prime candidates 
were IFN-γ and TNF-α which kill neurons and oligodendrocytes in tissue culture 
(Renno et al., 1995; Agresti et al., 1996; Baerwald and Popko, 1998; Andrews et 
al., 1998; Bate et al., 2006; Mount et al., 2007; Neniskyte et al, 2014) and 
contribute to the pathogenesis of EAE (Akassoglou et al., 1998; Kerschensteiner 
et al., 2004; Probert, 2000) and MS (Panitch, Hirsch, Schindler, & Johnson, 1987; 
Pegoretti et al., 2018). It should however be stressed cytotoxicity is only one 
facet of the roles these cytokines might play in disease development, as they 
can also promote cell survival and differentiation (Wang et al., 2018). In the 
case of TNF-α, signal transduction via TNFR1 enhances oligodendrocyte apoptosis 
and demyelination , whilst activation of TNFR2 promotes cell survival and 
oligodendrocyte maturation (Pegoretti et al., 2018; Probert, 2015). 
 
Concentrations of IFN-γ and TNF-α used in studies mentioned above varied 
considerably so a preliminary screen was carried out to identify concentrations 
that individually or in combination had no detrimental effect on myelin or axons 
following exposure for 3 days. These were then used to investigate whether GM-
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CSF amplified their cytopathic potential in myelinated cultures. At the selected 
concentrations (100 ng/ml IFN-γ; 25 ng/ml TNF-α) neither cytokine was 
cytotoxic or induced myelin or axonal injury in naïve cultures. However, in 
cultures primed for six days with GM-CSF this combination of cytokines was 
cytopathic and induced extensive demyelination and axonal loss. Moreover, this 
priming effect was long lasting and continued to exacerbate tissue damage 
caused by IFN-γ and TNF-α for at least twelve days after GM-CSF withdrawal. An 
observation that suggests once triggered this priming effect will continue to 
influence microglial function for many days after GM-CSF secreting T cells are 
cleared from the CNS in animals with EAE.   
To identify the mechanisms involved we focused on iNOS, as IFN-γ and TNF-α not 
only upregulate iNOS in microglia (Romero et al., 1996; Delgado, 2003; Lively 
and Schlichter, 2018; Ding et al., 2015; Ta et al., 2019) but its product, nitric 
oxide, plays a significant role in the pathogenesis of EAE (Willenborg, Staykova, 
& Cowden, 1999) and MS (Liu et al., 2001; Smith and Lassmann, 2002; Jack et 
al., 2007). In myelinated cultures priming with GM-CSF for 6 days followed by 24 
hours treatment with IFN-γ and TNF-α induced iNOS expression in approximately 
80% of microglia (Figure 5.2, 5.3). Some weak iNOS immunoreactive was also 
observed in GM-CSF primed cultures treated with IFN-γ as well as unprimed 
cultures treated with IFN-γ and TNF-α. This pattern of iNOS expression in 
response to different cytokine treatments was confirmed by western blotting 
and translated into a significant increase in nitric oxide production in GM-CSF 
primed cultures treated with IFN-γ and TNF-α (Figure 5.3 c). To eliminate a role 
for effects secondary to IFN-γ and/or TNF-α signalling in other cell types the 
study was repeated using primary mouse microglia. This replicated the findings 
made in myelinated cultures confirming IFN-γ and TNF-α act directly on GM-CSF 
primed microglia to induce expression of iNOS.  
The cytotoxic potential of this response was then investigated using AMT 
hydrochloride, a potent and selective iNOS inhibitor (Nakane et al., 1995). This 
revealed the cytopathic potential of IFN-γ and TNF-α was iNOS dependent in GM-
CSF primed cultures. This protective effect was seen in rat and mouse cultures 
demonstrating cytokine-mediated, iNOS-dependent cytotoxicity is not a species-
specific response. Previous studies led us to speculative this would not be 
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mediated by nitric oxide itself, but peroxynitrite generated by NO reacting with 
superoxide radicals (Beckman, Beckman, Chen, Marshall, & Freeman, 1990; 
Mander & Brown, 2005; Pacher, Beckman, & Liaudet, 2007). However, our data 
suggest this is not the case as the superoxide scavenger Tiron failed to inhibit 
iNOS-dependent injury. The concentration of Tiron used (1 mM) protects PC12 
cells from superoxide induced cell death (Yamada et al., 2003), but it would be 
prudent to test higher concentrations and/or alternative inhibitors before finally 
concluding cell death was mediated directly by nitric oxide.  Nonetheless several 
mechanisms are available by which increased bioavailability of nitric oxide may 
compromise survival of myelinating oligodendrocytes and/or neurons. The most 
important is likely to be its inhibitory effects on oxidative phosphorylation which 
are predicted to result in profound energy deficits and ultimately demyelination 
and neurodegeneration (Desai & Smith, 2017; Sadeghian et al., 2016). In 
addition, nitic oxide may S-nitrosylate myelin proteins leading to destabilisation 
of the myelin sheath (Bizzozero, Dejesus, & Howard, 2004). Together, these 
data suggest iNOS is an attractive target for therapeutic strategies designed to 
reduce tissue damage in the CNS in EAE and MS but this is impractical 
(Willenborg et al., 1999), because, in addition to its pro-inflammatory and 
cytotoxic properties (Bogdan, Röllinghoff and Diefenbach, 2000), nitric oxide is 
involved in multiple homeostatic and immunoregulatory pathways. This was first 
observed in iNOS-/- mice which developed more severe EAE than wild type 
controls (Fenyk-Melody et al., 1998), Subsequent studies revealed this is in part 
due in part to immunoregulatory effects that modulate T cell apoptosis and 
development of autoreactive Th1/17 T cell responses (Dalton and Wittmer, 
2005; Yang et al., 2013).  
To investigate if GM-CSF priming affects other microglial effector mechanisms 
we screened myelinating cultures and microglial supernatants for                   
pro-inflammatory cytokine production. There was significant variation between 
individual myelinating cultures, making it impossible to draw a clear conclusion. 
On the other hand, primary microglia primed with GM-CSF for 3 days before 
cytokine treatment revealed that priming significantly increased supernatant 
concentrations of IL-1β, IL-6, IL-15, CXCL1, CXCL2 and CCL2, but had no effect 
on cytokine mediated induction of CXCL10. These observations are similar to 
those reported by Parajuli and colleagues who found GM-CSF increases 
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production of Il-1β, IL-6 and TNF-α  by primary microglia after TLR-4 stimulation 
(Parajuli et al., 2012). Functionally these effects are important as all these 
cytokines modulate neuroinflammation in EAE. Disease severity is attenuated in 
mice deficient in IL-1 and IL6 signalling (Eugster et al., 1998;Sutton et al., 2006) 
whilst IL-15 knockout mice develop more severe disease (Gomez-Nicola, 
Spagnolo, Guaza, & Nieto-Sampedro, 2010) and CXCL1 (Hasseldam, Rasmussen, 
& Johansen, 2016), CXCL2 (Tran, Prince, & Owens, 2000; Tsutsui et al., 2018) 
and CCL2 (Mahad & Ransohoff, 2003)  chemokines contribute to immune cell 
recruitment across the blood brain-barrier. GM-CSF therefore primes microglia 
to amplify induction of multiple gene products predicted to exacerbate 
inflammatory activity in the CNS. But is this relevant to MS?  
It is not possible to provide a definitive answer to this question, but in MS 
patients concentrations of GM-CSF, IL-6, CCL2, CXCL1 and other factors are 
elevated in plasma and/or cerebrospinal fluid, compared with healthy subjects, 
and this correlates with lesion burden and MS clinical severity (Carrieri et al., 
1998; Ishizu et al., 2005; Campbell et al., 2010; Matsushita et al., 2013; Rumble 
et al., 2015). Immunopathological studies have also identified several of these 
cytokines in MS lesions (Filipovic, Jakovcevski, & Zecevic, 2003; Lin & Edelson, 
2017; McManus et al., 1998; Simpson, Newcombe, Cuzner, & Woodroofe, 1998). 
However, how these observations are related to reports that (a) GM-CSF 
producing T cells are enriched in cerebrospinal fluid from MS patients (Ghezzi et 
al., 2019) and (b) expression of GM-CSF defines a novel disease associated T cell 
subset (Galli et al., 2019) remain unclear. It is tempting to assume these 
associations are functionally related, but even if this is not the case, increasing 
evidence indicates GM-CSF is a relevant target in neuroinflammatory diseases 
(Aram et al., 2019; Becher et al., 2016; Hamilton, 2015). 
Nonetheless more research is required to determine the functional significance 
and mechanisms by which GM-CSF modulated cytokine networks potentiate 
tissue damage in the CNS. One approach to these questions is to use myelinating 
cultures as described in this this thesis. A start has been made in this direction 
by mapping transcriptional profiles induced by treatments with IFN-γ and TNF-α, 
individually and in combination, with and without GM-CSF priming. Analysis of 
preliminary microarray study is currently ongoing and some preliminary data will 
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be discussed in Chapter 6. However, rodent models do not reproduce fully many 
aspects of lesion development in MS, in particular expression of molecules 
associated with oxidative tissue damage (Höftberger, Leisser, Bauer, & 
Lassmann, 2015; Schuh et al., 2014). A better strategy would therefore be to 
exploit recent developments in reprogramming iPSC to generate co-cultures 
containing as appropriate defined populations of iPSC derived microglia, 
astrocytes, neurons and/or oligodendrocytes.  
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Chapter 6 
Elucidating the mechanism through which GM-
CSF synergises with IFN-γ and TNF-α to induce 
cytotoxicity 
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6 Elucidating the mechanism through which GM-
CSF synergises with IFN-γ and TNF-α to induce 
cytotoxicity 
6.1 Introduction 
The previous chapters demonstrate that priming myelinated cultures with GM-
CSF sensitises for TNF-α and IFN-γ to mediate iNOS-dependent demyelination 
and axonal loss. In this chapter I focus on the mechanism through which GM-CSF 
priming synergises with IFN-γ and TNF-α to up-regulate iNOS and induce tissue 
damage. We first investigated whether NO production and cytotoxicity are 
dependent on the concentration of GM-CSF used during priming, but also on the 
length of priming. Secondly, as NF-κB has been identified as one of the main 
transcription factors regulators of Nos2 expression (Farlik et al., 2010; Kleinert, 
Art, & Pautz, 2010) we explored if GM-CSF mediated cytotoxicity is also NF-κB 
dependent. Finally, to gain insight in the mechanistic relationship between GM-
CSF priming and cytokine-mediated induction of iNOS and cytotoxicity during 
inflammation we also investigated whether GM-CSF priming synergises with TLR3 
and TLR4 signalling.  
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6.2 Results 
6.2.1 GM-CSF priming is dose-dependent   
To investigate dose-dependent effects of GM-CSF priming on NO production and 
cytotoxicity, myelinating cultures were primed with various concentrations of 
GM-CSF for six days (0.001, 0.01, 0.1, 1, 10, and 100 ng/ml; 24 - 30 DIV). They 
were then treated with 100 ng/ml IFN-γ and 25 ng/ml TNF-α for 72h as 
described previously.  Dose response effects were observed for both parameters 
(NO concentration and LDH release), but across different concentration ranges.  
NO production increased from back ground levels to >40 M in cultures primed 
with between 0.1 to 100 ng whilst cytotoxicity only increased significantly 
between 1 and 100 GM-CSF/ml (Figure 6.1 b). 
 
Figure 6.1. GM-CSF priming is dose-dependent. Mouse myelinating cultures were 
primed with increasing concentrations of GM-CSF and after six days (at 30 DIV) treated 
with 100 ng/ml IFN-γ and 25 ng/ml TNF-α 72h after which culture supernatants were 
harvested and assayed for (a) NO production and (b) LDH release. Supernatants were 
assessed at 33 DIV. Data are presented as mean of five independent experiments ± SD; p 
values were calculated using a one-way ANOVA followed by a Tukey post-hoc test.  
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6.2.2. GM-CSF priming requires time to enhance NO 
production and cytotoxicity  
To determine if the effects of GM-CSF priming on NO production and cytotoxicity 
are time dependent, myelinating cultures were primed with 100 ng/ml GM-CSF 
for one, three or six days before treatment with 100 ng/ml IFN-γ and 25 ng/ml 
TNF-α treatment for 72h after which supernatants were harvested and assayed 
for NO and LDH (Figure 6.2).  Three days priming was required to induce a 
significant increase in cytokine induced NO production (primed, 36.54 ± 20.07 
μM; unprimed 6.746 ± 6.338 μM), but prolonging priming for six days had no 
further effect (primed, 41.30 ± 14 μM; unprimed 6.746 ± 6.338 μM) (Figure 6.2 
a). However, only 24 hours priming was required to increase the proportion of 
microglia expressing iNOS to values similar to those in cultures primed for six 
days (Figures 6.3 a and 6.4). Nonetheless, no increase in cytokine-mediated 
cytotoxicity was observed unless cultures were primed for six days as 
demonstrated by LDH release (Figure 6.2 b) and decrease in total cell number 
(Figure 6.3 c).  
These observations demonstrate that whilst short exposure to GM-CSF enhances 
cytokine-mediated expression of iNOS in microglia, considerably longer priming 
is necessary for this to translate into a cytopathic response. This is not a 
consequence of differences in NO production as there is no obvious correlation 
between NO2- concentration and LDH release in cultures primed for three or six 
days (Figure 6.2). Moreover, there was no significant difference in either the 
percentage or absolute number of iNOS+ microglia in cultures primed with GM-
CSF for three or six days (Figures 6.2 and 6.4). 
 
 
 
 
 
137 
 
 
Figure 6.2. GM-CSF associated NO production and cytotoxicity are priming 
time- dependent. Mouse myelinating cultures were primed with 100 ng/ml GM-
CSF for one, three or six days after which they were treated with 100 ng/ml IFN-γ 
and 25 ng/ml TNF-α for 72h after which supernatants were assayed for (a) NO 
production; (b) LDH release. Supernatants were assessed at 33 DIV. Data are 
presented as mean from three independent experiments ± SD, p values were 
calculated using a one-way ANOVA followed by a Tukey post-hoc test.  
 
 
 
 
 
 
 
Figure 6.3. Effect of GM-CSF priming duration on CD45+ microglia. Mouse myelinating 
cultures were primed with 100 ng/ml GM-CSF for one, three and six days after which 
they were treated with 100 ng/ml IFN-γ and 25 ng/ml TNF-α for 72h. Images were 
acquired at 33 DIV. (a) percentage CD45+ microglia expressing iNOS; (b) number of 
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CD45+ microglia/AOI. (c) total cell number/AOI, DAPI staining).  Data are presented as 
mean from three independent experiments ± SD, p values were calculated using a one-
way ANOVA followed by a Tukey post-hoc test. AOI= area of interest. 
 
 Figure 6.4. Representative images of mouse myelinating primed with GM-CSF for 
different lengths of time and treated with IFN-γ and TNF-α for 72h.  
(a) Untreated; (b)  IFN-γ + TNF-α  (c)  GM-CSF + IFN-γ + TNF-α; (d) GM-CSF primed for 
one day then IFN-γ + TNF-α; (e) GM-CSF primed for three days then IFN-γ + TNF-α; (f) 
GM-CSF primed for six days then IFN-γ + TNF-α. Images were acquired at 33 DIV. 
Microglia were visualized using an anti-CD45 antibody (green), iNOS (red) and nuclei 
visualised with DAPI (blue). 
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6.2.2 GM-CSF priming synergises with LPS and Poly I:C to induce 
rapid expression of iNOS in microglia and amplify NO 
production 
To gain insight in the mechanistic relationship between GM-CSF priming and 
cytokine-mediated induction of iNOS and cytotoxicity, we tested if GM-CSF 
priming had similar effects on TLR signalling. Myelinating cultures were primed 
as described previously (100 ng/ml GM-CSF from 24 to 30 DIV) then treated with 
1 µg/ml LPS (activates TLR4) or 10 µg/ml poly I:C (polyinosinic:polycytidylic 
acid, activates TLR 3). 
LPS induced low levels of iNOS immunoreactivity and NO production in unprimed 
myelinated cultures (Figure 6.5 a, e), but these effects increased significantly 
following priming with GM-CSF (Figure 6.5 b, e). LPS induced iNOS expression in 
approximately 60% of microglia in primed cultures, an effect associated with a 
significant increase in NO production (Figure 6.5 e, f). GM-CSF priming had a 
similar but less pronounced effect on induction of iNOS and NO production by 
poly I:C (Figure 6.5 c, d, I, j). It should be noted iNOS immunoreactivity induced 
by these TLR ligands was not restricted to microglia as it was also observed in 
occasional CD45- cells (Figure 6.5 b, d). This is not surprising as TLR3 and TLR4 
are expressed by many CNS cell types (Zhang et al., 2014). In neither case did 
GM-CSF priming enable these ligands to mediate a cytopathic effect (Figure 6.6). 
Although, poly I:C abolished the GM-CSF-mediated increase in CD45+ microglia 
number this was not associated with a significant increase in LDH release raising 
the possibility activation of TLR3 by poly I:C may down regulate expression of 
CD45 rather than killing these cells.  
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Figure 6.5. GM-CSF priming enhances induction of iNOS and NO production by LPS 
and Poly I:C. Representative images of mouse myelinating cultures after different 
cytokine treatments. (a) treated with 1 µg/ml LPS for 72h at 30 DIV; (b) primed 
with 100 ng/ml GM-CSF from 24 to 30 followed by 1 µg/ml LPS for 72h; (c) treated with 
10 µg/ml Poly I:C for 72h at 30 DIV; (d) primed with 100 ng/ml GM-CSF from 24 to 30 
followed by 10 µg/ml Poly:IC for 72h. Images were acquired and supernatants were 
assessed at 33 DIV. iNOS immune reactivity (red) is shown in the first column. Microglia 
were visualized using an anti-CD45 antibody (green), second column and nuclei 
visualised with DAPI (blue) in the third column.  The composite of the three channels is 
shown in the last column. Note intense iNOS immune reactivity in multiple CD45+ cells 
was only observed if cultures were first primed with GM-CSF and the treated with LPS 
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and Poly I:C. (e, f) There were significantly more microglia expressing iNOS and NO 
produced in cultures which were previously primed with GM-CSF and treated with LPS 
than LPS alone(p< 0.001, 0.001). (g) GM-CSF priming increased microglia density (p < 
0.05), while LPS treatment had no effect (p > 0.05). (h) The increase in microglia 
percentage expressing iNOS following GM-CSF priming at Poly I:C treatment did not 
reach statistical significance (p > 0.05). (i) GM-CSF priming followed by Poly I:C 
treatment induced NO production (p < 0.05). (j) GM-CSF priming increased microglia 
density (p < 0.01), while Poly I:C decreased CD45+ microglial density in GM-CSF primed 
cultures (p < 0.01). Data presented as mean ± SD from three independent experiments, 
p values were calculated using a one-way ANOVA followed by a Tukey post-hoc test. 
AOI= area of interest.  
 
Figure 6.6. GM-CSF priming does not potentiate LPS or Poly I:C cytotoxicity. (a) 
Treating with 1 µg/ml LPS for 72h on unprimed cultures at 30 DIV or cultures primed 
with 100 ng/ml GM-CSF from 24 to 30 has no effect on LDH release (p > 0.05). (b) 
Treating with 10 µg/ml Poly I:C for 72h on unprimed cultures at 30 DIV or cultures 
primed with 100 ng/ml GM-CSF from 24 to 30 has no effect on LDH release (p > 0.05). 
Supernatants were assessed at 33 DIV. Data presented as mean ± SD from three 
independent experiments, p values were calculated using a one-way ANOVA followed by 
a Tukey post-hoc test 
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6.2.3 NF-κB signalling is involved in GM-CSF mediated 
cytotoxicity 
6.2.3.1 Inhibiting NF-κB signalling globally inhibits iNOS expression and 
negates NO production, but has no effect on cytotoxicity  
The data presented above suggest priming with GM-CSF has two distinct effects 
on the response of myelinating cultures to treatment IFN-γ + TNF-α. First a 
relatively rapid effect of GM-CSF priming which cooperates with IFN-γ and TNF-α 
to induce microglia to express iNOS. Second, a response dependent on extended 
priming (over six days) necessary for these cytokines to mediate iNOS dependent 
cytotoxicity. As induction of iNOS is dependent on cooperation between NF-κB 
and ISGF3 transcription factors (Farlik et al., 2010) we therefore reasoned that 
inhibiting NF-kB would abolish the priming effects of GM-CSF on cytokine-
mediated induction of iNOS and cytotoxicity.  
To test this hypothesis, myelinating cultures were primed with 100 ng/ml GM-
CSF in  the presence or absence of 10 μM 2-[(aminocarbonyl)amino]-5 -(4-
fluorophenyl)-3-thiophenecarboxamide (TPCA-1), a well characterised IkB kinase 
(IKK) antagonist that inhibits activation of NF-B and its translocation to the 
nucleus (Podolin et al., 2005). TPCA-1 completely abolished iNOS expression by 
microglia in primed and unprimed cultures treated with IFN-γ + TNF-α (Figure 
6.7 a, 6.8 a), and led to a significant decrease in NO production (Figure 6.8 b). 
However, this was not associated with a significant decrease in LDH release 
(Figure 6.8 c), implying inhibition of NF-B exposes an alternative cytokine-
mediated cytopathic effect in GM-CSF primed cultures. 
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Figure 6.7. Representative images of mouse myelinating primed with GM-CSF and 
treated with IFN-γ and TNF-α in the presence of TPCA-1. Mouse myelinating cultures 
were primed or unprimed with 100 ng/ml GM-CSF from 24 to 30 DIV, followed by 
treatment with 100 ng/ml IFN-γ and 25 ng/ml TNF-α in the presence of 10 μM TPCA-1 or 
DMSO (vehicle control) for 72h. (b) TPCA-1 abolished iNOS immune reactivity in 
microglia after treatment with IFN-γ and TNF-α (p< 0.001). Images were acquired at 33 
DIV. 
 
 
 
Figure 6.8. TPCA-1, an IkB kinases inhibitor, decreases GM-CSF mediated NO 
production, but has no effect on cytotoxicity. Mouse myelinating cultures were 
primed or unprimed with 100 ng/ml GM-CSF from 24 to 30 DIV, followed by treatment 
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with 100 ng/ml IFN-γ and 25 ng/ml TNF-α in the presence of 10 μM TPCA-1 or DMSO 
(vehicle control) for 72h. Images were acquired and supernatants were assessed at 33 
DIV. (a) TPCA-1 inhibited iNOS expression in microglia and (b) and suppressed NO 
production (p< 0.001). (b) The reduction in NO by TPCA-1 did not translate into reduced 
LDH levels (p> 0.05). Data are presented as mean from four independent experiments ± 
SD, p values were calculated using a one-way ANOVA followed by a Tukey post-hoc test. 
AOI= area of interest.  
 
6.2.3.2 Givinostat, a histone deacetylase inhibitor, decreases NO production 
and ablates cytotoxicity and rescues axons and myelin 
To explore this further we used an alternative approach using Givinostat (a class 
I and II histone deacetylase (HDAC) inhibitor to modulate the transcriptional 
activity of NF-κB (Ghizzoni, Haisma, Maarsingh, & Dekker, 2011; Leoni et al., 
2005). Myelinating cultures were primed with 100 ng/ml GM-CSF (24-30 DIV) and 
then treated with 100 ng/ml IFN-γ and 25 ng/ml TNF-α for 72h in the presence 
or absence of 1 μM Givinostat. Givinostat reduced NO production induced by IFN-
γ + TNF-α in primed cultures by 75 % (GM-CSF + IFN-γ + TNF-α + DMSO = 48.07 ± 
18.09 μM vs GM-CSF + IFN-γ + TNF-α + Givinostat = 15.82 ± 10.49 μM, p< 0.001), 
an effect accompanied by a >65 % decrease in cytotoxicity (Percentage maximal 
LDH: GM-CSF + IFN-γ + TNF-α + DMSO, 46.86 ± 16.79 %; GM-CSF + IFN-γ + TNF-α + 
Givinostat, 21.35 ± 5.794 %; untreated  + DMSO, 8.921 ± 3.871% ) (Figure 6.10).  
However, this protective effect was not paralleled by a corresponding decrease 
in the percentage of CD45+ microglia expressing iNOS in GM-CSF primed cultures. 
Despite that, in unprimed cultures, Givinostat decreased the percentage of 
microglia expressing iNOS in cultures treated with IFN-γ and TNF-α by 75% (IFN-γ 
+ TNF-α + DMSO, 67.30 ± 10.85 %; IFN-γ + TNF-α + Givinostat, 17.39 ± 4.211 %, 
p< 0.001) but there was no significant effect in GM-CSF primed cultures (Figure 
6.9, 6.10). However, although there was also no significant change in the 
absolute number of CD45+ cells expressing iNOS, it appeared the relative 
intensity of CD45 immunoreactivity was reduced as evidenced by the present of 
more iNOSbrightCD45dim cells (Figure 6.9). Givinostat itself exhibited no inherent 
toxicity (Figure 6.10 c).  
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Figure 6.9. Representative images of mouse myelinating cultures primed with GM-CSF and 
treated with IFN-γ and TNF-α in the presence of Givinostat. Mouse myelinating cultures were 
primed or unprimed with 100 ng/ml GM-CSF from 24 to 30 DIV, followed by treatment with 100 
ng/ml IFN-γ and 25 ng/ml TNF-α in the presence of 1 μM Givinostat (histone deacetylase 
inhibitor) or DMSO (vehicle control) for 72h. Images were acquired at 33 DIV. (a, c) Givinostat 
decreased the iNOS immune reactivity in microglia after treatment with IFN-γ and TNF-α (p< 
0.001). (b, d) Givinostat had no obvious effect on iNOS staining in GM-CSF primed cultures 
treated with IFN-γ and TNF-α in, but appeared to decrease the intensity of CD45 staining.  
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Figure 6.10. Givinostat, a histone deacetylase inhibitor, decreases NO production 
and abrogates cytotoxicity. Mouse myelinating cultures were primed or unprimed 
with 100 ng/ml GM-CSF from 24 to 30 DIV, followed by treatment with 100 ng/ml IFN-γ 
and 25 ng/ml TNF-α in the presence of 1 μM Givinostat (histone deacetylase inhibitor) 
or DMSO (vehicle control) for 72h. Images were acquired and supernatants were 
assessed at 33 DIV. (a) Givinostat decreased the percentage of microglia expressing iNOS 
after treatment with IFN-γ and TNF-α (p < 0.001); the decrease in the percentage of 
iNOS expressing microglia in cultures primed with GM-CSF followed by IFN-γ and TNF-α  
treatment did not reach statistical significance (p< 0.05). (b) NO production was greatly 
suppressed when primed with 100 ng/ml GM-CSF followed by 100 ng/ml IFN-γ and 25 
ng/ml TNF-α in the presence of Givinostat (p< 0.001). (b) The reduction in NO by 
Givinostat was translated into a decrease of LDH release back to background levels (p< 
0.001). Data is presented as mean from four independent experiments ± SD, p values 
were calculated using a one-way ANOVA followed by a Tukey post-hoc test. AOI= area of 
interest.  
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Adding Givinostat simultaneously with IFN-γ and TNF-α after GM-CSF priming 
rescued axons and myelin. Givinostat impeded the loss of neurites (GM-CSF + 
IFN-γ + TNF-α + Givinostat = 74.81 ± 2.872 % vs GM-CSF + IFN-γ + TNF-α + DMSO = 
60.38 ± 5.302 %, p< 0.001; untreated DMSO = 74.1 ± 2.582 %, p> 0.05) and myelin 
(GM-CSF + IFN-γ + TNF-α + Givinostat = 5.517 ± 3.289 % vs GM-CSF + IFN-γ + TNF-
α + DMSO = 1.67 ± 1.349 %, p< 0.05; untreated DMSO = 3.355 ± 1.982 %, p> 0.05) 
(Figure 6.11 a, b). GM-CSF priming combined with IFN-γ and TNF-α treatment 
induced extensive loss of SMI31 (axons) and MBP (myelin) immunoreactivity 
(Figure 6.11 c). This was negated by Givinostat as demonstrated by the intact 
neurofilament (SMI31) and MBP staining in Figure 6.11 d.  
 
 
Figure 6.11. Givinostat rescues axons and myelin from the combinatorial effect of 
GM-CSF priming and IFN-γ and TNF-α. Mouse myelinating cultures were primed or 
unprimed with 100 ng/ml GM-CSF from 24 to 30 DIV, followed by treatment with 100 
ng/ml IFN-γ and 25 ng/ml TNF-α in the presence of 1 μM Givinostat (histone deacetylase 
inhibitor) or DMSO (vehicle control) for 72h. Images were acquired at 33 DIV. (a, b) 
Givinostat maintained axonal density and myelin when added together with IFN-γ and 
TNF-α on GM-CSF primed cultures (p< 0.001, 0.05). Representative images of cultures 
primed with 100 ng/ml GM-CSF from 24 to 30 DIV, followed by 100 ng/ml IFN-γ and 25 
ng/ml TNF-α in the (c) absence and (d) in the presence of Givinostat 1 μM for 72h. 
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Myelin and axons were visualized with anti-MBP (myelin basic protein, green) and anti-
neurofilament (SMI31, red) antibodies, respectively. To be noted that the (c) loss of 
neurofilament and MBP immune reactivity mediated by GM-CSF priming followed by IFN-
γ and TNF-α treatment was rescued by (d) Givinostat. Data are presented as mean from 
five independent experiments ± SD, p values were calculated using a one-way ANOVA 
followed by a Tukey post-hoc test 
 
 
 
6.3 Discussion 
Data presented in previous chapters demonstrated that priming myelinated 
cultures with GM-CSF sensitises for TNF-α and IFN-γ to mediate iNOS-dependent 
demyelination and axonal loss. It was assumed a linear relationship existed 
between these effects i.e. expression of iNOS results in production of NO which 
in turn causes cell death. However, data presented in this chapter demonstrate 
the situation is more complex as high levels of NO production do not necessarily 
result in cell death. This first became apparent from experiments investigating 
how duration of priming influenced iNOS expression by microglia, NO production 
and cytotoxicity. These revealed that priming with GM-CSF for 72 hours was 
sufficient to induce high levels of nitric oxide production, but this did not result 
in significant cell death as assessed by LDH release. This was not due to 
production of too little nitric oxide, as extending priming for a further three 
days resulted in extensive cell death in the absence of any additional effect on 
nitric oxide production. This was not simply due to insensitivity of the Griess 
assay to detect levels above those detected after 72 hours because the upper 
limit of the assay is 100 μM. This suggests GM-CSF priming mediates two distinct 
effects that act synergistically but differ in their kinetics. The first occurs within 
72 hours and senisitises for the synergy of TNF-α and IFN-γ to induce iNOS in 
microglia. The second is far slower (> 3 days) but once established acts to 
increase the susceptibility of CNS cells to damage by nitric oxide.  
 
The first phase, induction of iNOS, seems to require cooperative signalling 
between TNF-α and IFN-γ on microglia. This may be explained by the fact that 
the murine Nos2 promoter contains both an IFN response region and binding sites 
for NF-κB (Kleinert et al., 2010). Optimal expression of Nos2 is dependent on co-
operative signalling involving the transcription complex ISGF3 (comprised of 
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STAT1, STAT2, and IRF9) and NF-kB (Farlik et al., 2010).  We propose that in CNS 
myelinating cultures and the CNS in general, IFN-γ signals through the STAT/IRF3 
pathway to generate the ISGF3 complex which, in combination with NF-B, 
provides optimal transcription activation of Nos2 in microglia. However the 
question remains as to how GM-CSF signalling sensitises for TNF-α and IFN-γ to 
induce this effect.  
 
As cooperation between TNF/NF-B and IFN/ISGF pathways is required for 
maximal transcriptional induction of Nos2 it is logical to ask whether GM-CSF 
priming up-regulates expression of any key components of these pathways, or 
alternatively down-regulates expression of intrinsic inhibitors. To address this 
question a gene microarray study is underway to investigate the individual and 
combinatory effects of TNF-α and IFN-γ in GM-CSF primed versus unprimed 
myelinated cultures. This study is not yet complete but preliminary analysis 
indicates priming with GM-CSF increases TNF- and IFN- receptor expression 
(Tnfsfr1a, +2.42 fold; Infr1, +1.34 fold; Ifnr2, +1.34 fold – after six days) 
However, in isolation, this does not up-regulate expression of Nos2. This 
hypothesis will require validation, ideally using human microglia to dissect the 
relative importance of different components of each pathway. 
 
As NF-B signalling plays a major role in regulating induction of iNOS we 
investigated its importance using NF-B inhibitors with different modes of 
action. TCPA-1 is a potent IkB kinase inhibitor that prevents NF-B activation 
and its translocation to the nucleus (Podolin et al., 2005). TPCA-1 completely 
abolished cytokine-mediated induction of nitric oxide confirming this is NF-B 
dependent. However, abolition of iNOS activity had no significant effect on 
cytokine-mediated cytotoxicity in GM-CSF primed cultures. We propose this 
dichotomy reflects the functional pleiotropy of TNFR and NF-B signalling 
pathways in the CNS. NF-kB is a multifaceted transcription factor that mediates 
pro-survival functions as well as activating pro-inflammatory signalling cascades 
(Mincheva et al., 2011), whilst  TNF- signalling via TNFR1 is pro-inflammatory 
and via TNFR2 induces cell death (Wajant & Siegmund, 2019). Global inhibition 
of NF-B in GM-CSF primed cultures suppressed induction of iNOS but uncovered 
an alternative mechanism by which inhibtion of NF-B renders primed cultures 
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more susceptible to the effects of cytokine mediated cytotoxicity; an 
observation underlining the pro-survival role of this transcription factor in the 
nervous system (Dresselhaus & Meffert, 2019; Stone et al., 2017). 
 
Intriguingly, this was not observed when NF-B activity was down-regulated 
(rather than being completely inhibited) when we used Givinostat, a class I and 
II histone deacetylase (HDAC) inhibitor, to modulate the transcriptional activity 
of NF-B (Christensen et al., 2014; Ghizzoni et al., 2011; Leoni et al., 2005). 
Givinostat reduced cytokine induced nitric oxide production in primed cultures 
to a level at which it was unable to mediate cell death, axonal loss and 
demyelination. Indeed, reviewing data collected during this study indicates a 
threshold exists that NO production must exceed if it is to induce extensive cell 
death in myelinated cultures. Sensitivity to nitric oxide mediated cytotoxicity 
could be investigated in more detail using NO. donors to define its dependence 
on concentration and time of exposure in GM-CSF primed v unprimed cultures. 
Together, our data suggest that less NO is necessary to induce damage in GM-CSF 
primed cultures. However, one cannot be sure Givinostat mediated effects were 
entirely NF-B specific as in addition to non-histone effects such changing the 
acylation status of p65, HDAC inhibitors also mediate epigenetic effects may 
modulate Nos2 transcription in microglia (Kaminska et al., 2016; Leus, 
Zwinderman, & Dekker, 2016). 
 
Mining data obtained from the microarray study may provide further insight of 
temporal dependence and relationship between Nos2 expression, accumulation 
of iNOS, NO production and sensitivity to cytokine-mediated cytotoxicity. Our 
current data show three days priming with GM-CSF is sufficient to induce a 
significant increase in NO production, although six days of priming is required to 
induce a significant increase in numbers of iNOS+ microglia. This apparent 
discrepancy may be due to differences in the relative sensitivity of the methods 
used to assay these effects in myelinating cultures. One way forward would be 
to explore regulation of Nos2 and iNOS expression in enriched primary microglial 
cultures as these respond in the same way as microglia in myelinating culture 
(see Chapter 5). 
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However, this approach is not appropriate to investigate why extended priming 
is required to increase susceptibility of cultures to cytokine-mediated tissue 
damage because mechanisms such as increased substrate availability and/or 
decreased expression of intrinsic antioxidants might be important, and these 
might be absent in enriched microglial cultures. To add another layer of 
complexity, there is also evidence NO can itself regulate NF-B activity. 
Enhanced NO production increases the activities of the transcription factors p53 
and nuclear factor κB (NF-κB) in several models of disease-associated 
inflammation suggesting that above a certain threshold, this may establish a 
positive feedback loop (Nakazawa et al., 2017; Shinozaki et al., 2014). 
Conversely, other groups have shown NO mediated s-nitrosylation will inhibit NF-
κB signaling (Dela Torre, Schroeder, Punzalan, & Kuo, 1999; Marshall & Stamler, 
2001).  
 
The key question however is whether or not my observations are relevant to the 
pathogenesis of MS. This can only be answered by a more detailed analysis of 
GM-CSF availability in patients and possibly, by examining its effects in human 
iPSC derived and/or organoid culture models. A recent study reported the 
concentration of GM-CSF in the CSF of MS patients is 990.6 ± 517.9 pg/ml 
(Khaibullin et al., 2017). This is at the lower end of the concentration range 
required for GM-CSF priming to enhance NO production in myelinated cultures. 
Assuming local concentrations within the CNS will be significantly higher, we 
propose T and/or B cell derived GM-CSF will prime microglia in developing 
lesions to exacerbate NO dependent tissue damage (Imitola et al., 2018; Parajuli 
et al., 2012; Ponomarev et al., 2007; Rasouli et al., 2015). If this turns out 
indeed to be the case it will support the concept GM-CSF is an important 
therapeutic target in MS. 
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Chapter 7 
General discussion 
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7 General discussion  
GM-CSF is a key T cell derived cytokine necessary to induce tissue damage and 
neurological deficits in EAE (Codarri et al., 2011; McQualter et al., 2001; 
Ponomarev et al., 2007). The presence of increased GM-CSF levels and GM-CSF 
producing T cells in the CSF of MS patients suggest it plays a similar role in the 
immunopathogenesis of MS (Carrieri et al., 1998; Rasouli et al., 2015). Yet little 
is known about the mechanisms by which GM-CSF mediates tissue damage during 
these diseases. Microglia are the only cell expressing functional GM-CSFR in the 
CNS parenchyma and were therefore a logical starting point to investigate how 
GM-CSF contributes to lesion development in EAE (Y. Zhang et al., 2014). 
Our current view is EAE is initiated by reactivation of CNS autoantigen-specific 
effector memory T cells in the CNS (Wekerle, Linington, Lassmann, & 
Meyermann, 1986), in particular a subset of T cell that produce GM-CSF. 
Reactivation may involve contributions from a number of different antigen 
presenting cells (Waisman & Johann, 2018), but it is probable microglia play an 
important early role in this reactivation event (Sosa et al., 2013). To investigate 
down stream effects of T cell derived GM-CSF within the CNS we used 
myelinating cultures, a model of the CNS that is devoid of immune input from 
the periphery. This provided insight into the role of GM-CSF in the pathogenesis 
of EAE and possibly more importantly, additional data confirming its significance 
as a potential therapeutic target in MS.  
The first important observation was that GM-CSF had no detrimental effect on 
neurites, oligodendrocytes or myelin in this culture system, despite inducing a 
marked microglial response characterised by an increase in microglial density 
and “activation” as defined by a change from a ramified to rounded morphology. 
This led us to speculate GM-CSF primes microglia to contribute to lesion 
development, a concept supported by data from an RNAseq study of the effects 
of this cytokine on myelinated cultures and other studies (Davis et al., 1994; 
Kettenmann et al., 2011; Zrzavy et al., 2017a).  GM-CSF induced a 
transcriptional fingerprint dominated by up-regulation of genes associated with 
microglia. Intriguingly these included genes with immunomodulatory and 
homeostatic functions raising the possibility GM–CSF may also support responses 
that limit inflammatory damage in the CNS. One of these was  Clec10a which 
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encodes Mgl1 a C-type lectin that can induce apoptosis of CD4+ T cells (Ilarregui 
et al., 2019). Intriguingly Clec10a is most highly expressed during recovery from 
EAE, and  Clec10a “knock-out” mice show an exacerbated disease course 
(Ilarregui et al., 2019). The same research group also reported its human 
homologue (MGL) is expressed on “anti-inflammatory” M2-like microglia in vitro 
and by microglia in active and chronic active MS lesions. Observations that led 
the authors to conclude MGL is a microglial anti-inflammatory and 
immunomodulatory marker that may act in part by inducing apoptosis of 
encephalitogenic T cells (Ilarregui et al., 2019). However our RNAseq data 
demonstrated Clec10a is just one of a number of C-type lectins and other cell 
surface receptors up regulated by GM-CSF. Functionally, this translated into a 
generalised increase in phagocytosis by microglia.  This too may be interpreted 
as a beneficial response as clearance of myelin debris enhances remyelination in 
the CNS (Adams & Lloyd, 1997; Bijland et al., 2019; Chung et al., 2014; Grajchen 
et al., 2018; Kotter et al., 2006; Lampron et al., 2015; Miron et al., 2013). 
However, this effect might be a doubled-edged sword as  phagocytosis of myelin 
debris and the concomitant up-regulation of molecules involved in antigen 
presentation an processing could contribute to epitope spreading and 
reactivation of encephalitogenic T cells (H. Li et al., 2011; Ong et al., 1999; Re 
et al., 2002). Moreover, in some experimental models GM-CSF primes myeloid 
cells, including microglia, to target myelin and exacerbate tissue damage 
(Codarri et al., 2011; Ousman & David, 2001; Ponomarev et al., 2007). Whatever 
the final outcome of GM-CSF priming, its effects are long-lasting rather than 
transient, as demonstrated by the maintenance of Dectin2 expression by 
microglia after GM-CSF withdrawal. If we would extrapolate this to targeting 
GM-CSF as a treatment for MS, we would predict the effects of neutralizing GM-
CSF would not be immediate but would ultimately suppress development of new 
lesions.  This of course pre-supposes GM-CSF primes microglia to induce tissue 
damage.  
We reasoned that any contribution of GM-CSF to lesion development would 
involve other cytokines derived initially from reactivated encephalitogenic T 
cells infiltrating the CNS. We considered IFN-γ and TNF-α as prime candidates  as 
these pro-inflammatory cytokines are not only produced by encephalitogenic 
CD4+ T cells, but are also cytotoxic under certain conditions and implicated as 
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key contributors to lesion pathogenesis in MS (Beck et al., 1988; Montgomery & 
Bowers, 2012; Patel & Balabanov, 2012). We therefore investigated whether GM-
CSF can enhance the cytopathic effect of IFN-γ and TNF-α in myelinated 
cultures. GM-CSF priming markedly sensitised for IFN-γ and TNF-α to induce 
cellular damage, an effect that was dependent on NO production by iNOS. This 
priming effect was mediated by physiologic concentrations of GM-CSF and was 
long lasting as it was still functional 12 days after GM-CSF was withdrawn. Such a 
dramatic and long-lasting effect was not anticipated, reinforcing our view 
priming by T cell derived GM-CSF mediates a long-lasting effect that exacerbates 
cytokine mediated cytotoxicity in EAE.  Figure 7.1 summarizes how T cell 
derived GM-CSF and microglia cooperate to mediate tissue damage in EAE and 
potentially MS. We reasoned this effect might play a wider role in 
neuroinflammatory diseases other than EAE and MS, and preliminary data 
obtained using two TLR agonists suggest this is the case, as   GM-CSF also 
enhance induction of iNOS by LPS (activates TLR4) or and poly I:C (activates 
TLR3). Observations suggesting GM-CSF might contribute to the 
immunopathogenesis of bacterial and viral infections of the nervous system.   
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Figure 7.1.Potential mechanism through which GM-CSF contributes to tissue damage 
during neuroflammation. Encephalitogenic T cells of different phenotypes cross the 
blood-brain barrier and enter the CNS. Once in the CNS, they get reactivated and 
produce a plethora of cytokines including GM-CSF, IFN-γ and TNF-α. GM-CSF primes 
microglia which will synergise with IFN-γ and TNF-α to produce nitric oxide and other 
pro-inflammatory factors resulting in myelin and axonal destruction. Peripheral myeloid 
cells are also an important source of TNF-α. We do not exclude that invading myeloid 
cells mediate tissue damage via the same mechanism. Diagram created in 
www.Biorender. 
 
A key question that remains unanswered is how does GM-CSF sensitise for 
cytokine mediated cytotoxicity? Mining of the transcriptional data generated by 
IFN-γ and TNF-α individually or combined on GM-CSF primed cultures is currently 
underway and we hope will address this point. We are looking to extract 
candidates involved in iNOS regulation, such as components of the NF-b 
pathway or transcription factors and test them functionally. We already know 
from our experiments that NF-b signalling contributes to NO production and 
should investigate the iNOS promoter for any additive transcription factor 
binding sites and epigenetic modifications. As demonstrated by our experiments 
using Givinostat, it is possible that an epigenetic component plays a role in GM-
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CSF exacerbation of cytotoxicity. Additionally, we plan on investigating if any of 
the pathways involved in downstream GM-CSF signalling is hyperactivated in 
microglia and contributes to iNOS induction by IFN-γ and TNF-α. An elegant and 
efficient way to investigate pathway signalling in this context would be 
detection of phosphorylation status of key pathway components by HTRF 
(homogenous time resolved fluorescence).  
In the context of EAE and by extrapolation MS, it is logical to anticipate GM-CSF 
will also affect infiltrating myeloid cells. On this note, we should investigate the 
behaviour of microglia versus peripheral phagocytes in the CNS. One possible 
approach would be to co-culture bone-marrow derived macrophages in 
myelinating cultures. Peripheral myeloid cells can be harvested from a 
fluorescent transgenic mouse strain to distinguish them from resident microglia 
expressing an alternative fluorophore, a strategy that would enable these cell 
populations to be analysed independently after recovery by FACSorting.  
Our data all point towards GM-CSF signalling being a prime therapeutic target in 
MS, but this will require demonstrating human microglia respond in a similar 
manner to GM-CSF, ideally in a cellular context that replicates that of the CNS. 
A logical option would be to use iPSC-derived human organoids (Lancaster et al., 
2013). It was recently demonstrated that microglia develop within cerebral 
organoids and mimic the transcriptome and inflammatory responses of adult 
human microglia isolated from post-mortem brain tissue (Ormel et al., 2018). It 
is important to note that despite extensive homology between mouse and human 
NOS2, there are known differences in their regulation and NOS2 promoter is not 
as readily inducible as the rodent gene (X. Zhang et al., 1996). Multiple groups 
reporting mouse microglia are more robust at producing NO when stimulated 
with LPS, poly I:C, or IFN-γ than human microglia. This reduction in NO 
productions was attributed to post-transcriptional repression of human iNOS 
expression (Hoos et al., 2014; Schneemann & Schoeden, 2007; Taylor et al., 
1998). It is crucial that we determine if our in vitro mouse model can be 
replicated using human cells to determine if GM-CSF priming exacerbates 
cytokine mediated tissue damage via NO or other effector pathways.  
To summarise, we demonstrated that GM-CSF alone did not induce tissue 
damage in myelinating cultures, but prime microglia to up-regulate pathways 
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that enable them to respond more rapidly to infectious or autoimmune insults to 
the CNS. We demonstrated that GM-CSF priming sensitises for IFN-γ and TNF-α to 
induce tissue damage. Our data revealed that iNOS is central to the cytopathic 
mechanism underlying the synergism between GM-CSF, IFN-γ and TNF-α.  
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8 Appendices  
 
 
Figure 8.1. Neurite density and myelination rates for cultures used for RNAseq. (a, 
b) Representative images of myelinating cultures grown in the presence or absence of 
100 ng/ml GM-CSF for 24 hours at 24 DIV. Myelin and axons were visualized with anti-
MOG (clone Z2, green) and anti-neurofilament (SMI31, red) antibodies, respectively. 
GM-CSF had no effect on either (c) neurite out growth (p = 0.119) or (d) myelination (p= 
0.6340). Data presented as mean ± SD from three independent experiments, p values 
were calculated using a paired Student's t test.  
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Figure 8.2 a. Figure showing a comparison between the genes differentially 
expressed by GM-CSF in our RNAseq ordered alphabetically and genes 
differentially expressed by microglia isolated from mice with EAE (compared 
to naive controls. Microglia were isolated from animals with an EAE score of 0 
Gene logFC  RNASeq Naïve Score  0 Score 3 FC N > 0 FC N > 3
1600014C10Rik 0.425288487 0.583571 10.2629 4.91603 17.58638 8.424048
4921529L05Rik 3.179896731
Adap2 -0.920374697 27.2771 48.2882 55.3445 1.770283 2.028973
Adora3 2.247250035 28.0441 13.8053 17.3854 -2.0314 -1.61308
Amica1 2.444388821 0 0.029807 0.027211 infinite infinite
Arc 0.423204343
B3gnt7 0.914677926 3.9919 0.028059 5.12399 -142.268 1.283597
Batf 1.775251132 0.099525 0.406073 5.5251 4.080127 55.51492
Bcl2a1a 3.941623235 16.6624 8.65976 73.5233 -1.92412 4.412528
Bcl2a1d 2.223197837 80.1245 26.4127 167.545 -3.03356 2.091058
Bcl6 -0.443995992 3.12684 2.49123 4.928 -1.25514 1.576032
Ccl12 3.407990043 25.9769 276.906 509.311 10.6597 19.6063
Ccl2 1.869521628 61.9474 298.591 744.025 4.820073 12.01059
Ccl6 3.406591217 13.2708 16.088 17.4417 1.212286 1.314292
Ccl7 2.051569371 2.96498 52.7327 162.455 17.78518 54.79126
Ccl8 1.378187256 0 8.2806 11.5751 infinite infinite
Ccl9 1.696582232 10.4173 10.0864 10.6506 -1.03281 1.022395
Ccr1 4.488449156 0.277042 1.73301 1.8853 6.255405 6.805105
Ccr2 4.806610325 1.83556 5.86154 0.668425 3.193325 0.364153
Ccr5 1.65372468 72.0889 91.7798 69.3395 1.273147 0.961861
Cd180 -1.211599841 170.795 227.798 330.329 1.333751 1.934067
Cd274 1.456670427 2.8585 11.9118 52.5628 4.167151 18.38825
Cd300lf 3.583926492 0.095474 10.8326 26.9979 113.461 282.7769
Cd33 1.314299656 97.2793 61.1371 89.44 -1.59117 -1.08765
Cd36 -0.864602996 27.9931 30.936 32.4598 1.105129 1.159564
Cd5l -1.245089011
Cd72 -1.170235475 0.205112 11.717 18.7842 57.12489 91.58021
Cd74 2.852683038 128.26 414.505 5588.54 3.231756 43.57196
Cdh1 3.088046576 0 0 0
Cebpb 0.825605176 4.77128 3.52617 4.41126 -1.35311 -1.08161
Ch25h 1.08798765 0.059023 1.61844 0.927778 27.42073 15.71906
Cish 0.88735608 0.136084 0.103376 8.08138 -1.3164 59.38523
Clec10a 2.923191689 0 0.105738 1.39718 infinite infinite
Clec4n 3.448354214 0.145703 0.074094 0.132967 -1.96645 -1.09578
Clec5a 1.306924312 9.37289 4.43799 4.38969 -2.11197 -2.13521
Clec7a 1.329270782 11.7387 7.89232 10.8496 -1.48736 -1.08195
Cmah -2.234445493
Coro1a 0.49312775 48.3746 85.1655 85.5162 1.760542 1.767791
Coro2a 0.821955173 1.60836 2.80073 7.01817 1.741358 4.363557
Csf2rb 1.992224715 13.9275 27.0485 66.8757 1.942093 4.801702
Ctla2b -1.524023304 0.873828 2.13922 13.8873 2.448102 15.89249
Ctsc 1.068894164 31.1 103.811 152.206 3.337974 4.894084
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and 3 and naive controls ) (Lewis et al., 2014). Additionally, we determined that 
fold changes (FC) between naive and diseased animals at both scores. 
 
 
 
Figure 7.8 b. Continued. 
Gene logFC  RNASeq Naïve Score  0 Score 3 FC N > 0 FC N > 3
Cxcr3 -1.964620856 0 0 0 0 0
Cysltr1 1.054881859 5.68534 9.22133 1.41551 1.621949 0.248975
Dna2 0.727031873 0 2.851 2.48169 infinite infinite
Egr1 0.75302589 1320.49 616.344 1027.61 -2.14246 -1.28501
Egr2 1.380003145 31.2444 12.4268 13.74 -2.51428 -2.27397
Emilin2 0.854264619 3.48064 2.83696 1.57531 -1.22689 -2.2095
F13a1 1.961582213 4.77911 2.20644 0.249967 -2.16598 -19.119
Fam167b 2.199644785 4.31383 1.14718 6.07325 -3.76038 1.407856
Fcgr2b 1.34149901 30.873 42.8612 92.8834 1.388307 3.008564
Fcgr3 1.007673273 50.8869 69.5479 150.609 1.366715 2.959681
Fcgr4 -1.124353619 11.9041 18.3115 30.3176 1.538252 2.54682
Fcrl1 -2.018170852 59.8317 2.46678 1.57479 -24.255 -37.9934
Fos 0.557385457 861.069 301.48 494.798 -2.85614 -1.74024
Fyb -1.064468102 40.3642 23.5297 92.6527 0.582935 2.295418
G530011O06Rik -1.350345515 122.329 125.061 72.6091 1.022333 -1.68476
Gapt 1.793630473 0 0 0.033294 0 infinite
Gbp3 0.762525772 1.74148 7.18808 22.6078 4.12757 12.98195
Gbp4 2.162368155 0.062783 13.6178 21.2776 216.903 338.9076
Gbp7 1.049414412 0.983936 14.852 37.081 15.09448 37.68639
Gbp9 1.06642005 2.97637 11.7633 25.2309 3.95223 8.477071
Gm14005 1.548786203 0 7.7198 0.666055 infinite infinite
Gm16194 4.365003604
Gm1966 3.504852291
Gm26714 -1.26969578
Gm29291 -2.026077522
Gm6377 -1.946979896 0.203855 0 0.35324 0 1.7328
Gm8995 1.193092908
Gpr160 1.040465754 4.33939 3.72916 10.641 -1.16364 2.452188
Gpr34 -1.018719048 62.1008 27.4296 28.483 -2.26401 -2.18028
Gpr34 -1.018719048 62.1008 27.4296 28.483 -2.26401 -2.18028
H2-DMa 1.0833675 85.1039 220.198 385.116 2.587402 4.525245
H2-DMb2 2.412916112 0.608294 13.6496 4.76781 22.43915 7.838003
Hmga2 -1.42599572
I830077J02Rik 1.654689274 5.98037 11.4438 26.2566 1.913561 4.390464
Ier3 0.828143355 17.6602 26.6413 69.5641 1.50855 3.939032
Ighm -0.949042006
Il18rap 1.734669014 0 0.117992 0.053861 infinite infinite
Il1rl2 1.831374044 0.956162 1.62775 1.23735 1.702379 1.29408
Il4ra 1.204609441 13.8997 24.5017 24.2729 1.76275 1.746289
Itgal 0.974565867 0.143783 10.6171 20.3234 73.84114 141.3477
Itgax 2.294974078 0.034434 1.86258 7.1715 54.09068 208.2656
Kcnj2 -0.610306507 7.1266 6.1277 6.97751 -1.16301 -1.02137
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Figure 8.2 c. Continued. 
 
 
Gene logFC  RNASeq Naïve Score  0 Score 3 FC N > 0 FC N > 3
Kynu 2.352608038 0 0 2.20173 0 infinite
Lsr 1.079997122 0.150942 0.420597 0.139521 2.786481 0.924335
Mgl2 6.545282515
Mmp12 1.664112593
Mmp13 2.47058141
Mmp8 4.481159722 3.95425 6.00475 0.572733 1.518556 0.14484
Mpeg1 -0.800784486 80.0409 144.034 208.649 1.799505 2.60678
Mrc1 1.778685815 4.03943 0.67387 0.983436 -5.99438 -4.10747
Ms4a4a 1.278668275
Ms4a7 -1.072208526 0 0.890233 0.096371 infinite infinite
Msr1 1.419889846 1.13266 1.2859 1.96613 1.135292 1.735852
Nabp1 0.844596414
P2ry13 1.024009565 184.627 92.2896 83.2047 -2.00052 -2.21895
P2ry14 1.45170909 0 0.085163 4.7139 infinite infinite
Pik3ap1 -0.925640822 8.96075 20.1702 27.41 2.25095 3.058896
Pik3r6 1.328436996 2.08906 2.44332 8.97576 1.169579 4.296554
Pilra 1.80643162 2.64851 3.4639 24.7802 1.307867 9.35628
Pilrb2 3.050372323 0.000336 0.330321 0.4665 982.2125 1387.142
Pim1 0.780398588 0.562423 2.58793 7.9187 4.601394 14.07962
Pkd2l1 -1.112199988
Plaur 1.087021952 3.68901 1.09487 3.0436 -3.36936 -1.21205
Plxna4os1 -2.350420189
Pnp 0.867773697 12.7765 36.691 24.3634 2.871757 1.906892
Prr15 1.458988871
Pstpip2 1.284738382 0 1.5052 4.27067 infinite infinite
Ptgs1 1.220168414 144.804 97.5304 122.651 -1.48471 -1.18062
Pyhin1 1.265975562 0.220197 3.40325 16.4294 15.45548 74.61228
Rab44 3.323055825 0 0.068181 1.49558 Infinite infinite
Rasgrp4 1.828526493 2.48796 3.32488 0.42126 1.336388 -5.906
Rgs14 0.819441689 0.833469 0.187534 0.998566 0.225004 1.198084
Rhoh 1.373597766 7.90655 5.63407 5.35485 -1.40335 -1.47652
Rmrp -3.999815987 12.771 29.9718 5.473 2.346864 -2.33346
Runx1 1.141073608 24.2346 22.092 24.4064 0.911589 1.007089
Scel 1.655480637
Scimp 2.973231189
Serpina3f 3.028042799 0 1.9999 19.61 infinite
Serpinb6b -1.346470985 0.040411 0 0.747102 0 18.48754
Siglecf 2.333866561
Sla 1.749324245 30.1503 18.3596 53.0993 -1.64221 1.761153
Slamf9 -1.107234685 13.884 5.76675 26.488 -2.4076 1.907808
Slc16a10 -1.080087919 4.05554 2.63609 6.9574 -1.53847 1.71553
Slc1a5 0.863831038 0.051838 1.75738 6.17998 33.90139 119.2172
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Figure 8.2 d. Continued. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene logFC  RNASeq Naïve Score  0 Score 3 FC N > 0 FC N > 3
Slco4a1 0.900685007 1.39714 2.24758 2.85741 1.608701 2.045185
Slfn2 1.214450439 8.4619 11.139 22.9359 1.316371 2.710491
Slfn3 1.919752727 0 0.093576 0.115576 infinite infinite
Snx2 0.390796274 11.6906 11.2468 19.1575 -1.03946 1.63871
Spint1 3.981624006 12.527 50.7422 43.6408 4.050627 3.483739
St14 1.011414257 0.586628 0.941992 2.40741 1.605774 4.10381
Tfec 3.199487073 0.042527 0 0.039312 0 -1.08177
Tifab 1.957254753 11.7869 7.40001 11.6317 -1.59282 -1.01334
Tnfsf8 3.222936517 0.098604 0.166433 3.97962 1.687895 40.35966
Trem1 3.747021001 0 0.30808 0 infinite 0
Trim30c 2.090532863
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 Figure 8.3. Raw western blot data, relative intensity found in figure 5.3.  
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Experiment performed four times. Equal amount of protein was loaded for each sample. 
Near Infrared detection system (Li-cor) was used to visualise the membranes (β-actin in 
red- housekeeping protein; iNOS in green) standard exposure settings used to scan the 
membranes. No red marker on the protein ladder - The Odyssey blocking buffer blocked 
the protein marker in the red channel (common problem according to the Li-cor 
company representative). 
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